It is my pleasure to invite you to attend the Annual Meeting of Stockholders of Anika Therapeutics, Inc.~~, a Delaware corporation (“Anika"), will~~ to be held on ~~Tuesday,~~ June 16, ~~2020~~2021, at ~~11:30~~9:00 a.m., Eastern time. This year’s Annual Meeting will be a “virtual meeting” conducted via live audio ~~webcast.~~webcast, consistent with last year’s practice and with prudent planning in light of the public health risks attributable to the COVID-19 pandemic. Each ~~stockholder~~holder of common stock as of 5 p.m., Eastern time, on the record ~~at the close~~date of ~~business on~~ April 20, ~~2020, the record date,~~2021 will be able to participate in the Annual Meeting by accessing a live webcast atvirtualshareholdermeeting.com/~~ANIK2020~~ANIK2021 and entering the control number included on the ~~stockholder’s~~holder’s Notice of Internet Availability of Proxy Materials or proxy card. Stockholders will also be able to vote their shares and submit questions via the Internet during the meeting by participating in the webcast. At

During the Annual Meeting ~~the following matters~~stockholders will be ~~considered:~~asked to elect two Class I directors, to approve an amendment to our 2017 Omnibus Incentive Plan, to approve our 2021 Employee Stock Purchase Plan, and to ratify the appointment of Deloitte & Touche LLP as our independent auditor for 2021. We will also be asking stockholders to approve, by an advisory vote, our 2020 executive compensation as disclosed in the Proxy Statement for the Annual Meeting (a “say-on-pay” vote). Each of these matters is important, and we urge you to vote in favor of the election of each of the director nominees, the approval of our 2017 Omnibus Incentive Plan amendment and our 2021 Employee Stock Purchase Plan, the ratification of the appointment of our independent auditor, and the approval on an advisory basis of our 2020 executive compensation.

~~Proxies are being solicited on behalf of the Board of Directors.~~ We are furnishing proxy materials to our stockholders over the Internet. This ~~e-proxy~~ process expedites ~~stockholders’ receipt~~the delivery of proxy materials to our stockholders, lowers our costs, and reduces the environmental impact of the Annual Meeting. Today we ~~sent~~are sending to ~~most~~each of our stockholders a Notice of Internet Availability of Proxy Materials containing instructions on how to access our Proxy Statement for the Annual Meeting and our ~~2019~~2020 Annual Report to Stockholders, as well as how to vote via proxy either by telephone or over the Internet. Other stockholders will receive copies of the Proxy Statement, a proxy card and the ~~2019~~2020 Annual Report by mail or e-mail. If you received a Notice of Internet Availability of Proxy Materials by mail and would like to receive a printed copy of our proxy materials, you may request those materials by following the instructions included in your Notice of Internet Availability of Proxy Material.

It is important that you vote your shares of common stock virtually or by proxy, regardless of the number of shares you own. You will find the instructions for voting on your Notice of Internet Availability of Proxy Materials and proxy card. We appreciate your prompt attention.

The Board of Directors invites you to participate in the Annual Meeting where Anika will address appropriate general questions about the business as time allows. Thank you for your support, and we look forward to joining you at the Annual Meeting.

The Board of Directors of Anika Therapeutics, Inc., a Delaware corporation (“Anika"), is soliciting proxies for use at Anika’s 2021 Annual Meeting of Stockholders being held on Wednesday, June 16, 2021, at 9:00 a.m., Eastern time (the “Annual Meeting”). You are receiving the enclosed proxy statement because you were a holder of Anika’s common stock as of 5 p.m., Eastern time, on the record date of April 20, 2021 and therefore are entitled to vote at the Annual Meeting. You may participate in the Annual Meeting, including casting votes and asking questions, by accessing a live webcast at virtualshareholdermeeting.com/ANIK2021 and entering the control number included on the Notice of Internet Availability of Proxy Materials or proxy card. Online check-in to the Annual Meeting will begin at 8:45 a.m., Eastern time, and stockholders are encouraged to allow ample time to log in to the meeting webcast and test their computer and audio system. There will be no physical location for the Annual Meeting.

Each share of common stock is entitled to one vote for each director position and other proposal. In accordance with rules of the Securities and Exchange Commission, we are providing stockholders with access to proxy materials on the Internet, instead of mailing printed copies. We are mailing to stockholders, commencing on or about April 30, 2021, a Notice of Internet Availability of Proxy Materials to provide:

Other stockholders will receive copies of the Proxy Statement, a proxy card and the 2020 Annual Report by mail or e-mail. If you received a Notice of Internet Availability of Proxy Materials by mail and would like to receive a printed copy of our proxy materials, you may request those materials by following the instructions included in the Notice of Internet Availability of Proxy Materials.

Your vote is important. Whether or not you plan to participate in the Annual Meeting, please complete and return your proxy card or vote by telephone or via the Internet by following the instructions on the Notice of Internet Availability of Proxy Materials. Returning a proxy card or otherwise submitting your proxy does not deprive you of your right to access the Annual Meeting and vote during the webcast at that time.

Anika will maintain a list of stockholders of record as of the record date at Anika’s corporate headquarters, 32 Wiggins Avenue, Bedford, Massachusetts, for a period beginning ten days prior to the Annual Meeting and ending at the close of the Annual Meeting.

Anika Therapeutics, Inc., a Delaware corporation, is furnishing this Proxy Statement and the related proxy materials in connection with the solicitation by its Board of Directors of proxies to be voted at its ~~2020~~2021 Annual Meeting of Stockholders and any postponements or adjournments thereof. Anika Therapeutics, Inc. is providing these materials to the holders of record of its common stock as of the close of business on April 20, ~~2020~~2021 and is first making available or mailing the materials on or about April ~~29, 2020.~~30, 2021.

References in this Proxy Statement to “Anika,” “we,” “us,” “our,” “our company” and similar references refer to Anika Therapeutics, Inc. and its subsidiaries, unless the context requires otherwise.

~~ANIKA, ANIKA THERAPEUTICS, MONOVISC, TACTOSET~~Anika, Anika Therapeutics, Arthrosurface, Parcus Medical, WristMotion, Hyalofast, and ~~CINGAL~~Cingal are our registered trademarks. For convenience, these registered trademarks appear in this Proxy Statement without ® symbols, but that practice does not mean we will not assert, to the fullest extent under applicable law, our rights to the registered trademarks. This Proxy Statement also contains trademarks and service marks that are the property of other companies, including certain trademarks licensed to us.

Online check-in to the Annual Meeting webcast will begin at ~~11:15~~8:45 a.m., Eastern time. We encourage you to allow ample time to log in to the meeting webcast and test your computer audio system.

These materials were first made available on the Internet or mailed to stockholders on or about April ~~29, 2020.~~30, 2021.

The Notice of Internet Availability of Proxy Materials tells you how to access and review the proxy materials on the Internet and how to vote on the Internet. The Notice also provides instructions you may follow to request paper or e-mailed copies of our proxy materials.

An organization that holds your beneficially owned shares in street name will vote in accordance with the instructions you provide. If you do not provide the organization with specific voting instructions with respect to a proposal, under the rules of the NASDAQ Stock Market, Inc., or NASDAQ, the organization’s authority to vote your shares will depend upon whether the proposal is considered a “routine” or non-routine matter.

For the purpose of determining a quorum, we will treat as present at the Annual Meeting any proxies that are voted on any of the ~~four~~five proposals to be acted upon by the stockholders, including abstentions or proxies containing broker non-votes.

If you hold shares in street name, you may vote by following the voting instructions provided by your bank, broker, or other nominee. In general, you may vote prior to the Annual Meeting as follows:

For your information, voting via the Internet is the least expensive to us, followed by telephone voting, with voting by mail being the most expensive. Also, you may help us to save the expense of a second mailing if you vote promptly.

The virtual format allows stockholders to submit questions during the meeting. We are utilizing technology from Broadridge Financial Solutions, Inc., or Broadridge, the leading virtual meeting solution. The Broadridge platform is expected to accommodate most, if not all, stockholders. Both we and Broadridge will test the platform technology before going “live” for the Annual Meeting.

If you are a beneficial owner of shares held in street name, you should contact your bank, broker, or other nominee for instructions as to whether, and how, you can change or revoke your proxy.

If you are a beneficial owner of shares held in street name and do not provide specific voting instructions to the broker, bank, or other organization that is the stockholder of record of your shares, the organization generally may not vote on some proposals. Instead, the organization will inform the inspector of election that it does not have the authority to vote on the specific matter. As a result, beneficial owners of shares held in street name that do not provide specific voting instructions may not have an effect on the outcome of certain proposals. See “Q.What does it mean for a broker or other nominee to hold shares in ‘street name’?” above.

Our company is managed under the oversight of the Board of Directors, which is led by an independent chair. The ~~Board utilizes its~~directors utilize their deep experience in business and science – including biotech, pharmaceuticals, and medical devices – as well as ~~its~~their diverse backgrounds to provide management with guidance and oversight ~~as they deliver~~in delivering innovative therapies to meet the needs of ~~our~~clinicians and the patients that they treat, and ~~execute~~in executing on our strategy for value creation.

The Board sets high standards for management and employees tied to our core values of principled and ethical behavior, and we apply those same standards to the Board, undertaking regular and rigorous reviews of ~~our~~the directors’ performance both collectively and individually. This is evidenced in our ongoing approach to Board refreshment, having added ~~three~~four of our current eight directors in the past ~~five years; two of those since the 2018 annual stockholder meeting.~~three years. The current mix of longer-serving and ~~newly-added~~recently added directors provides an appropriate balance of perspectives as ~~our~~the Board holds management accountable for delivering long-term value and keeping the interests of our stockholders and stakeholders, including clinicians and their patients, employees and business partners, at the center of our priorities.

The Board is currently comprised of ~~six~~eight directors and is divided into three classes: Class I, Class II and Class III. Each class of directors serves for a three-year term, with one class of directors being elected by our stockholders at each annual meeting. ~~Joseph Bower~~Stephen Richard and Jeffery Thompson serve as Class I Directors, with terms of office expiring at the ~~2021~~year’s Annual Meeting. Joseph Bower, who currently serves as a Class I director, will not stand for re-election at this year’s Annual Meeting. Cheryl Blanchard, Raymond Land and Glenn Larsen serve as Class II Directors, with terms of office expiring at the 2022 Annual Meeting. Susan N. Vogt ~~serves~~and John Henneman serve as Class III ~~Director,~~Directors, with ~~a term~~terms of office expiring at ~~this year’s~~the 2023 Annual Meeting.

~~Ms. Vogt is~~Messrs. Richard and Thompson are the Board’s ~~nominee~~nominees for election to the Board at the Annual Meeting. ~~The~~Each Class ~~III~~I Director will be elected to hold office until the ~~2023~~2024 Annual Meeting and until ~~her~~his successor is duly elected and qualified. Unless otherwise instructed, the persons named in the accompanying proxy will vote, as permitted by our bylaws, to elect ~~Ms. Vogt~~Messrs. Richard and Thompson as the Class ~~III Director.~~I Directors. If ~~Ms. Vogt~~either Mr. Richard or Mr. Thompson becomes unavailable or declines to serve, the persons acting under the accompanying proxy may vote the proxy for the election of a substitute in their discretion. The Board has no reason to believe that ~~Ms. Vogt~~either Mr. Richard or Mr. Thompson will be unable or unwilling to serve if elected.

There are no arrangements or understandings between any nominee and any other person pursuant to which the nominee was selected.

At the Annual Meeting, the election of a director requires the affirmative vote of a majority of the shares of common stock that are voting in the election of directors, meaning that, to be elected, the shares voted “FOR” a nominee must exceed the number ~~“WITHHELD” from~~of shares voted “AGAINST” that nominee. Abstentions and ~~broker~~Broker non-votes will not be treated as votes cast and will have no impact on the proposal. Under our Majority Voting in Uncontested Director Elections Policy, if a director receives a greater number of votes “against” than “for” election, the director must promptly offer the director’s resignation for consideration by the Governance and Nominating Committee. Please see the section captioned “Majority Voting in Uncontested Director Elections Policy” for more details on this policy and its impact on the election of director nominees.

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE ELECTION OF ~~SUSAN N. VOGT,~~EACH OF STEPHEN O. RICHARD AND JEFFERY S. THOMPSON, THE DIRECTOR ~~NOMINEE.~~

The following table sets forth the name of ~~each~~our current ~~director, including~~directors, and includes the ~~nominee~~nominees for ~~Class III Director,~~re-election as directors at the Annual Meeting, together with ~~his or her age~~their ages (as of the record date) and the ~~year~~years in which ~~he or she~~they became a director. As noted elsewhere, Dr. Bower will not stand for re-election at the Annual Meeting.

Other Public Company Board Service

~~Other Public Company Board Service~~
·	~~Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on products for psychiatric disorders, since February 2019~~
·	Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health, since November 2019

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on products for psychiatric disorders, from February 2019 to June 2020

Other Public Company Board Service

Aprea Therapeutics Inc. (NASDAQ:APRE), a biotechnology company focused on novel cancer therapeutics, since August 2019 (lead independent director since September 2020)

	·	R1 RCM, Inc. (NASDAQ:RCM), a provider of revenue cycle management services to healthcare providers, since February 2016
	·	~~Loews~~SeaSpine Holdings Corporation ~~(NYSE: L)~~(NASDAQ:SPNE), a ~~multi-industry holding company with businesses in the insurance, energy, hospitality~~spinal implant and ~~packaging industries, since 2001~~
·	~~The New America High Income Fund, Inc. (NYSE: HYB), a diversified, closed-end investment~~orthobiologics company, since ~~1988~~July 2015

Education

~~Education~~
·	Ph.D. and M.S. in Materials Science and Engineering from the University of Texas-Austin
	·	B.S. in Ceramic Engineering from Alfred University

Education

~~Education~~	·	J.D. from University of Michigan Law School
	·	~~D.B.A., M.B.A. and B.A.~~A.B. in Politics from ~~Harvard~~Princeton University

Relevant Skills

~~Relevant Skills~~
·	~~Private and public company CEO experience~~
·	Strong scientific background in biologics and regenerative medicine Industry

	·	Extensive experience in management, including as a CEO, business development and developing and commercializing medical device and regenerative medicine and drug delivery products at multiple companies in the life science industry
	·	Significant experience in innovative research and product development

Relevant Skills

~~Relevant Skills~~
·	More than ~~five decades~~25 years of senior management experience ~~teaching at Harvard Business School, with an emphasis~~in the medical technology and biotechnology industries

	·	Significant experience in serving on ~~corporate management, organization and leadership~~boards of directors, including boards of publicly held life science companies
	·	Extensive experience ~~consulting with numerous organizations on matters related to~~in the areas of finance, financial accounting, business ~~strategy, organizational development~~transactions, law, and ~~succession planning~~
·	~~Expertise in advising boards on fulfilling their oversight responsibilities~~mergers and ~~other corporate governance issues, based on book and article authorship and more than thirty years of public company board experience~~acquisitions

1416

Raymond J. Land

Anika Board Service:

· Tenure: 1415 years

· Committees:

○ Audit (Chair, Financial Expert)

○ ~~Governance and Nominating~~Compensation

~~INDEPENDE~~INDEPENDENTNT

Age: 7576

Professional Experience

~~Professional Experience~~
·	Director since January 2006

Retired Certified Public Accountant

Interim Chief Financial Officer of BioAmber Inc., a developer of chemicals from renewable feedstocks, for three months during 2017

Senior Vice President and Chief Financial Officer of Clarient, Inc., an advanced molecular diagnostics company, from 2008 until his retirement in 2010

Senior Vice President and Chief Financial Officer of Safeguard Scientifics, Inc., a venture capital firm, from 2007 to 2008

Executive Vice President and Chief Financial Officer of Medcenter Solutions, Inc., a pharmaceutical marketing company, during 2006

Senior Vice President and Chief Financial Officer of Orchid Cellmark, a DNA testing company, from 2005 to 2006

Senior Vice President and Chief Financial Officer of Genencor International, Inc., a biotechnology company focusing on bioproducts and healthcare, from 1997 until its acquisition in 2005

Other Public Company Board Service

~~Other Public Company Board Service~~
·	BioAmber Inc. (OTC:BIOAQ), a developer of chemicals from renewable feedstocks, from 2011 and chairman from 2012 through July 2018

Glenn R. Larsen, Ph.D.

Anika Board Service

· Tenure: 56 years

· Committees:

○ Compensation

○ Governance and Nominating

~~INDEPENDE~~INDEPENDENTNT

Age: 6667

Professional Experience

~~Professional Experience~~
·	Director since February 2015

Chairman, President, Chief Executive Officer and co-founder of Aquinnah Pharmaceuticals, Inc., a pharmaceutical company focused on the development of treatments for ALS, Alzheimer’s and other neurodegenerative diseases, since February 2014

Chairman, ~~of the Board~~President, and ~~co-founder~~Chief Executive Officer of 180 Therapeutics L.P., a clinical stage musculoskeletal drug development company, ~~focusing on treating fibrosis, since~~from 2013 until its merger with NASDAQ-listed 180 LifeSciences in 2020.

Chief Scientific Officer and Executive Vice President of Research and Development of SpringLeaf Therapeutics, Inc., a producer of combination drug delivery devices, from 2010 to 2013

	·	Chief Operating Officer, Executive Vice President of Research and Development and director of Hydra Biosciences, Inc., a biopharmaceutical company focused on developing pain therapeutic drugs, from 2003 to 2010
	·	Series of drug discovery and development leadership positions, including Vice President Musculoskeletal Sciences, at Wyeth (now Pfizer)/Genetics Institute, where he directed Wyeth’s second-largest therapeutic area with responsibility for Enbrel, an anti-TNF therapeutic for arthritic pain with multi-billion dollar annual sales, and the development of Infuse Bone Graft, the 1^st regenerative biologic medicine approved for numerous orthopedic bone regeneration indications

Education

~~Education~~
·	B.S. in accounting and finance from Temple University

Education

~~Education~~
·	Ph.D. in Biochemistry from Stony Brook University
	·	P.M.D. from Harvard University

Relevant Skills

~~Relevant Skills~~
·	Education, training and experience in accounting and finance, including as Certified Public Accountant

	·	More than 35 years of experience as chief financial officer and other senior accounting and finance roles at multiple companies, including several in the life science industry
	·	Transactional experience in merger and acquisitions and financings

Relevant Skills

~~Relevant Skills~~
·	Strong scientific background in pharmaceuticals, biotech, orthopedics, pain management and regenerative medicine

	·	Extensive experience in management, product development and business development at multiple companies in the life science industry
	·	Significant experience in innovative research and product development and commercial development

1517

Stephen O. Richard

Anika Board Service

· Tenure: 0.5 years

· Committees:

○ Audit (Financial Expert)

INDEPENDENT

Age: 58

Professional Experience

Director since September 2020

Senior Vice President, Chief Risk Officer since May 2019 and Chief Audit Executive since 2016 of Becton, Dickinson and Company, a medical technology company

	·	Various offices in the areas of finance, operations and business development of the National Basketball Association organization from 1998 to 2016, including Senior Vice President, Business Development and Global Operations of NBA Properties, Inc. from 2013 to 2016, Chief Financial Officer of NBA China from 2010 to 2013 and Interim Chief Executive Officer of NBA China from 2010 to 2011
	·	Earlier in his career, Mr. Richard served as, among other positions, Regional Audit Director, U.S. Consumer Businesses at Citigroup Inc., District Manager, Financial Planning and Analysis at AT&T Corporation, and Senior Manager at Deloitte & Touche LLP

Jeffery S. Thompson

Anika Board Service

· Tenure: 910 years

· ~~Committees:~~

○ ~~Audit~~

○ ~~Compensation~~

○ ~~Governance and Nominating (Chair)~~Chair of the Board

~~INDEPENDE~~INDEPENDENTNT

Age: 5455

Professional Experience

~~Professional Experience~~
·	Director since January 2011

Partner with HealthEdge Investment Partners, LLC, or HealthEdge, a private equity firm providing strategic capital exclusively to the healthcare industry, since 2008, where he sits on the investment team and serves as a director for numerous HealthEdge affiliated companies, including ITRACs, Legacy Xspire Holdings, LifeSync and Westone

Previously, Chairman, Chief Executive Officer and President of Advanced Bio-Technologies, Inc. and Enaltus LLC, both HealthEdge portfolio company specializing in skincare solutions sold to consumers and direct to physicians from 2008 to 2017

Non-executive director of Sinclair Pharma, plc, a publicly traded international aesthetic dermatology company from September 2014 until its acquisition by China Grand in November 2018

	·	Director of Stiefel Laboratories, Inc., an independent pharmaceutical company specializing in dermatology, and President of Glades Pharmaceuticals, both of which were sold to GlaxoSmithKline in 2008
	·	Earlier in his career, Mr. Thompson held sales and business management positions at Bausch & Lomb Pharmaceuticals and SmithKline Beecham

Education

	·	M.B.A. in Finance from Columbia Business School.
	·	B.S. in Accounting from Northeastern University

Education

B.S. in General Science from University of Pittsburgh

Relevant Skills

	·	Education, training and experience in accounting and finance, reflected in status as a Certified Public Accountant, multiple senior accounting roles and the Chairman of the Committee on Governance, Risk and Compliance of Financial Executives International, an association of financial executives serving public and private companies
	·	Significant senior management experience, including in the medical technology industry

Relevant Skills

Extensive experience serving on boards of directors of numerous life sciences, biotechnology, and healthcare services companies

	·	Significant experience as chief executive officer of life sciences and healthcare services companies
	·	More than a decade of experience advising HealthEdge portfolio and other life science companies on business development strategies and transactions

Susan N. Vogt

Anika Board Service:

· Tenure: ~~1.5~~2.5 years

· Committees:

o○ Audit (Financial Expert)

o ~~Compensation~~

o○ Governance and Nominating (Chair)

~~INDEPENDE~~INDEPENDENTNT

Age: 6667

Professional Experience

~~Professional Experience~~
·	Director since October 2018

Chief Executive Officer and President of Aushon Biosystems, Inc., a developer of a multiplex immunoassay platform, from 2013 until its acquisition in January 2018

Chief Executive Officer, President, and a director of SeraCare Life Sciences, Inc., a NASDAQ-listed life sciences developer of products facilitating human diagnostics and therapeutics, from 2006 to 2011

Former director of Andor Technology (LSE:AND) from 2010 to 2013

From 1981 to 2005, various management and officer positions at Millipore Corporation (now part of MilliporeSigma, the life science business of Merck KGaA), an NYSE-listed developer of technologies for life science research, drug development and manufacturing for the biotechnology and pharmaceutical industries, including, among other leadership roles, President of the Biopharmaceutical Division, Vice President and General Manager of the Laboratory Water Division, Vice President and General Manager of the Analytical Products ~~Division, Vice President and General Manager of the Analytical Division, Vice President of Marketing and Research & Development of the Analytical Division~~,~~and Finance Manager, Division Controller~~Division.

Other Public Company Board Service


~~Other Public Company Board Service~~
·	Sharps Compliance, Inc. (NASDAQ: SMED) a leading full-service national provider of comprehensive waste management services, including medical, pharmaceutical, and hazardous, since October 2019

~~Education~~
·	~~B.S. in General Science from University~~Charlotte’s Web Holdings, Inc. (TSX: CWEB) a leading provider of ~~Pittsburgh~~CBD wellness products, since September 2020

Education

~~Education~~
·	M.B.A. from Boston University, concentration in Finance
	·	A.B. in Art History from Brown University

Relevant Skills

~~Relevant Skills~~
·	~~Extensive experience serving on boards of directors of numerous biotechnology and medical device companies~~
·	~~Significant experience as chief executive officer of life science companies~~
·	~~More than a decade of experience advising HealthEdge portfolio and other life science companies on business development strategies and transactions~~

~~Relevant Skills~~
·	More than thirty-five years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics industries

	·	Proven record of driving operational efficiency and productivity, successfully scaling commercial operations, enhancing profitability by streamlining, restructuring and consolidating operations, and delivering sustained revenue and cash flow growth at multiple companies
	·	Deep understanding of finance and accounting as a result of her education, financial-based roles during her career and serving on audit committees of several companies

1619

Governance of the Company

Board’s Role in Risk Oversight

The role of the Board of Directors in our risk oversight process includes receiving reports from management and the Chairs of Board committees on areas of material risk to our company, including operational, financial, commercial, legal, regulatory, strategic, and reputational risks. The Board has delegated primary responsibility to the Audit Committee to review these reports and discuss with management the process by which management assesses and manages our risk exposure, risk management, and risk mitigation strategies. The Audit Committee also works with other committees to assess areas of risk under the particular purview of those committees. When the Audit Committee receives a report from management or another committee, the Chair of the Audit Committee reviews the report and then summarizes the review results in a presentation to the full Board. This enables the Board and its committees to coordinate the risk oversight role to ensure that all directors receive all significant risk-related information. The Board also administers its risk oversight function through the required approval by the Board (or a committee of the Board) of significant transactions and other material decisions and through regular periodic reports from our independent registered public accounting firm and other outside consultants regarding various areas of potential risk, including, among others, those relating to our internal controls and financial reporting. In addition, as part of its charter, the Audit Committee discusses with management and our independent registered public accounting firm significant risks and exposures, as well as the steps management has taken to minimize those risks.

Board’s Increased Involvement due to COVID-19 and Executive Team Changes

In 2020, the Board made it a priority to oversee and support the company’s management and thereby manage risk following the onset of the COVID-19 pandemic. The COVID-19 pandemic impacted not just our employees and our traditional operations, but also significantly impacted our business as many of the medical procedures in which our products are used were either cancelled or delayed due to global quarantine orders or other shut-downs of healthcare facilities. The Board’s oversight and frequent involvement with management during 2020 was especially important in light of our acquisitions of Parcus Medical and Arthrosurface early in the year and the changes in our executive management team throughout the year, including the appointment of Dr. Cheryl Blanchard as our President and Chief Executive Officer following the unexpected passing of Joseph Darling in January 2020. The Board’s increased involvement took the form of additional meetings with the executive management team held on a more frequent basis than was its historical practice, including bi-weekly meetings for a number of months during the spring, to review and discuss steps that management was taking to support employee health and safety and to review business progress reports, bi-weekly financial updates and projections, and other strategic responses to the COVID-19 pandemic.

Board Leadership Structure

~~Joseph Bower~~Jeffery Thompson has served as the Chair of the Board since ~~March 2018. Dr. Bower previously served as lead director when the Board of Directors did not have a Chair.~~September 2020. Separating the roles of Chair and Chief Executive Officer allows our Chief Executive Officer to focus on the strategic management of our day-to-day business, while allowing the Chair to focus on leading the Board of Directors in its fundamental role of providing advice to, and independently overseeing, management. The Board recognizes the time, effort, and energy that the Chief Executive Officer is required to devote to the position in the current business environment, as well as the commitment required to serve as our Chair, particularly as the Board’s oversight responsibilities continue to grow. The Board believes that having separate positions, with an independent, non-executive director serving as the Chair, is the appropriate leadership structure for our company at this time and allows the Board to fulfill its role with appropriate independence.

Corporate Governance and Board Matters

The Board of Directors annually reviews the independence of all non-employee directors. In April 2020, the Board established categorical standards consistent with the corporate governance standards of Nasdaq to assist the Board in making determinations of the independence of Board members. A copy of our Standards for Director Independence, which was adopted by the Board in April 2020, is available on the investor relations portion of ~~Anika’s~~our website athttps://ir.anikatherapeutics.com/corporate-governance. These categorical standards require that, to be independent, a director may not have a material relationship with our company. Even if a director meets all categorical standards for independence, the Board reviews other relationships with Anika in order to conclude that each independent director has no material relationship with ~~the company~~Anika either directly or indirectly.

The Board ~~of Directors~~ has determined that each of its members, ~~except for~~including the director nominees, but excluding our President and Chief Executive Officer Cheryl R. Blanchard, ~~Ph.D.,~~ is “independent” within the meaning of the director independence standards of NASDAQ and the SEC. The Board based these determinations primarily on a review of the responses of each director to questions regarding employment and compensation history, affiliations, and family and other relationships, and on other relevant discussions with the directors.

Independent directors meet regularly in executive sessions without management participation. The executive sessions generally occur in connection with regularly scheduled meetings of the Board and committees of the Board, and at other times the independent directors deem appropriate. The executive sessions are chaired either by the Chair of the Board or by the ~~Chair~~chair of the Board committee having jurisdiction over the particular subject matter to be discussed at the particular meeting or portion of a meeting.

The Board reviews matters related to our corporate governance annually at a regularly scheduled meeting of the Board. This includes an evaluation of our bylaws, committee charters, diversity programs, corporate social responsibility initiatives, and other matters related to our governance. During this review, the Board assesses input from management and outside consultants to discern whether any actions should be taken on any of these topics. Furthermore, the Board conducts periodic evaluations that focus on the effectiveness of the Board as a whole and of its committees. Board members complete a detailed questionnaire that provides for quantitative rankings in key areas and seeks subjective comments in each of those areas. In addition, members of each Board committee complete a detailed questionnaire to evaluate how well their committee is operating and to make suggestions for improvement. The evaluation process is managed by the Chair of the Governance and Nominating Committee, with advice from outside counsel. Outside counsel ~~conducts~~may conduct separate, confidential interviews with ~~each~~some or all of the directors to follow-up on responses and comments reflected in the ~~questionnaires.~~questionnaires to the extent it is determined helpful or necessary. An anonymized summary of the principal findings from the ~~questionnaires and interviews~~evaluation process is prepared by outside counsel and is used as the basis for self-assessment discussions by the Board and its committees.

The Board met ~~ten~~23 times during ~~2019.~~2020. No director attended less than ~~80%~~90% of the total number of Board meetings during the director’s term. As described elsewhere in this Proxy Statement, the Board made it a priority to oversee and support the executive management team following the onset of the COVID-19 pandemic, including through bi-weekly meetings with key executive members for a number of months during the spring. The Board placed great importance on taking this approach in light of our ongoing company transformation following our early 2020 acquisitions of Parcus Medical and Arthrosurface and the changes in our management team, including the appointment of Dr. Cheryl Blanchard as President and Chief Executive Officer. In these meetings, the Board focused on key business updates, regular financial updates, including monitoring our liquidity and cash position, and providing support to the management team to ensure an appropriate and well-measured response to the COVID-19 pandemic. The key goal, which we believe was achieved, was to support employee health and safety, while avoiding significant operational disruptions to the business.

Our Annual Meetings of Stockholders are generally held to coincide with one of the Board’s regular quarterly meetings. Although we have no formal policy requiring attendance, directors are encouraged to attend Annual Meetings of Stockholders. Each of the then-serving or nominated directors attended the ~~2019~~2020 Annual ~~Meeting of Stockholders.~~Meeting.

Board Committees

The Board of Directors currently has three standing committees:

Audit Committee;

Compensation Committee; and

Governance and Nominating Committee.

The membership of each standing committees was as follows as of April 20, ~~2020:~~2021:

	~~Committee~~
Director	~~Audit~~			~~Compensation~~	~~Governance and~~ ~~Nominating~~Committee	Independent Under SEC Rules	Financial Expert Under SEC Rules
Director	Audit	Compensation	Governance and Nominating			Independent Under SEC Rules	Financial Expert Under SEC Rules
Joseph L. Bower	✓	Chair		✓
John B. Henneman III		✓	✓	✓
Raymond J. Land	Chair	✓	✓	✓	✓
Glenn R. Larsen		✓	✓	✓
Stephen O. Richard	✓			✓	✓
Jeffery S. Thompson	✓	✓	~~Chair~~	✓
Susan N. Vogt	✓	✓	✓Chair	✓	✓

The Board has adopted a written charter for each standing committee, which is reviewed yearly by that committee. You can find these charters on the investor relations portion of ~~Anika’s~~our website athttps://ir.anikatherapeutics.com/corporate-governance. The information contained on the website is not incorporated by reference in, or considered to be a part of, this Proxy Statement.

1822

Audit Committee

Role and Key Responsibilities

ü	Overseeing accounting and financial reporting processes
ü	Overseeing audits of our financial statements and internal controls
ü	Taking, or recommending that the Board of Directors take, appropriate action to oversee the qualifications, independence and performance of our independent registered public accounting firm
ü	Leading the review of our risk management processes and exposure to risk
ü	Preparing an Audit Committee report, as required by the SEC, for inclusion in our annual Proxy Statement
ü	Selecting, retaining, overseeing, and, when appropriate, terminating our independent registered public accounting firm
ü	Conferring with the independent registered public accounting firm and reporting to the Board regarding the scope, method, and result of the audit of our books and records
ü	Reviewing and discussing proposed earnings press releases and financial information and guidance proposed to be provided to ~~analysts~~investors
ü	Establishing, overseeing and periodically reviewing procedures for complaints regarding accounting or auditing matters
ü	Establishing and monitoring a policy relative to non-audit services provided by the independent registered public accounting firm in order to ensure the firm’s independence

The Audit Committee held 5 meetings in ~~2019.~~2020. No member attended less than ~~80%~~90% of the total number of Audit Committee meetings held while the member served on the Audit Committee. The Audit Committee holds separate sessions of its meetings, outside the presence of management, with our independent auditor in conjunction with each regularly scheduled Audit Committee meeting in which the independent auditor participates. During ~~2019,~~2020, the Audit Committee met privately with our management ~~on 5 occasions~~ and held 3 executive sessions with only non-employee directors in ~~attendance.~~attendance as appropriate. No director is eligible to serve on the Audit Committee if that director simultaneously serves on the audit committees of ~~three~~four or more other public companies.

The current members of the Audit Committee are ~~Joseph Bower,~~ Raymond Land, who serves as Chair, ~~Jeffery Thompson~~Stephen Richard and Susan Vogt. The Board has determined that each member is independent, as defined for purposes of the SEC and NASDAQ, is financially literate, and has the requisite financial sophistication to serve on the Audit Committee. The Board has also determined that each ~~of Mr. Land and Ms. Vogt qualify~~member qualifies under SEC rules as an “audit committee financial expert,” which designation is an SEC disclosure requirement related to ~~Mr. Land’s and Ms. Vogt’s~~their experience and understanding of certain accounting and auditing matters. The designation does not impose upon ~~Mr. Land or Ms. Vogt~~any of the three members any duties, obligations, or liabilities that are greater than those otherwise imposed on them as members of the Audit Committee and the Board, and their designation as an audit committee financial expert pursuant to this SEC requirement does not affect the duties, obligations or liabilities of any other member of the Audit Committee or the Board.

1923

Compensation Committee

Role and Key Responsibilities

ü	Managing our overall compensation philosophy, structure, policies, processes, procedures, and programs
ü	Reviewing and approving corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other executive officers
ü	Reviewing the performance of and determining the compensation of the Chief Executive Officer
ü	Reviewing the performance of and determining, with the advice and assistance of the Chief Executive Officer, the compensation of our executive officers other than the Chief Executive Officer
ü	Annually reviewing and recommending to the Board of Directors compensation for non-employee directors
ü	Overseeing our overall compensation programs, including the granting of awards under our omnibus incentive plan
ü	Preparing a report on executive compensation for inclusion in our annual Proxy Statement
ü	Reviewing, discussing with management and any compensation consultant, and recommending the inclusion of disclosures under “Compensation Discussion and Analysis” in our Proxy Statement
ü	Periodically conducting a risk assessment to evaluate whether forms of pay encourage unnecessary or excessive risk taking and assisting the Audit Committee in assessing and managing potential risks created by our compensation practices, policies and programs
ü	Reviewing, approving, recommending to the Board for approval, and considering the results of stockholder advisory ~~“say on pay”~~“say-on-pay” and ~~“say on frequency”~~“say-on-frequency” votes and reviewing and recommending to the Board whether to submit a stockholder advisory vote on certain acquisition-related compensation arrangements
ü	Appointing, retaining, compensating, terminating, and overseeing the work of any compensation consultant or other compensation adviser, as well as considering the independence of any compensation consultant or other compensation adviser

The Compensation Committee held 516 meetings in ~~2019.~~2020. No member attended less than ~~80%~~90% of the total number of Compensation Committee meetings held while the member served on the Compensation Committee. During ~~2019~~2020, the Compensation Committee held 5 executive sessions with only non-employee directors in ~~attendance.~~attendance as appropriate, including when evaluating the performance of Dr. Cheryl Blanchard. In 2020, the number of Compensation Committee meetings exceeded historical practice, largely in response to changes to our executive management team and the COVID-19 pandemic. The Compensation Committee was engaged in significant discussions, including with its independent compensation consultant, regarding the compensation of Dr. Blanchard in relation to her appointments as our interim Chief Executive Officer, and then as our President and Chief Executive Officer, as well as that of David Colleran and Michael Levitz in relation to their appointments to our executive management team. In addition, the Compensation Committee met multiple times to monitor and discuss the impact of the COVID-19 pandemic and its impact on our organization, especially in light of the cancellation or delay of many clinical procedures and the impacts of the pandemic and global quarantine orders were having on the company’s clinical trials, to ensure that there continued to be strong engagement and appropriate incentivization for our employee base. The Compensation Committee also used these meetings, in certain cases, to send messages to the company’s employees through the executive management team in support of their engagement and efforts to continue to design, manufacture, support, market, and sell our medical products in spite of the difficult environment created by COVID-19, and to provide assurances and comfort around our compensation program and plans.

The current members of the Compensation Committee are Joseph Bower, who serves as Chair, John Henneman, Raymond Land, and Glenn ~~Larsen, Jeffery Thompson, and Susan Vogt.~~Larsen. The Board has determined that each current member of the Compensation Committee is independent, as defined in the listing standards of NASDAQ.

2024

Governance and Nominating Committee

Role and Key Responsibilities

ü	Recommending to the Board of Directors the criteria for Board and committee membership
ü	Identifying, evaluating, and recommending nominees to stand for election as directors at each Annual Meeting of Stockholders, including incumbent directors and candidates recommended by stockholders
ü	Developing succession plans for the Board, the Chief Executive Officer and other executives
ü	Coordinating performance evaluations of the Board and its standing committees
ü	Recommending to the Board assignments of directors to each Board committee and monitoring compliance with Board and committee membership criteria
ü	Overseeing and administering Board education programs
ü	Overseeing corporate governance affairs of the Board and our company

The Governance and Nominating Committee held 67 meetings in ~~2019.~~2020. No member attended less than ~~80%~~90% of the total number of Governance and Nominating Committee meetings held while the member served on the Governance and Nominating Committee. During ~~2019~~2020, the Governance and Nominating Committee held 1 executive ~~session~~sessions with only non-employee directors in ~~attendance.~~attendance as appropriate. In 2020, the Governance and Nominating committee focused on the creation and oversight of the process to replace our Chief Executive Officer following the passing of Mr. Darling, as well as the activities required to identify, recruit, and onboard our new directors, Mr. Henneman and Mr. Richard.

The current members of the Governance and Nominating Committee are ~~Raymond Land,~~John Henneman, Glenn Larsen, ~~Jeffery Thompson,~~and Susan Vogt, who serves as ~~Chair, and Susan Vogt.~~Chair. The Board has determined that each current member of the Governance and Nominating Committee is independent, as defined in the listing standards of NASDAQ.

Board Membership Qualifications and Procedures

When considering candidates for director, the Governance and Nominating Committee takes into account a number of factors, including the following minimum qualifications: the nominee (a) shall have the highest personal and professional integrity, (b) shall have demonstrated exceptional ability and judgment, and (c) shall be most effective, in conjunction with the other members of the Board of Directors, in collectively serving the long-term interests of the stockholders. In addition, the Governance and Nominating Committee will take into consideration such other factors as it deems appropriate, including any direct experience in the biotechnology, pharmaceutical, medical device, and/or life sciences industries, or in the markets in which we operate. The Governance and Nominating Committee may also consider, among other things, the skills of the candidate, his or her availability, the candidate’s depth and breadth of experience or other background characteristics, and his or her independence.

In addition to the considerations above, the Board strongly believes that diversity is an important component of a ~~Board~~successful and effective board of ~~Directors~~directors and good corporate governance, including diversity of background, skills, experience, gender, race, and ethnicity. ~~Although we do not have a formal diversity policy, the~~The Governance and Nominating Committee, guided by its charter, assesses and considers the diversity of the Board prior to nominating candidates and seeks to identify director candidates who will enhance the Board’s overall diversity. The Governance and Nominating Committee and the Board select candidates on the basis of qualifications and experience without discriminating on the basis of race, color, national origin, gender, sex, sexual preference, or religion. Accordingly, ~~although we do not have a formal policy,~~ it is the practice of the Governance and Nominating Committee to include, and we request that the search firms we engage include, women and minority or underrepresented candidates in ~~the~~any pool from which the Governance and Nominating Committee selects director candidates. We believe that our current Board members collectively ~~possess~~reflect diverse knowledge, expertise, and experience in the disciplines that impact our business.

2125

Our bylaws include a procedure that stockholders must follow ~~in order~~ to nominate a person for election as a director at an annual meeting of stockholders. The bylaws require that timely notice of the nomination in proper written form, including all required information as specified in the bylaws, be mailed to the Governance and Nominating Committee in care of our Chief Executive Officer, Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730. A copy of our bylaws can be viewed on the investor relations portion of ~~Anika’s~~our website athttps://ir.anikatherapeutics.com/corporate-governance. The Governance and Nominating Committee will consider director nominees recommended by stockholders in accordance with ~~our~~the Anika Therapeutics, Inc. Policy and Procedures for Stockholder Nominations to the Board adopted by the Governance and Nominating Committee and approved by the Board in April 2020, a copy of which is available on the investor relations portion of ~~Anika’s~~our website athttps://ir.anikatherapeutics.com/corporate-governance. Recommendations should be submitted to our Secretary in writing at Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730, along with additional required information about the nominee and the stockholder making the recommendation. Information on qualifications for nominations to the Board and procedures for stockholder nominations to the Board is included below under “Proposal 1. Election of Directors—Board Membership Qualifications and Procedures” and “Stockholder Proposals.” The Governance and Nominating Committee may solicit recommendations for candidates for directors from non-management directors, the Chief Executive Officer, other executive officers, third-party search firms, and such other sources as it deems appropriate, including stockholders. The Governance and Nominating Committee will review and evaluate the qualifications of all such proposed candidates in the same manner and without regard to the source of the recommendation.

Communications with Directors

~~At Anika, our~~Our directors seek input from a wide variety of sources to inform their ~~work. This includes input~~work, including from ~~shareholders.~~stockholders. The Board of Directors welcomes ~~shareholder~~stockholder input via voting, via participating in our ~~annual meetings,~~Annual Meetings of Stockholders, via our ~~shareholder~~stockholder engagement program, and, more formally, via mail. If you wish to communicate with any of our directors or the Board ~~of Directors~~ as a group, you may do so by writing to the individual director or to the Board, in care of our Chief Executive Officer, Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730. We recommend that all correspondence be sent via certified U.S. mail, return receipt requested. All correspondence received by the Chief Executive Officer will be forwarded promptly to the appropriate addressee.

2226

Code of Business Conduct and Ethics

It is our policy that all of our officers, directors, and employees worldwide conduct our business in an honest and ethical manner and in compliance with all applicable laws and regulations. The Board of Directors has adopted the Anika Therapeutics, Inc. Code of Business Conduct and Ethics ~~in order~~ to clarify, disseminate, and enforce this policy. The Code of Business Conduct and Ethics applies to all of our officers, directors, and employees worldwide, including our Chief Executive Officer and Chief Financial Officer. The Code of Business Conduct and Ethics can be viewed on the investor relations portion of ~~Anika’s~~our website athttps://ir.anikatherapeutics.com/corporate-governance. Please note that the information contained on the website is not incorporated by reference in, or considered to be part of, this Proxy Statement.

~~Corporate Social Responsibility~~Commitment to Compliance

We are committed to maintaining a strong culture of compliance across our entire organization. We believe that a workplace with a culture of “do the right thing,” guided by high standards and comprehensive policies, is the bedrock of our success as a healthcare company and our ability to deliver life-changing solutions to the customers we serve and all of the patients they treat around the world. As part of setting this culture and maintaining a strong tone at the top, the following quote from our President and Chief Executive Officer, Dr. Blanchard, is included in our strategic plan as presented to the Board and at the beginning of each individual and annual compliance training session:

“At Anika, a commitment to ethics and quality, as realized and demonstrated through personal integrity and accountability, forms the basis for everything we do and forges the path to all that we can achieve. These foundational tenets of our company are non-negotiable and do not take a day off.”

In addition, in 2020, in conjunction with the acquisitions of Parcus Medical and Arthrosurface and the expansion of our commercial infrastructure in the United States, and with the support of the Board, we substantially expanded our company-wide Compliance Program focused on healthcare fraud and abuse, anti-kickback, and foreign corrupt practices act regulations, among others, and instituted more robust processes to ensure that appropriate controls are in place for compliance with these laws and regulations.

Corporate Social Responsibility – Environmental Sustainability, Social, and Governance Matters

We are committed to good corporate citizenship and to creating a sustainable and diverse workplace, while ensuring ~~it operates~~we operate with the highest standards of quality, ethics, and corporate governance. ~~The company has~~

We maintain a global Health, Safety, and Environment (HSE) policy to make good on our commitment to the health and safety of our employees and the protection of the environment. Key principles of this policy include, among others, maintaining a goal of zero workplace injuries or accidents, proactively integrating HSE considerations into all business activities, and minimizing the environmental impact of our operations. We have a broad range of environmental practices focused on reducing ~~its~~our consumption of energy, water, and natural resources and minimizing ~~its~~our production of waste. We have implemented material recycling, ozone depleting substance, heat recovery, and efficient lighting programs to better our environmental footprint.

As a result of the COVID-19 pandemic, we immediately implemented a cross-functional COVID-19 task force to provide senior leadership with guidance and recommendations to ensure an appropriate response to the pandemic and promote health and safety for our employees worldwide. We established strict safety policies and protocols, and we regularly update our employees with respect to any changes. We transitioned much of our administrative workforce to work remotely to protect the health of those who must be onsite to perform their jobs, including our manufacturing staff, and we have adjusted attendance policies to encourage those who may be ill to stay home. We have provided an abundance of personal protective equipment and cleaning supplies, including sending a COVID-19 care package including multiple masks, face shields, hand sanitizer, and other personal protective equipment to all of our employees to support them and their families when there were shortages of certain of these items. We require masks to be worn in our facilities and initially prohibited all non-essential domestic and international travel for all employees, though we have relaxed that restriction for certain personnel as travel carriers have developed additional safety protocols and vaccinations have become more prevalent. We have also provided general information updates and support for our employees to ensure that they have resources and information to protect their health and that of those around them, including their families and co-workers. In conjunction with certain of our partners, we also donated personal protection equipment and other supplies to frontline healthcare workers as part of our COVID-19 response.

We are dedicated to attracting and retaining highly talented people, fostering a diverse and inclusive workforce, and providing a safe and healthy work environment for our employees. We have a strong employee wellness program that includes both on- and off-site activities aimed at keeping our employees active. We collaborate with multiple charitable organizations and educational institutions to ensure that we give back to the communities that support us, including through grants to universities and other charitable organizations. ~~In conjunction with certain of~~For additional information about how we view and support our ~~partners, we also donated personal protection equipment and other supplies to frontline healthcare workers as part of our COVID-19 response.~~ workforce, please see the following section, Human Capital Management.

We are dedicated to strong governance practices as can be seen through ~~our refreshment~~the recent changes we have made to the Board of ~~the Board~~Directors and its diversity, as well our commitment to appropriate risk management strategies and corporate ~~policies.~~policies, as are described in more detail throughout this Proxy Statement. Our commitments to diversity and sustainability are designed to make us a best-in-class business with efficient processes and operations, and we believe that these values can also be key drivers of ~~company~~our company’s success and growth, and increase stockholder return over the long-term.

Human Capital Management

We believe that a diverse, talented, and inclusive workplace is a central aspect to our culture and increases employee engagement, innovation, operational excellence, and overall individual and company performance. In turn, this culture and drive for performance helps us attract and retain qualified employees and key talent. Our culture is centered around our fundamental values of:

	·	People: We engage and invest in each other in a community that values diversity and inclusion.
	·	Innovation: We are agile and entrepreneurial in developing and delivering meaningful solutions to our healthcare stakeholders within our target markets.
	·	Quality: We strive for the highest quality and compliance in everything we do.
	·	Teamwork: We operate with mutual respect and trust and are collaborative as we grow together.
	·	Integrity: We live up to our promises and do the right thing, every day.
	·	Accountability: We are empowered and accountable to deliver results and value to all of our stakeholders.

We substantially increased our employee base in 2020 with the acquisitions of Parcus Medical and Arthrosurface as well as our hiring of additional people to support our expanded operations, and we expect to continue to add employees in 2021 and beyond as we grow and transform our business. Our Compensation Committee and executive management team are focused on attracting and retaining top industry talent and key employees, and we offer market competitive total rewards packages consisting of base salary, a potential cash bonus based on individual and company performance, and a comprehensive benefits package to all employees. We also provide equity-based compensation to a large segment of our employee population based on various criteria, including their level within the company, to ensure that our employees contribute to our strategic objectives and that their compensation is aligned with the best interests of our stockholders. Ongoing employee development is a key component of our overall business strategy. To facilitate this, we support our employees’ development through individualized development plans, mentoring, coaching, group training, conference attendance, financial support, including tuition reimbursement for qualified programs, and access to a broad-based learning management platform for self-directed learning and improvement.

In early 2021, to coincide with our annual equity granting cycle, our Compensation Committee determined to make the “One Anika Grant,” a unique, one-time grant of stock options to all employees below the level of Vice President. The message from Dr. Blanchard accompanying this grant praised the efforts of all of our employees in integrating our acquired companies and the work that had been done to build collaborative relationships throughout the organization. The message also relayed the company’s belief regarding the importance of each employee having the opportunity to be a stockholder of the company with the potential to see appreciating value as the result of shared success.

The Board of Directors and executive management team believe that employees understanding how their work contributes to our overall strategy and performance is key to our success. In order to communicate with respect to these important topics in ways that are engaging and accessible to our team, we utilize a variety of channels, including quarterly company-wide town hall meetings with presentations by members of senior management, regular email updates from our chief executive officer and other key members of the executive team, and employee engagement surveys.

In addition, in 2020, Dr. Blanchard, with the support of the Board of Directors, signed the Massachusetts Biotechnology Council “CEO Pledge for a More Equitable and Inclusive Life Sciences Industry.” The signers of this pledge “recognize that racial inequity exists in [the life sciences] industry and in [life sciences] companies, and [they] must take responsibility to fix that injustice through comprehensive equity, diversity, and inclusion initiatives that are broad in scope, specific in action, and measurable in results.” The full text of the pledge can be found at: https://www.massbio.org/initiatives/equity-diversity-and-inclusion/open-letter/. Both the development of plans to fulfill the equity, diversity, and inclusion goals of the CEO pledge and the continued discussion and implementation of plans to address the feedback received in the 2020 employee engagement survey are corporate goals for this coming year and have been shared and agreed upon with the Board of Directors.

Director Overboarding Guidelines

The Board of Directors recognizes that its members benefit from service on the boards of other companies and it encourages such service. The Board also believes, however, that it is critical that directors are able to dedicate sufficient time to their service on the Board. The Board adopted our Commitment to the Board; Service on Other Boards; Change in Status Guidelines on March 17, 2021. Pursuant to these guidelines, unless the Board determines that such service would not impair the ability of a director to effectively serve on the Board or the Audit Committee of the Board:

no director who serves as the chief executive officer of any public company, including Anika, may serve on the boards of directors of more than three public companies, including Anika.

no other director may serve on the board of directors of more than five public companies, including Anika; and

no member of the Audit Committee should serve simultaneously on the audit committees of more than four public companies, including Anika.

Directors must notify the Chair of the Governance and Nominating Committee and our Corporate Secretary before accepting a seat on the board of directors of, or any assignment to the audit committee of, another public company so that the potential for conflicts or other factors compromising the director’s ability to perform his or her duties may be fully assessed.

Prohibition on Employee, Officer, and Director Hedging and Pledging

It is our policy that all employees and directors, as well as their family members, must not hedge or pledge any Anika securities they hold directly. An exception to this prohibition may be granted where a person wishes to pledge Anika securities as collateral for a loan, upon approval by our Chief Financial Officer, if certain other conditions are met. The prohibition on hedging is included in our Insider Trading Policy, which was implemented by the Board of Directors on December 20, 2016, as amended on July 16, 2020, and as subsequently amended on March 17, 2021. A copy of our Insider Trading Policy is available on our website and can be viewed on the investor relations portion of our website at https://ir.anikatherapeutics.com/corporate-governance.

Majority Voting in Uncontested Director Elections Policy

On December 8, 2015, the Board of Directors adopted our “Majority Voting in Uncontested Director Elections Policy.” An uncontested election occurs when the number of director nominees is equal to the number of Board positions to be filled through election and proxies are being solicited for such election of directors solely by our company. Pursuant to our policy in such an election, if a director receives a greater number of votes ~~“withheld”~~“against” than “for” his or her election, such director shall promptly offer his or her resignation for consideration by the Governance and Nominating Committee. The Governance and Nominating Committee shall then consider all of the relevant facts and circumstances and recommend to the Board whether or not to accept such offer of resignation. The final decision of whether or not to accept such resignation shall be made by the Board, and, if required or determined by the Board to be desirable, we shall appropriately disclose the decision of the Board along with the rationale for such decision.

2330

Transactions with Related Persons and Conflict of Interest Policy

It is our policy that all employees and directors, as well as their family members, must avoid any activity that is, or has the appearance of, conflicting with our business interests. This policy is included in our Code of Business Conduct and Ethics, and it is supplemented by our Conflict of Interest Policy, which was implemented by the Board of Directors on October 6, 2015, and can be viewed on the investor relations portion of ~~Anika’s~~our website athttps://ir.anikatherapeutics.com/corporate-governance. Both the Code of Business Conduct and Ethics and the Conflict of Interest Policy are reviewed ~~annually.~~at least every three years, or more often as necessary or advisable. Among other things, this policy requires each director and officer to provide to the Chair of the Board (or to the Chief Executive Officer, if such transaction involves the Chair of the Board) written notice of any potential related party transaction, defined by our policy to mirror the definition of Item 404 of Regulation S-K under the Securities Exchange Act of 1934, or the Exchange Act, (with the exception that our policy includes a monetary threshold of $100,000 as opposed to the threshold of $120,000 set by Item 404 of Regulation S-K under the Exchange Act). Any such notice must include all information requested by the Chair of the Board (or the Chief Executive Officer). Upon receiving all relevant information, the disinterested members of the Board may approve the transaction if they determine that the transaction is in the best interests of, and fair to, ~~us,~~Anika, may require modifications to the transaction to make it acceptable for approval, or may reject it. The Board may also establish guidelines for ongoing management of a specific related party transaction. The policy requires continuing related party transactions to be reviewed on at least an annual basis. Additionally, the policy requires all of our executives and directors to complete a director and officer questionnaire in connection with each of our annual proxy statements, which asks them to disclose family relationships and other related party transactions.

From January 1, ~~2019~~2020 through April ~~29, 2020,~~30, 2021, we had no reportable related party transactions.

2431

Beneficial Ownership of Common Stock

The following table sets forth the beneficial ownership of common stock as of April 20, ~~2020,~~2021, by:

●	each director who served during ~~2019~~2020 or ~~2020;~~2021;
●	each of the current Named Executive Officers named in the Summary Compensation Table set forth under “Executive Compensation” ~~as well as our current Executive Officers;~~;
●	each other person who is known by us to beneficially own 5% or more of our common stock; and
●	current directors and executive officers as a group.

The number of shares of common stock owned by each person is determined under the rules of the SEC. Under these rules, beneficial ownership includes any shares as to which the individual has sole or shared voting power or investment power and ~~also~~ any shares that the individual has the right to acquire by June 19, ~~2020~~2021 (sixty days after April 20, ~~2020)~~2021) through the conversion of a security or other right. Unless otherwise indicated, each person has sole investment and voting power, or shares such power with a family member, with respect to the shares set forth in the following table. The inclusion in this table of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of those shares for any other purpose. As of April 20, ~~2020,~~2021, there were ~~14,197,948~~14,366,686 shares of common stock outstanding. Shares not outstanding, but deemed beneficially owned by virtue of the right of a person to acquire those shares, are treated as outstanding only for purposes of determining the number and percent of shares of common stock owned by such person or group.

Unless otherwise noted below, the address of each person listed on the table is in care of Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730.

2532

Beneficial Owner Amount and
Nature of
Beneficial
Ownership Percentage of
Common Stock
Outstanding
Directors and Named Executive officers:
Joseph L. Bower 19,117 ⁽¹⁾ *
Raymond J. Land 13,399 ⁽²⁾ *
Glenn R. Larsen, Ph.D. 11,697 ⁽²⁾ *
Jeffery S. Thompson 10,949 ⁽²⁾ *
Susan N. Vogt 11,652 ⁽²⁾ *
Steven E. Wheeler 34,594 ⁽³⁾ *
Cheryl R. Blanchard 11,697 ⁽⁴⁾ *
Sylvia Cheung 262,924 ⁽⁵⁾ 1.82%
David Colleran - ⁽⁶⁾ *
Thomas Finnerty 23,648 ⁽⁷⁾ *
James Loerop - ⁽⁸⁾ *
Joseph G. Darling 40,341 ⁽⁹⁾ *
Edward S. Ahn, Ph.D. - ⁽¹⁰⁾ *
Current directors and executive officers as a group (9 persons) 365,083 ⁽¹¹⁾ 2.53%
5% and Above Stockholders:
Blackrock, Inc.
55 East 52nd Street
New York, NY 10055 2,127,249 ⁽¹²⁾ 14.88%
Kayne Anderson Rudnick Investment Management LLC
1800 Avenue of the Stars, 2nd Floor
Los Angeles, CA 90067 1,383,328 ⁽¹³⁾ 9.74%
Dimensional Fund Advisors LP
Building One, 6300 Bee Cave Road
Austin, TX 78746 1,001,294 ⁽¹⁴⁾ 7.05%
The Vanguard Group
100 Vanguard Blvd.
Malvern, PA 19355 915,596 ⁽¹⁵⁾ 6.45%
State Street Corporation
1 Lincoln Street
Boston, MA 02111 860,507 ⁽¹⁶⁾ 5.69%

* Indicates less than 1%

Beneficial Owner	Amount and Nature of Beneficial Ownership		Percentage of Common Stock Outstanding
Directors and Named Executive officers:
Joseph L. Bower	19,117	⁽¹⁾	*
John B. Henneman, III	3,103	⁽²⁾	*
Raymond J. Land	9,953		*
Glenn R. Larsen, Ph.D.	11,697		*
Stephen O. Richard	3,103	⁽³⁾	*
Jeffery S. Thompson	10,949		*
Susan N. Vogt	11,652		*
Cheryl R. Blanchard, Ph.D.	69,357	⁽⁴⁾	*
David Colleran	2,500		*
Michael L. Levitz	-	⁽⁵⁾	-
Thomas Finnerty	11,701		*
James Loerop	3,323	⁽⁶⁾	*
Current directors and executive officers as a group (12 persons)	156,455	⁽⁷⁾	1.09%
5% and Above Stockholders:
BlackRock, Inc.
55 East 52nd Street
New York, NY 10055	2,250,290	⁽⁸⁾	15.80%
Kayne Anderson Rudnick Investment Management LLC
1800 Avenue of the Stars, 2nd Floor
Los Angeles, CA 90067	1,546,263	⁽⁹⁾	10.88%
Ameriprise Financial, Inc.
145 Ameriprise Financial Center
Minneapolis, MN 55474	1,004,108	⁽¹⁰⁾	7.07%
The Vanguard Group
100 Vanguard Blvd.
Malvern, PA 19355	934,282	⁽¹¹⁾	6.57%
Dimensional Fund Advisors LP
6300 Bee Cave Road, Building One
Austin, TX 78746	884,116	⁽¹²⁾	6.20%
State Street Corporation
State Street Financial Center
One Lincoln Street
Boston, MA 02111	820,746	⁽¹³⁾	5.77%
Renaissance Technologies LLC
800 Third Avenue
New York, NY, 10022	809,117	⁽¹⁴⁾	5.69%
Avidity Partners Management LP
2828 N Harwood Street, Suite 1220
Dallas, TX 75201	731,000	⁽¹⁵⁾	5.10%

* Indicates less than 1%

2633

(1)	This amount includes ~~(i) 4,107 shares subject to restricted stock units and (ii)~~ 2,000 shares owned by Dr. ~~Bower’s~~Bower's spouse.
(2)	This amount includes ~~4,107~~3,103 shares subject to restricted stock ~~units.~~units vesting within sixty days of April 20, 2021.
(3)	~~Mr. Wheeler retired from the Board of Directors effective February 8, 2019.~~ This amount ~~reflects his beneficial ownership as~~includes 3,103 shares subject to restricted stock units vesting within sixty days of ~~that date.~~April 20, 2021.
(4)	This amount includes 4,231 shares subject to restricted stock units, which vested on April 26, 2020. This amount does not include the grants made to Dr. Blanchard when she became our President and Chief Executive Officer on April 26, 2020, which are discussed in the “Compensation Analysis and Discussion” portion of this Proxy Statement.
~~(5)~~	~~This amount includes 213,643~~34,879 shares subject to stock options ~~and stock appreciation rights~~ that are exercisable within sixty days of April 20, ~~2020.~~2021 and 24,575 shares of restricted stock units expected to vest within 60 days of April 20, 2021.
~~(6)~~(5)	Mr. ~~Colleran~~Levitz joined our company on ~~March 4,~~August 10, 2020, and he does not currently beneficially own any shares of our common stock.
(6)	This amount includes 1,567 deferred stock units that vested on February 25, 2021 and to be settled in a lump sum within 60 days of the anniversary of "separation from service" as that term is defined in Section 409A of the Internal Revenue Code.
(7)	This amount includes ~~15,401~~34,879 shares subject to stock options that are exercisable within sixty days of April ~~15, 2019~~20, 2021 and ~~2,267~~30,781 shares of restricted stock ~~vesting in three equal annual installments commencing one year from the applicable grant date.~~units expected to vest within 60 days of April 20, 2021.
(8)	~~Mr. Loerop joined our company on July 8, 2019, and he does not currently beneficially own any shares of our common stock.~~
~~(9)~~	~~Mr. Darling passed away on January 29, 2020. This amount reflects his beneficial ownership as of that date.~~
~~(10)~~	~~Dr. Ahn’s employment with the company as our Chief Technology and Strategy Officer ended on July 5, 2019.~~
~~(11)~~	~~This amount does not include shares beneficially owned by Mr. Wheeler, Mr. Darling, or Dr. Ahn.~~
~~(12)~~	Such information is provided based on an amended Schedule 13G filed with the SEC on behalf of ~~Blackrock,~~BlackRock, Inc. on ~~February 4, 2020. Blackrock,~~January 25, 2021. BlackRock, Inc. has sole voting power with respect to ~~2,094,575~~2,225,545 shares and sole dispositive power with respect to ~~2,127,249~~2,250,290 shares.
~~(13)~~(9)	Such information is provided based on an amended Schedule 13G filed with the SEC on behalf of Kayne Anderson Rudnick Investment Management LLC on February ~~14, 2020.~~11, 2021. Kayne Anderson Rudnick Investment Management LLC has sole voting power with respect to ~~1,038,0538~~1,110,920 shares, shared voting power with respect to ~~344,790~~435,343 shares, sole dispositive power with respect to ~~1,038,538~~1,110,920 shares, and shared dispositive power with respect to ~~344,790~~435,343 shares.
~~(14)~~(10)	Such information is provided based on ~~an amended~~ Schedule 13G filed with the SEC on behalf of ~~Dimensional Fund Advisors LP. On~~Ameriprise Financial, Inc. and its subsidiaries, Columbia Management Investment Advisers, LLC and Columbia Wanger Asset Management, LLC, on February 12, ~~2020. Dimensional Fund Advisors LP~~2021. Ameriprise Financial, Inc. beneficially owns 1,004,108 shares of shares, has ~~sole~~shared voting power with respect to ~~936,960~~1,003,580 shares, and ~~sole~~shared dispositive power with respect to ~~1,001,294~~1,004,108 shares. Columbia Management Investment Advisers, LLC beneficially owns 1,003,590 shares, has shared voting power with respect to 1,003,580 shares, and shared dispositive power with respect to 1,003,590 shares. Columbia Wanger Asset Management, LLC beneficially owns 932,719 shares, has shared voting power with respect to 932,719 shares, and shared dispositive power with respect to 932,719 shares.
~~(15)~~(11)	Such information is provided based on an amended Schedule 13G filed with the SEC on behalf of The Vanguard Group on February ~~12, 2020.~~10, 2021. The Vanguard Group has ~~sole voting power with respect to 13,197 shares,~~ shared voting power with respect to ~~1,100~~14,356 shares, sole dispositive power with respect to ~~915,596~~910,086 shares, and shared dispositive power with respect to ~~12,454~~24,196 shares.
~~(16)~~(12)	Such information is provided based on anamended Schedule 13G filed with the SEC on behalf of Dimensional Fund Advisors LP on February 12, 2021. Dimensional Fund Advisors LP has sole voting power with respect to 835,206 shares and sole dispositive power with respect to 884,116 shares.
(13)	Such information is provided based on amended Schedule 13G filed with the SEC on behalf of State Street Corporation on February ~~13, 2020.~~5, 2021. State Street Corporation has shared voting power with respect to ~~807,435~~758,662 shares and shared dispositive power with respect to ~~860,507~~820,746 shares.
(14)	Such information is provided based on Schedule 13G filed with the SEC on behalf of Renaissance Technologies LLC on February 10, 2021. Renaissance Technologies LLC has sole voting power with respect to 809,117 shares and sole dispositive power with respect to 809,117 shares.
(15)	Such information is provided based on Schedule 13G filed with the SEC on behalf of Avidity Partners Management LP on February 16, 2021. Avidity Partners Management LP has shared voting power with respect to 731,000 shares and shared dispositive power with respect to 731,000 shares.

~~Section 16(a) Beneficial Ownership Reporting Compliance~~

The Exchange Act requires that our officers, directors, and persons who own more than 10% of our common stock file initial reports of ownership and report of changes in ownership with the SEC and NASDAQ. Officers, directors and persons who beneficially own more than 10% of our common stock are also required to furnish us with a copy of all forms they file pursuant to Section 16(a) of the Exchange Act. To our knowledge, based solely upon a review of Forms 3, 4 and 5 and other applicable forms as well as amendments thereto furnished to us under Rule 16a-3(e) of the Exchange Act for the year ended December 31, 2019, no officer, director, or person who owns more than 10% of our outstanding shares of common stock failed to file such reports on a timely basis during 2019.

2834

Executive Officers

The Board of Directors elects our executive officers annually at a regular meeting held immediately preceding an Annual Meeting of Stockholders. The Board also elects executive officers throughout the year as such individuals are hired by us. ~~Such executive~~Executive officers hold office until the next Annual Meeting of Stockholders or until their successors are duly elected and qualified, unless they sooner resign or are removed from office. There are no family relationships between any of our directors (including director ~~nominees,~~nominees) or executive officers.

The following table lists ~~the current~~our executive officers ~~of Anika Therapeutics~~ and ~~certain information concerning the executive officers of Anika Therapeutics.~~their offices and ages, all as April 30, 2021. It is ~~anticipated~~currently expected that each of these officers will be re-appointed to their current offices by the Board immediately preceding the Annual Meeting:

Name	Position	Age
Cheryl R. Blanchard, Ph.D.	President and Chief Executive Officer	5556
~~Sylvia Cheung~~Michael L. Levitz	Executive Vice President, Chief Financial Officer ~~Treasurer~~ and ~~Assistant Secretary~~Treasurer	4547
David Colleran	~~EVP,~~Executive Vice President, General Counsel and Secretary	4849
Thomas Finnerty	~~EVP~~Executive Vice President, Human Resources	6263
James Loerop	~~EVP~~Executive Vice President, Business Development and Strategic Planning	5657

Dr. Blanchard’s biography is included above in the section titled “Proposal 1: Election of Directors – Information Regarding the Directors.”

~~Sylvia Cheung~~Michael L. Levitz was appointed Executive Vice President, Chief Financial Officer and Treasurer ~~and Secretary~~ in ~~April 2013. Ms. Cheung transitioned from Secretary to Assistant Secretary in March 2020 when~~August 2020. Mr. ~~Colleran joined the company. Ms. Cheung~~Levitz served as ~~our~~the Senior Vice President, Chief Financial Officer and Treasurer of ~~Strategic Processes commencing in 2012.~~Insulet Corporation, a publicly traded, global medical device and drug delivery company, from 2015 to May 2019. From ~~October 2014 through February 2019, she has also served as General Manager for our Italy-based subsidiary, Anika Therapeutics S.r.l.~~2009 to 2015, Mr. Levitz was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider of medical guidance, diagnostic imaging, and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc Corporation (which merged with Hologic), ~~and she~~Mr. Levitz served in various capacities including Vice President and Corporate Controller. Mr. Levitz began his career in the ~~same role from 2010 to 2011. Ms. Cheung originally joined our company as its Controller~~high technology audit practice at Arthur Andersen LLP. Mr. Levitz earned his Bachelor of Arts in ~~2005, and,~~Business Economics, with emphasis in addition to fulfilling these financial responsibilities, she led our integration of Anika S.r.l. subsequent to its acquisition in 2009. Prior to joining Anika, she held a series of progressively responsible financial management positions at Transkaryotic Therapies, Inc. From 1995 to 2000, Ms. Cheung worked for PricewaterhouseCoopers LLP as an Audit Senior Associate with a focus in technology companies. Ms. Cheung holds a B.S. in business administration and accountingAccounting, from the University of ~~Massachusetts in Amherst~~California Santa Barbara and ~~an M.B.A. from Boston University, and she~~ is a ~~Certified Public Accountant (inactive).~~certified public accountant.

David Colleran was appointed Executive Vice President, General Counsel and Secretary onin March 4, 2020. Most recently, ~~David~~Mr. Colleran served as Senior Vice President, General Counsel, Secretary and Chief Compliance Officer at Insulet Corporation, a publicly traded, global medical device and drug delivery company, from July 2015 through March 2019. Prior to that, from 2010 to 2015, he held the role of Vice President and General Counsel of the Medical Supplies ~~Segment~~segment, and from 2006 to 2010, he held the role of Associate General Counsel, both at Covidien, a global manufacturer of medical devices and supplies acquired by Medtronic ~~from 2010~~in 2015. Prior to ~~2015 and~~that, he was Corporate Counsel at Ocean Spray Cranberries. Mr. Colleran began his career as a corporate attorney at the law firm Choate, Hall & Stewart. Mr. Colleran holds a B.A. in Political Science from Boston College and a J.D. from Boston College Law ~~School, and he is admitted to the Massachusetts Bar.~~School.

Thomas Finnerty was appointed Chief Human Resource Officer onin October ~~30,~~ 2017, and his title was changed to Executive Vice President, Human Resources in July 2019 to align with our corporate convention. From June 2017 to October 2017, Mr. Finnerty served as a human resources consultant to our company. Prior to his work with Anika, Mr. Finnerty served as the Senior Vice President of Human Resources at Smith & Nephew, a leading portfolio medical technology company manufacturing products for global distribution, from 1999 through April 2016, where he was responsible for delivering value-added programs, processes, and leadership in global human capital management. Mr. Finnerty has also held human resources positions at Novartis/Chiron Diagnostics and the Foxboro Company. Mr. Finnerty holds a B.S. in business from the University of Massachusetts Dartmouth and an M.B.A. from Babson College.

James Loerop was appointed Executive Vice President, of Business Development and Strategic Planning onin July ~~8th,~~ 2019. Most recently, Mr. Loerop served as Chief Corporate Development Officer for Lupin Pharmaceuticals from September 2017 to July 2019, where he was a member of the company’s Executive Leadership Team and was responsible for global business development and corporate development activities. Prior to his work with Lupin, ~~Jim~~Mr. Loerop held senior leadership roles at various companies in the pharmaceutical and life sciences industry, including at Alexion Pharmaceuticals as Senior Vice President of Global Business Development from April 2015 to September 2017, GlaxoSmithKline as Vice President of North America Business Development from September 2010 to April 2015, and ~~Steifel~~Stiefel Laboratories as Senior Vice President of Global Corporate Development, prior to GSK’s acquisition of Stiefel. Mr. Loerop holds a B.S. in Marketing from Western Michigan University.

3035

Compensation Discussion and Analysis

This section describes and analyzes the material elements of the ~~2019~~2020 compensation for our named executive officers, or NEOs, ~~identified~~determined in ~~the Summary Compensation Table,~~accordance with SEC rules, as follows:

	Name	Title (as of December 31, ~~2019)~~2020)
	~~Joseph G. Darling~~Cheryl R. Blanchard, Ph.D.*	President and Chief Executive Officer
Michael L. Levitz	~~Sylvia Cheung~~	EVP, Chief Financial Officer, and Treasurer
David Colleran	EVP, General Counsel, and Secretary
	Thomas Finnerty	EVP, Human Resources
	James Loerop	EVP, Business Development &and Strategic Planning
Joseph G. Darling**	Former President and Chief Executive Officer
	~~Edward S. Ahn, Ph.D.~~Sylvia Cheung***	Former Chief ~~Technology~~Financial Officer, Treasurer, and ~~Strategy Officer~~	Assistant Secretary

Dr. ~~Ahn’s employment with the company~~Blanchard was appointed as our interim Chief Executive Officer on February 10, 2020 and as our President and Chief Executive Officer on April 26, 2020.

Mr. Darling unexpectedly passed away on January 29, 2020.

***

Ms. Cheung resigned from her role as our Chief ~~Technology~~Financial Officer, Treasurer, and ~~Strategy Officer ended July 5, 2019.~~

Assistant Secretary as of August 10, 2020.

We have divided this discussion into five parts:

Executive Summary

Compensation Philosophy

Key Compensation Policies and Practices

~~2019~~2020 Compensation Decisions

Other Compensation Matters

Executive Summary

Our Fiscal Year ~~2019~~2020 Business Performance

Fiscal Year ~~2019~~2020 was a ~~strong performance~~transformative year for Anika, as we ~~generated a record $114.6 million in total revenue, a 9% year-over-year increase. Most importantly, we~~ completed our ~~five-year strategic plan~~acquisitions of Parcus Medical, LLC, or Parcus Medical, and ~~took significant steps~~Arthrosurface, Inc., or Arthrosurface. These acquisitions in early 2020 expanded our overall technology portfolio and product pipeline, significantly enhanced our global footprint and commercial infrastructure, diversified our revenue streams in faster growing segments, and grew our overall market opportunity from the over $1 billion global osteoarthritis, or OA, pain management market to ~~transform~~ the ~~company into a global commercial organization focused on~~over $8 billion joint preservation market (which includes the faster growing sports medicine and ~~restoration. We delivered significant accomplishments executing on~~bone preserving extremities segments). Following these acquisitions, we successfully managed our business through the ~~key pillars~~COVID-19 pandemic to prioritize the health and safety of our ~~five-year strategic plan~~employees while continuing to deliver high-quality products and support for our customers and their patients with no significant operational interruptions. We also delivered other important accomplishments in talent acquisition, commercial organization integration, and ~~strategic business acquisitions.~~new product launches. These achievements in a year of tremendous change and challenges have positioned us to ~~further enhance~~meet our ~~performance~~previously-stated growth targets of doubling overall revenue by 2024 (over fiscal year 2019 results) and ~~set the stage for accelerated~~expanding profitability with double-digit adjusted EBITDA growth ~~and profitability over the next several years as we look to maximize returns from our key markets~~¹, thus creating significant value for our ~~stakeholders.~~customers, their patients, and our stockholders. In ~~2019, these activities~~2020, specific accomplishments included:

¹ Adjusted EBITDA is a Non-GAAP financial measure. Please see pages 35-37 in the section captioned “Non-GAAP Financial Measures” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 5, 2021 for the reconciliation to Net Income prepared in accordance with GAAP.

~~adding world-class talent to our executive leadership team with key hires to execute our growth strategies;~~

~~performing key diligence, negotiation and pre-closing activities related to~~completing the acquisitions of Parcus Medical ~~LLC~~ and Arthrosurface, ~~Incorporated, which closed in early 2020~~accelerating our revenue diversification and ~~significantly enhanced~~expansion beyond our ~~commercial capabilities and product portfolio;~~historic $1 billion global OA pain management market to the over $8 billion joint preservation market;

completing the ~~buildout~~integration of our ~~small internal hybrid~~U.S. and international commercial ~~salesforce~~organizations, through which we enhanced our own direct selling capabilities in the ~~United States for~~U.S. and fortified our ~~current~~large network of domestic and ~~future surgical-based orthopedic products;~~international distributors;

navigating Anika through the COVID-19 pandemic without any significant operational disruption or reduction in workforce;

strengthening our senior leadership team and board of directors through the addition of seven senior leaders and two new board members, bringing deep industry experience and complementary skill sets to our team;

launching several new joint preservation products and receiving 510(k) clearance for our ~~first surgical orthopedic product, TACTOSET,~~WristMotion Total Arthroplasty System in the United ~~States under our hybrid commercial model;~~

~~expanding internationally with 20% year-over-year international viscosupplement revenue growth;~~

advancing our CINGAL program in the United States by making the decision to initiate our pilot study in 2020, including planning work and preparation associated with protocol development and site selection;

~~continuing to progress on the enrollment of patients in our Hyalofast Phase III clinical trial designed to gain FDA approval;~~

~~focusing on operational excellence as we stressed manufacturing efficiency and year-over-year product gross margin improvement, which improved our product gross margin from 70% in 2018 to 75% in 2019;~~

~~returning $30 million of value to our stockholders through an accelerated share repurchase program, which concluded in January 2020;~~States; and

~~making significant progress on the execution of~~initiating enrollment in our ~~five-year strategic plan, including through~~pilot clinical study for Cingal and resuming enrollment in our ~~acquisitions and commercial infrastructure development.~~clinical trial for Hyalofast to support U.S. approval, while continuing to sell these products in over 30 markets internationally.

In addition to these operational efforts, our financial highlights for ~~2019~~2020 included:

~~record~~ total revenue ~~$114.6 million;~~

~~Cingal revenue growth~~ of ~~30% internationally;~~

~~net income of $27.2 million;~~$130.5 million, up 14% as compared to 2019;

product gross margin of ~~75% for~~53%, including a 13 point negative impact due to acquisition-related expenses;

$13.1 million of cash flows from operations despite a reported net loss of $24 million, which included the ~~full year, up from 70% in 2018;~~impact of acquisition-related expenses and non-cash adjustments;

cash, cash equivalents and investments totaling ~~$185~~$98.3 million as of December 31, ~~2019, reflecting the achievement of $37 million of cash from operations generated in 2019;~~

~~no debt as of December 31, 2019;~~2020; and

~~51% shareholder return~~repayment in ~~2019.~~full of the $50 million drawn from our credit facility in April 2020 out of precaution at the onset of the COVID-19 pandemic in the United States.

Compensation Decisions

WeAs described more fully below, we made compensation decisions for our NEOs for ~~2019~~2020 that were ~~directly~~generally linked to our performance. In particular, the Compensation Committee:

~~determined~~paid the ~~vesting~~NEOs annual cash bonuses, generally at 90% of ~~performance-based awards granted~~target (subject to proration for NEOs hired in ~~2018;~~2020), based on the company’s business performance results above, including the strong stewardship of the company through the unprecedented circumstances associated with the COVID-19 pandemic, and a review of each NEO’s individual accomplishments;

paid the NEOs annual cash bonuses based on the business performance results above and a review of individual performance accomplishments, with awards generally above target and ranging from 120% to 150% of target;

other than Dr. Blanchard, granted the NEOs restricted stock unit awards in early ~~2019~~2020, or on their hire date, split ~~based~~evenly (based on ~~the number of shares covered, evenly~~target achievement) between time-vesting awards and performance-based awards with multi-year ~~targets;~~targets (excepting certain adjustments for NEOs as described more fully below);

granted Dr. Blanchard time-vesting restricted stock units upon her appointment as interim Chief Executive Officer in February 2020 and, upon her subsequent appointment as President and Chief Executive Officer in April 2020, granted her (1) time-vesting restricted stock units, (2) performance-based restricted stock units, (3) time-vesting stock options, and (4) performance-based stock options that vest based on the company’s total shareholder return relative to a comparison group of companies as described more fully below that, in their totality and assuming target performance, are split nearly evenly between time-vesting and performance-based awards and represent an appropriate starting equity package in comparison to chief executive officers at peer group companies;

granted Mr. ~~Loerop,~~Colleran and Mr. Levitz, who ~~became our Executive Vice President Business Development~~joined the company in March and ~~Strategic Planning in July 2019, an~~August 2020, respectively, additional ~~award~~time-vesting stock option awards covering 35,000 and 57,145 shares of ~~27,000~~ common stock, ~~options~~respectively, as an inducement to join the company;

~~increased the~~continued to utilize a multi-year performance period ~~historically used~~ for new performance-based restricted stock unit ~~grants;~~grants and, as described above, implemented a relative metric based on total shareholder return for the vesting of our President and Chief Executive Officer’s new-hire performance-based stock option grant; and

implemented changes to our ~~2019 and~~ 2020 NEO compensation programs to address the feedback that we received from ~~stockholders;~~stockholder outreach in 2019 and

~~implemented a deferred stock program that allows our directors and executives, at their discretion, to defer settlement of restricted units granted to them.~~ 2020.

Stockholder Outreach

In our say-on-pay vote last year, approximately ~~84%~~98% of the votes were cast in favor of our NEO ~~compensation.~~compensation for 2019. We were pleased with the improved results as compared to the prior two years when ~~80%~~84% and ~~58%~~80% of the votes were cast in favor, ~~respectively, but we continue to seek to achieve future results more aligned with the over 90% support we have regularly received on say-on-pay votes in the years before 2017.~~respectively. We routinely speak with many of our large and small stockholders and solicit feedback on our executive compensation program to understand issues orand concerns pertinent to our investors. ~~In general,~~

Our management spoke to stockholders that we believe ~~that our Chief Executive Officer and/~~owned or ~~our Chief Financial Officer spoke to shareholders representing~~represented over 80% of our outstanding shares during ~~2019.~~both 2019 and 2020. Some general themes from these conversations have been that our investors ~~want~~would like to understand how we align performance and compensation through enhanced narrative disclosure, including specific metrics considered by us in our short- and long-term incentive compensation, ~~that they~~ would like ~~to see~~more clarity around the vesting of equity awards, including in the context of a change in control of the company, and appreciate the more equitable split of time-based and performance-based grants under our equity programs beginning in 2019. They would also like to ensure that relative metrics and ~~that they would like caps put~~multi-year targets continue to be included in ~~place with respect to our short-term incentive compensation. As a result, we~~performance-based grants.

We have implemented changes to our ~~2019~~2020 and ~~2020~~2021 compensation programs to address the feedback that we received, including ~~increasing the proportion of equity awards tied to specific performance conditions, implementing a 50/50~~maintaining an even split ~~based on the number of shares covered,~~ between time-based and performance-based equity ~~awards,~~grants (excluding new hire stock option grants provided to induce key employees to join the company and ~~limiting short-term incentive bonus payouts to 2 times targeted amounts.~~certain adjustments for our other NEOs), implementing multi-year performance periods for each performance metric included in performance-based grants, and, as described above, utilizing a relative metric based on total shareholder return in our President and Chief Executive Officer’s new-hire performance-based stock option grant. We always appreciate the feedback that we receive from our stockholders, and we have, and will continue to, consider ~~these concerns~~this feedback and enhance our compensation program and disclosure around it, including in the following discussion.

Compensation Philosophy

The Compensation Committee ~~approves our compensation policies and~~ oversees our overall compensation ~~program.~~program and approves our compensation policies. The overriding goal of our compensation program is to drive long-term high performance and increase stockholder value ~~creation~~ through our pay programs and corporate culture. As a result, the Compensation Committee ~~ties~~incorporates performance tointo many aspects of our compensation program, including pay levels, incentive payouts, and pay opportunities. Corporate and individual goals are set through our yearly budgeting ~~process~~ and ~~in order to be able to communicate those~~strategic planning processes and these goals ~~to the NEOs near the beginning of the relevant performance period,~~ are ultimately reviewed and approved by the Board prior to, or at the beginning of, each year.

The Compensation Committee, utilizing both the structure of our compensation program and its discretion, as ~~necessary,~~appropriate, structures our executive compensation program to reward our NEOs when their performance exceeds stated goals. A significant portion of each NEO’s incentive compensation is weighted towards ~~overall~~the leadership ~~team~~team’s achievement against targeted goals (rather than individual performance), so that if we meet or exceed our goals, the ~~teams earn~~team earns awards at or above target ~~or better awards.~~levels. Conversely, if the team fails to meet the minimum thresholds, ~~components of performance-based compensation~~they will not be ~~awarded.~~awarded the targeted components of the performance-based compensation.

As a general matter, the Compensation Committee uses ~~competitive~~ compensation data from the annual compensation study of competitive peer companies to inform its decisions about overall compensation opportunities and specific compensation elements. Additionally, the Compensation Committee uses multiple reference points when establishing targeted compensation levels, and it does not benchmark specific elements or total compensation to any specific level or percentile relative to peer companies or the broader market. ~~Instead,~~Rather than rely on a specific formula-based model, the Compensation Committee applies judgment and discretion in establishing targeted pay levels, taking into account not only competitive market data, but also factors such as company, business, and individual performance, scope of responsibility, critical needs and skill sets, leadership potential, and succession planning. The Compensation Committee believes that retaining this discretion gives the Compensation Committee the ability to more accurately reflect factors and individual contributions that cannot be absolutely quantified. The Compensation Committee also considers the company’s primary physical location near Boston, Massachusetts, the high level of competition for life sciences employees in that area, and the need to remain competitive with the compensation offered by other life sciences companies to ensure the successful recruitment and retention of top performing executives and employees. We have designed our compensation program ~~to achieve the following:~~to:

1.·

motivate and reward our executives to achieve or exceed our financial and operating performance objectives;

2.·

propel our business forward through a focus on operational excellence and execution of our business strategy;

3.·

link each NEO’s compensation with specific business objectives;

4.·

align each NEO’s compensation with the interests of long-term stockholders by tying a significant portion of total compensation opportunity to the value of our stock;

5.·

reinforce accountability and cooperation by tying a significant portion of total NEO compensation to overall company performance;

6.·

attract and retain talented leaders who can drive and implement our growth and operational excellence strategies;

7.·

reward individual performance and accomplishments; and

8.·

keep the compensation packages competitive with those of our peers and other companies with whom we compete for talent.

Key Compensation Policies and Practices

Key Features

We believe that our executive compensation program includes key features that align the ~~interests~~performance and objectives of the NEOs and the company with the interests of our stockholders and does not include features that misalign ~~their~~NEO and company objectives with stockholder interests. During ~~2019,~~2020, we arranged our compensation program in accordance with the practices set forth below:

What We Do

~~What We Don’t Do~~

ü	~~Align NEO pay with our performance~~
ü	Align a significant portion of NEO ~~pay~~compensation with ~~stockholders~~our performance
ü	Allocate a significant portion of NEO compensation with stockholders’ interests through long-term incentives, including ~~multi-year,~~grants of performance-based ~~RSU~~ awards in ~~2019~~2020 with exclusively multi-year performance metrics and 3-year cliff vesting
ü	Balance our equity grants to NEOs evenly between time-vesting and performance-based awards (excepting certain new-hire awards of time-vesting stock options and certain adjustments for other NEOs as described more fully below)
ü	Include a relative total shareholder return performance measure in the new-hire grant of performance-based stock options to our President and Chief Executive Officer
ü	Balance short-term and long-term incentives
ü	Require NEOs to own significant amounts of stock through robust stock ownership guidelines (see page 5160 of this Proxy Statement)
ü	Include ~~in our equity compensation plan,~~ minimum vesting requirements for equity awards in our equity compensation plan, subject to certain exceptions
ü	~~Double-trigger~~Incorporate double-trigger vesting upon a change in control for all equity awards ~~granted after January 29,~~to NEOs in 2019 and beyond
ü	~~Bonus~~Cap annual cash bonus payouts ~~capped~~ at 2x target
ü	Utilize aan independent compensation consultant annually to ~~annually review~~assist our assessment of our compensation program
ü	Solicit say-on-pay votes annually

What We Don’t Do

Ä	No automatic or guaranteed annual salary increases
Ä	No guaranteed ~~bonus~~short- or long-term incentive awards
Ä	No repricing of stock options or SARs without stockholder approval
Ä	No hedging/pledging of our stock per our ~~insider trading policy~~Insider Trading Policy
Ä	No ~~change in control~~“golden parachute” excise tax gross-ups
Ä	No granting of stock options or SARs at ana per share exercise price less than fair market value on the grant date
Ä	No pension or other special benefits

Key Performance Factors

In setting the compensation for our executive officers, the Compensation Committee relies primarily on our overall financial performance and an assessment of each individual’s performance and contribution to the achievement of our ~~development and achievements.~~goals. The Compensation Committee seeks to align the metrics it uses in evaluating our executive compensation with the metrics that we use to evaluate our performance more generally, including those metrics that we publicly disclose. Financial performance measures form the majority of the ~~performance~~ criteria for performance-based equity awards, and the Compensation Committee balances financial and individual performance (as set forth below) in making decisions on annual cash bonus payments. In 2020, decisions on annual cash bonus payments also included as a key component the Compensation Committee’s consideration of the role the NEOs played in guiding the company through the challenges of the COVID-19 pandemic with no significant operational disruption. Typical achievement measures considered by the Compensation Committee include, but may not be limited to, the following:

3440

Company Financial Performance

~~Individual Performance~~

·	Revenue growth
·	Adjusted ~~EBITA~~EBITDA (as ~~publicly discussed by us)~~previously described)
·	Vitality index (i.e., revenue from new products as a percentage of total revenue)
·	Net income ~~achievement~~and adjusted net income (as publicly discussed by us)
·	Adjusted EBITDA margin
·	~~Product gross~~Gross margin
·	Cash flow
·	Share price performance

Individual Performance

·	~~Franchise~~Product family or geographic revenue growth
·	Strategic transactions
·	Significant integration and infrastructure implementation
·	New product launches in key geographies (especially the United States)
·	Achievement of regulatory approvals for new products or line extensions
·	Clinical trial achievements or ~~completion~~
·	~~Strategic transactions~~completions
·	Key employee recruitment or retention
·	Completion of strategic projects that drive current or future company growth
·	~~Procurement of patents~~Contributions towards expanding or ~~other~~strengthening the company’s intellectual property portfolio

Peer Group and Role of Compensation Consultant

In addition to the company and individual performance metrics set forth above, the Compensation Committee weighs other quantitative factors, such as general compensation ~~trends.~~trends, in making compensation decisions. In this regard, the Compensation Committee periodically reviews surveys of executive compensation and information concerning compensation at similarly situated companies. In ~~2019,~~2020, as in prior years, the Compensation Committee engaged the Radford advisory team of the Rewards Solution practice at Aon, ~~specifically members of the~~or Radford, ~~advisory team (“Radford”),~~ to provide executive compensation consulting services to the Compensation Committee, to assist the Compensation Committee in selecting an appropriate peer group for compensation comparisons, and to perform an executive compensation review.

The Compensation Committee, with the assistance of Radford, has performed this analysis each year from 2015 through ~~2019,~~2020, and it currently intends to continue the practice of performing this analysis yearly. In completing its analysis for ~~the 2019 compensation season,~~2020, the Compensation Committee reviewed competitive data compiled by Radford from a peer group comprised of 1918 companies in related businesses at similar stages of development and of similar size in terms of market capitalization and ~~related businesses.~~employee population. The Compensation Committee also reviewed market data from the ~~2017~~2019 Radford Global Life Sciences Executive Survey (the “Radford Survey”) covering 65 public biopharmaceutical and medical device companies. The Compensation Committee uses competitive compensation data from these peer company and industry reviews to inform its decisions about overall compensation opportunities and specific compensation elements. Additionally, the Compensation Committee uses multiple reference points when establishing targeted compensation levels. The Compensation Committee does not benchmark specific compensation elements or total compensation to any specific level or percentile relative to the peer companies or the broader United States market. ~~Instead,~~Rather than rely on a specific formula-based model, the Compensation Committee applies judgment and discretion in establishing targeted pay levels, ~~taking into account~~considering not only competitive market data, but also factors such as ~~Company,~~company, business, and individual performance, scope of responsibility, critical needs and skill sets, leadership potential, and succession planning. The Compensation Committee believes that retaining this discretion gives the Compensation Committee the ability to more accurately reflect factors and individual contributions that cannot be absolutely quantified. The Compensation Committee also considers the company’s primary physical location near Boston, Massachusetts, the high level of competition for life sciences employees in that area, and the need to remain competitive with the compensation offered by other life sciences companies to ensure the successful recruitment and retention of top performing executives and employees.

With Radford’s assistance, we review and adjust our Peer Group annually to ensure that the industry data we review is relevant to our current and near-term future activities and goals. We believe that the adjustments we made to our ~~2019~~2020 Peer Group are appropriate to better reflect changes in our company over time, based on our history of strong financial performance, growing product pipeline, commercial strategies, and change in our Global Industrial Classification System (GICS) Code from 35101020 (Health Care Supplies) to 35201010 (Biotechnology). Given this ~~changing~~ dynamic, we felt it ~~more~~ appropriate to blend biopharmaceutical companies with medical device companies in a ratio of approximately 2/3 to 1/3.3, as we did in 2019. The following is the composition of the peer group utilized for ~~our 2019 compensation analysis:~~

	~~Peer Group Companies~~
	~~Biopharmaceutical Companies~~	~~Medical Device Companies~~
	~~AMAG Pharmaceuticals, Inc.~~	~~AtriCure, Inc.~~
	~~Glaukos Corporation~~	~~Atrion Corporation~~
	~~Insys Therapeutics, Inc.~~	~~Avid Biosciences, Inc.~~
	~~MacroGenics, Inc.~~	~~CONMED Corporation~~
	~~MiMedx Group, Inc.~~	~~CryoLife Inc.~~
	~~Momenta Pharmaceuticals, Inc.~~	~~K2M Group Holdings~~
	~~Omeros Corporation~~	~~Orthofix, Inc.~~
	~~Repligen Corporation~~
	~~Retrophin, Inc.~~
	~~Spectrum Pharmaceuticals, Inc.~~
	~~Vanda Pharmaceuticals, Inc.~~
	~~Vericel Corporation~~

With Radford’s assistance, we have further refined the peer group for our 2020 compensation program to build on some of the changes we made to the group from 2018 to 2019. We believe the adjustments were appropriate to continue to reflect changes in our strategic plan and commercial strategies. The 2020 peer group will be:2020:

	Peer Group Companies
	Biopharmaceutical Companies	Medical Device Companies
	AMAG Pharmaceuticals, Inc.	AtriCure, Inc.
	Avid Biosciences, Inc. Halozyme Therapeutics, Inc.	Atrion Corporation Axogen, Inc.
	MacroGenics, Inc.	Cryolife, Inc.
	Momenta Pharmaceuticals, Inc.	Glaukos Corporation
	Omeros Corporation	Orthofix, Inc.
	Portola Pharmaceutics, Inc.
	Radius Health, Inc.
	Retrophin, Inc.
	Spectrum Pharmaceuticals, Inc.
	Vanda Pharmaceuticals, Inc.
	Vericel Corporation

With Radford’s assistance, we have further refined the peer group for our 2021 compensation program to build on some of the changes we made to the group from 2019 to 2020. The 2021 peers were selected to provide a reasonable set of comparable companies in terms of commercial products, market value, headcount, and revenue. We believe the adjustments were appropriate to continue to reflect changes in our company’s direction and commercial strategies. The 2021 peer group is:

	Peer Group Companies
	Biopharmaceutical Companies	Medical Device Companies
	AMAG Pharmaceuticals, Inc.	AtriCure, Inc.
	Avid Biosciences, Inc. Collegium Pharmaceutical, Inc.	Atrion Corporation Axogen, Inc.
	Flexion Therapeutics, Inc.	Cryolife, Inc.
	MacroGenics, Inc.	Glaukos Corporation
	Momenta Pharmaceuticals, Inc.	Orthofix, Inc.
	Omeros Corporation	SurModics, Inc.
	~~Portola Pharmaceutics,~~ Organogenesis, Inc.
	Radius Health, Inc.
	Retrophin, Inc.
	Spectrum Pharmaceuticals, Inc.
	Vanda Pharmaceuticals, Inc.
	Vericel Corporation

~~2019~~2020 Compensation Decisions

Our ~~2019~~2020 NEO compensation was made up of three key components:

base ~~salary,~~salary;

discretionary annual ~~bonuses,~~bonuses; and

equity-based long-term incentive awards, generally in the form of ~~time~~time- and performance-based stock ~~options.~~options and restricted stock units.

Aside from Dr. Blanchard, each of the NEOs is an at-will employee with terms of employment documented on the company’s standard form of offer letter. For additional detailed information regarding the compensation of Dr. Blanchard resulting from her employment agreement with the company, please see the section captioned “Other Compensation Matters – The ~~Compensation Committee separately reviews~~Death of Mr. Darling and ~~decides each component, but keeps in mind~~ the overall intent that total compensation should approximate the competitive median, before adjusting for actual performance. The Compensation Committee does not affirmatively set out in any given year, or with respect to any given NEO, to apportion compensation in any specific ratio among the various categoriesAppointment of ~~compensation (i.e., between annual cash bonuses and long-term equity awards, or between non-performance based and performance-based compensation)~~Dr. Blanchard. Rather, the Compensation Committee uses the principles described in this Proxy Statement, including taking into account engagement with our stockholders, as a guide in assessing the proper allocation among those categories.”

Base Salary

The first principal component of compensation for our executive officers is base salary, which is generally paid to our NEOs to recognize fulfillment of their job responsibilities. Base salaries for our NEOs are subject to annual review by the Compensation Committee. For this purpose, the Compensation Committee considers a number of factors, including the individual’s level of responsibility, experience, and performance, including both past company performance and individual performance in accordance with the metrics previously ~~discussed, as well as competitive~~discussed. The Compensation Committee also considers market practices as ~~determined by our analysis of management compensation surveys, and a review of other published data relating to executive compensation, including peer group data, and~~described above, taking into account any contractual obligations. Salaries are reviewed and determined at the discretion of the Compensation Committee on an annual basis, and there is no guaranteed year-over-year increase to any of the ~~NEO’s~~NEOs’ salaries.

For ~~2019,~~2020, base salaries and compensation increases, as applicable, for the NEOs are set forth below. Dr. Blanchard, Mr. Levitz, and Mr. Colleran were hired by the company in 2020, and their 2020 salaries reflect the annualized salaries approved by the Compensation Committee at the time of their hire (in the case of Dr. Blanchard, her appointment as President and Chief Executive Officer on April 26, 2020). Mr. Finnerty received a 3.5% salary increase, which was largely in line with the rest of the company, while Mr. Loerop received a more modest increase because we hired him mid-way through 2019. Mr. Darling and Ms. Cheung received comparatively larger salary increases to reflect competitive market practices for their positions and their ~~2018 efforts on behalf of~~2019 performance, including with respect to the ~~company. Mr. Finnerty received a 3.5% salary increase, which was largely in line with the rest of the organization. Mr. Loerop’s 2019 salary reflects~~Parcus Medical and Arthrosurface acquisitions.

In addition to the annualized salary ~~negotiated~~reflected below, Dr. Blanchard received compensation at an annualized rate of $600,000 during the term of her employment as the company’s interim Chief Executive Officer, which resulted in ~~his offer letter based on competitive benchmark data to induce him to join us on July 8, 2019.~~base salary payments of $115,385.

~~2019~~2020 Base Salary ~~Adjustments~~

Name 2018 Salary 2019 Salary % Change
Joseph G. Darling $550,000 $599,500 9.0%
Sylvia Cheung $371,653 $392,094 5.5%
Thomas Finnerty $330,000 $341,550 3.5%
James Loerop n/a $375,000 n/a
Edward S. Ahn, Ph.D. $357,660 $364,813 2.0%

Name	2019 Salary	2020 Salary	% Change
Cheryl R. Blanchard, Ph.D.	n/a	$625,000	n/a
Michael L. Levitz	n/a	$450,000	n/a
David Colleran	n/a	$420,000	n/a
Thomas Finnerty	$341,550	$353,505	3.5%
James Loerop	$375,000	$381,563	1.8%
Joseph G. Darling	$599,500	$650,000	8.4%
Sylvia Cheung	$392,094	$427,383	9.0%

Annual Cash Bonus

The second principal component of our compensation policy for executive officers consists of cash bonuses, which are generally paid to our NEOs to motivate attainment of our near-term goals that are consistent with our long-term strategic plan.

Each NEO has a target annual bonus amount established by the Compensation Committee at the beginning of each year that is expressed as a percentage of the NEO’s base salary. In ~~2019,~~2020, these targets were ~~consistent with~~unchanged from the targets from the prior ~~several years.~~year for individuals in similar positions. The Compensation Committee establishes the target bonus amounts consistent with ~~its review~~the compensation philosophy described above, including consideration of ~~peer group~~market practices, and to provide, in its view, an appropriate balance between fixed (salary) and variable (bonus) cash compensation. The ~~2019~~2020 target bonus amounts for the NEOs were as follows:

~~2019~~

2020 Annual Cash Bonus Targets

Name	% of Salary	Amount	% of Salary	Amount at Target
Cheryl R. Blanchard, Ph.D.*			85%	$531,250
Michael L. Levitz*			45%	$202,500
David Colleran*			45%	$189,000
Thomas Finnerty			45%	$159,077
James Loerop			45%	$171,703
Joseph G. Darling	85%	$509,575	85%	$552,500
Sylvia Cheung	45%	$176,442	45%	$192,322
Thomas Finnerty	45%	$153,698
James Loerop*	45%	$168,750
Edward S. Ahn, Ph.D.	45%	$164,165

For Dr. Blanchard, Mr. ~~Loerop, his initial offer letter with the Company~~Levitz, and Mr. Colleran, each of their new-hire employment documentation provided that any bonus ~~payment~~ paid for ~~2019~~2020 would ~~not~~ be prorated based on ~~his date~~their dates of ~~hire.~~hire (in the case of Dr. Blanchard, her appointment as President and Chief Executive Officer on April 26, 2020).

Actual bonus amounts awarded are not formulaic and depend on the Compensation Committee’s ~~objective and subjective~~ assessment of both our business and individual NEO performance after the completion of each year. The Compensation Committee considers our financial performance in accordance with metrics previously discussed, our overall operational performance, and our contribution to increasing stockholder value at its discretion to determine an appropriate level of baseline cash bonus compensation for our NEOs. Once the Compensation Committee has established this baseline, it considers the applicable individual performance with respect to individual goals and contribution to overall company performance in its discretion to adjust each individual NEO’s cash bonus ~~payment.~~award. See “Key Performance Factors” above regarding the key financial and individual performance factors considered. Historically, cash bonuses for the most recently completed year are awarded contemporaneously with annual compensation reviews for ~~the subsequent~~that year. Bonuses ~~may be~~are generally prorated in the year of hire, provided that this requirement may be waived ~~in order~~ to induce top talent to join the organization ~~as was the case with the hire of Mr. Loerop.~~in certain circumstances. The Compensation Committee may also, in certain circumstances, grant cash bonuses for executive retention purposes, taking into account, among other things, general industry practices, special performance bonuses in exceptional circumstances, and any contractual obligations.

After the completion of the ~~2019~~2020 fiscal year, the Compensation Committee, with the assistance of the Chief Executive Officer, reviewed our performance, as well as the individual performance of each executive officer (other than ~~his~~her own performance). The accomplishments set forth in the Executive Summary section titled “Our Fiscal Year ~~2019~~2020 Business Performance” were ~~taken into account~~considered in this review. For the year, the Compensation Committee determined that we made ~~excellent~~strong overall business progress transforming our organization and ~~executed very strongly against~~integrating our ~~five-year strategic plan. The strong performance was seen~~acquisitions, especially in ~~both~~light of the challenges presented by the COVID-19 pandemic. While the COVID-19 pandemic, in conjunction with the impact of purchase accounting, had a major impact on the financial results delivered by the organization, ~~and~~especially as compared to prior years, the company delivered on the significant strategic and operational achievements set forth in the section captioned “Our Fiscal Year ~~2019~~2020 Business Performance” above, including ~~the work completed in preparation for~~completing the acquisitions of Parcus Medical and ~~Arthrosurface, the commercial launch of TACTOSET through our U.S. hybrid commercial model, and our international expansion successes.~~Arthrosurface. In addition, the ~~NEO’s generally exceeded~~company completed the ~~goals~~integration of the commercial organizations across the entire company, launched seven new products, built out the company’s management team and board of directors with nine new additions, and guided the company through the COVID-19 pandemic with no significant operational disruption or reductions in workforce. These achievements transformed the company and set ~~forth~~the stage for ~~them specifically during~~execution of the ~~annual budgeting~~company’s strategic plan and ~~goal-setting process previously described. These goals were strongly aligned~~delivery of value to all of its stakeholders over the ~~broader corporate goals, and strong individual performance led to our successful operating results as previously described.~~coming years. As a result, the Compensation Committee, using its informed judgment in considering the company’s performance in relation to its 2020 corporate objectives, including in light of macroeconomic business factors such as the COVID-19 pandemic, and without any pre-established formulas or target levels, set a cash bonus payment baseline of ~~100%~~90% of the target for each NEO, subject to adjustment based on individual performance achievement with respect to individual goals and contribution to overall company performance. ~~Special consideration was given to~~The Compensation Committee recognized the role that Mr. Loerop played in leading the company through the acquisitions of ~~Mr. Darling in directing strategic initiatives, including with respect to our acquisitions completed in early 2020, that generated long-term stockholder value during a year~~Parcus Medical and Arthrosurface, and the initial integration activities thereafter, and awarded him 100% of ~~transformation.~~his target bonus. Overall, each NEO had a strong performance during the year and significantly contributed to the company’s ~~growth.~~growth and business and financial highlights outlined above. The bonus targets based on annualized salary and final, individual ~~results, which~~actual bonus amounts paid are included in the ~~“Bonus” column~~table below.

In addition to the 2020 annual bonus amounts reflected below, Dr. Blanchard received a cash retention bonus of $127,500 to recognize her service as the company’s interim Chief Executive Officer in accordance with the ~~Summary Compensation Table, were as follows:~~ terms of a letter agreement executed between her and the company.

~~2019~~

2020 Cash Bonus Decisions

Name Bonus Target % Achieved Bonus Paid
Joseph G. Darling $509,575 150% $764,363
Sylvia Cheung $176,442 125% $220,553
Thomas Finnerty $153,698 120% $184,437
James Loerop* $168,750 120% $202,500
Edward S. Ahn, Ph.D.** $164,165 n/a n/a

Name	Bonus Target	% Achieved	Bonus Paid
Cheryl R. Blanchard, Ph.D.*	$531,250	90%	$331,010
Michael L. Levitz*	$202,500	90%	$73,601
David Colleran*	$189,000	90%	$143,931
Thomas Finnerty	$159,077	90%	$143,169
James Loerop**	$171,703	100%	$171,703
Joseph G. Darling***	$552,500	n/a	n/a
Sylvia Cheung***	$192,322	n/a	n/a

For Dr. Blanchard, Mr. ~~Loerop, his initial offer letter with~~Levitz, and Mr. Colleran, each of the ~~Company provided that any bonus payment~~bonuses paid for ~~2019 would not be~~2020 were prorated based on ~~his date~~their dates of ~~hire.~~hire (in the case of Dr. Blanchard, her appointment as our President and Chief Executive Officer on April 26, 2020).

~~Dr. Ahn’s~~Mr. Loerop received 100% of target due to achievement of additional business development and transactional goals, as further described in the “Annual Cash Bonus” section above.

***

Neither Mr. Darling nor Ms. Cheung were eligible for 2020 bonus payments as their employment with the ~~Company ended on July 5, 2019. As a result, no bonus was paid to Dr. Ahn for 2019.~~company ceased during 2020.

Equity-Based Grants

The third principal component of our compensation policy for executive officers consists of grants under our equity incentive plan, which are generally provided to our NEOs to align their ~~interests~~goals and objectives with ~~those~~the interests of our stockholders, to motivate attainment of our long-term strategic vision, and for retention purposes. Under our equity compensation plan, NEOs may be granted stock options or other forms of equity ~~securities,~~awards, including stock appreciation rights, restricted stock awards and units, and performance-based equity awards. Equity awards are approved at a regularly-scheduled Compensation Committee meeting, generally during the first quarter of each year given the meeting’s proximity to the beginning of the performance period for performance-based awards, and generally granted effective on the third full business day following our announcement of financial and business results for the completed prior fiscal year. During 2019, we implemented a deferred stock program that allows our directors and executives, at their discretion, to defer settlement of restricted ~~units~~stock unit awards granted to them ~~for grants of RSUs starting~~ in ~~2020.~~2020 and thereafter. We implemented this program to remain competitive with market practices and to encourage our NEO’s to hold shares of our common stock, thereby aligning their long-term incentives with those of our stockholders.

We also note that we are seeking shareholder approval to make an additional 1,100,000 shares available for issuance under our equity incentive plan. As discussed further in Proposal 2, as we refine our strategic objectives and initiatives and position our company for future growth, we are seeking shareholder approval for an amount of additional shares equivalent to our estimate of the number of shares we would grant over the course of the next year based on our current share price, recent burn rate history, and new-hire and annual grant practices to ensure that we are able to appropriately recruit, retain, and motivate our employees over the next year. Furthermore, in connection with this approval and our business strategy, we will review our compensation strategy as a whole, including the appropriate goals and metrics under our performance-based awards to drive long-term shareholder value.

The amount and form of equity-based grants each year are determined by the Compensation Committee using the compensation philosophy described above, including its informed judgment, and taking into account company performance, competitive market practices, ~~median total compensation levels at the company’s peers,~~ past and expected individual performance achievements, past and expected contributions to overall company performance, and the need to attract and retain talented executives who can drive and implement our growth and operational excellence strategies. Based on the foregoing principles, the Compensation Committee determined that Mr. Darling’s prior equity-based compensation grants were below market levels. Consequently, Mr. Darling’s 2019 equity-based grants include an additional number of shares intended as a “catch-up” to account for this determination. For the last several years, the Compensation Committee has increasingly used performance-based equity awards to align the interests of our NEOs with those of our stockholders.

In 2020, Dr. Blanchard was granted equity awards that, in their totality and ~~on January 29, 2019, the Compensation Committee approved grants, effective February 26, 2019, with a ratio of time-based to~~assuming target achievement, are split nearly evenly between time-vesting and performance-based awards and represent an appropriate starting equity package in comparison to chief executive officers of ~~1:1.~~comparable companies, and are intended to begin to align Dr. Blanchard’s equity ownership with that of chief executive officers of comparable companies. As a result, the value of Dr. Blanchard’s 2020 equity awards is larger than the value of equity awards that we expect to grant to her in near-term future years. Mr. Levitz and Mr. Colleran were granted restricted stock units evenly split between time-vesting and performance-based awards, as well as a new hire grant of time-vesting stock options as an additional inducement to join the company, in line with our past practices. Ms. Cheung, Mr. Finnerty, and Mr. Loerop were each granted restricted stock units split between time-vesting and performance-based awards using an even split as a baseline. In the case of Ms. Cheung and Mr. Finnerty, this split was adjusted towards a slightly greater amount of time-vesting restricted stock units to ensure market competitiveness and to account for prior granting history, expected future performance, and retention concerns. In the case of Mr. Loerop, his award was adjusted to a slightly greater amount of performance-based restricted stock units as a result of his hire around the midpoint of 2019 and the equity award he received in connection with his hire. For ~~2019,~~2020, the Compensation Committee awarded the NEOs a balanced mix of time-vesting and performance-based restricted stock units ~~or RSUs,~~and stock options as ~~follows~~follows:

~~2019~~2020 Restricted Stock Unit Grants

Name	Time-Vesting RSUs (# of shares)	Performance-Based RSUs (# of shares at target)	Time-Vesting RSUs (# of shares)	Performance-Based RSUs (# of shares at target)
Joseph G. Darling	63,000
Cheryl R. Blanchard, Ph.D.*			77,957	80,620
Michael L. Levitz			11,577
David Colleran			7,500
Thomas Finnerty			8,500	6,200
James Loerop			4,700	6,200
Joseph G. Darling**			n/a
Sylvia Cheung	9,000		11,700	10,000
Thomas Finnerty	9,000
James Loerop*	9,000
Edward S. Ahn, Ph.D.	4,500

Dr. Blanchard received 4,231 time-vesting restricted stock units upon her appointment as interim Chief Executive Officer on February 10, 2020 and the balance of her awards upon her appointment as our President and Chief Executive Officer on April 26, 2020.

Mr. ~~Loerop received a stock option award of 27,000 common stock options upon~~Darling was not granted any equity awards in 2020 due to his ~~commencement of his employment on July 8, 2019.~~passing in January 2020.

~~2019~~2020 Stock Option Grants

Name	Time-Vesting Stock Options (New Hire Grants)	Performance-Based Stock Options (# of shares at target)
Cheryl R. Blanchard, Ph.D.	104,638	104,638
Michael L. Levitz	57,145	n/a
David Colleran	35,000	n/a

2020 Time-Based ~~RSUs~~Restricted Stock Units

The restricted stock units were granted ~~in accordance with~~under our 2017 Omnibus Incentive Plan, or the Plan. ~~Each~~Except for the award to Dr. Blanchard associated with her appointment as interim Chief Executive Officer, each award vests in three equal annual installments beginning one year from the effective date of ~~grant, February~~grant. Dr. Blanchard’s award associated with her appointment as interim Chief Executive Officer vested on April 26, 2019. Except for the award to Mr. Darling, each award was granted on our standard form under the Plan. With respect to Mr. Darling’s award, the first installment of stock units, if and once vested, was to be settled upon the earlier of Mr. Darling’s “separation from service” as defined2020 in ~~the Plan, death, disability, or change in control as defined in the Plan. The remainder of~~accordance with the terms ~~in Mr. Darling’s award aligned to our standard form under~~of a letter agreement executed between her and the ~~Plan.~~company.

~~2019~~

2020 Performance-Based ~~RSUs~~Restricted Stock Units

The performance-based restricted stock units, or PSUs, were approved at a target level, but will be earned based upon the achievement of three performance metrics. The performance metrics for each NEO are identical. In order for the awards to vest and for the NEOs to receive the vested shares that are earned based on performance, the PSUs generally require continued employment through the date on which performance is measured against the stated metrics, which will occur after our independent public accounting firm renders its opinion on our fiscal year ~~2021~~2022 financial results. The first performance metric accounts for ~~30%~~60% of the target award level and relates to ~~successfully launching TACTOSET via~~certain financial milestones associated with our ~~newly-implemented U.S. hybrid commercial model, which metric we completed successfully during the third quarter of 2019.~~newly-acquired businesses and their contributions to our consolidated results. The second metric accounts for ~~55%~~20% of the target award level and ~~ratably measures our vitality index during the performance period. This aligns~~is linked to our publicly-stated goal of achieving a 25% vitality index by the end of fiscal year 2021. We define vitality index as recognized revenue from products launched or acquired after January 1, 2019 as a percentage of total recognized revenue in fiscal year 2021.enrollment progress and certain clinical trial milestones. The third metric accounts for ~~15%~~20% of the target award level and ratably measures our adjusted fiscal year 2021 EBITDA margin, a measure routinely used by management and our Board of Directors to evaluate our operating effectiveness, against a pre-set target. We define adjusted EBITDA margin as GAAP operating income, excluding any extraordinary one-time charges, plus depreciation, amortization and stock-based compensation amortization expenses divided by total revenue.is associated with certain new product regulatory milestones. The maximum possible payout under the ~~2019~~2020 PSUs is ~~135%~~150% of the target shares set forth in the table above. We generally do not disclose forward-looking goals for our multi-year incentive programs, because we do not provide forward-looking guidance to our investors with respect to multi-year periods, and the forward-looking multi-year goals contain competitively sensitive information. We will disclose multi-year performance goals in our regular programs in full after the close of the performance period.

~~These 2019 equity grants are shown in the Summary Compensation Table under the “Stock Awards,” and for Mr. Loerop “Option Awards,” columns, and additional details are included in the~~2020 Stock Option Grants ~~of Plan-Based Awards Table.~~

~~2018 Performance-Based Stock Options~~

The time-vesting stock options were granted in accordance with our Plan, and each award vests in three equal annual installments beginning one year from the effective date of grant. The performance-based stock options granted ~~in 2018 were~~to Dr. Blanchard are eligible to ~~be earned~~vest as to 150% of the target shares reported in the table based on the company’s total shareholder return relative to a ~~combination~~comparison group of ~~our 2018 net income results~~companies set forth in Dr. Blanchard’s employment agreement through December 31, 2022. The comparison group of companies excludes Anika and ~~achievement~~includes (1) the Global Industry Classification Standard (GICS) 3520 (Pharmaceuticals, Biotechnology & Life Sciences) companies in the Russell 2000 Value Index determined as of ~~specified business milestones unique to each individual NEO. Based on~~April 26, 2020, (2) the ~~Board’s review~~GICS 3510 (Health Care Equipment) companies in the Russell 2000 Value Index as of ~~the business~~April 26, 2020, and our 2018 budget, the Compensation Committee set a net income results target of $18.6 million with a maximum award threshold of 150% targeted at $20.5 million. Awards were prorated from 100% to 150% for achievement of net income results between the target and maximum threshold amounts. In 2019, the Compensation Committee determined that, for the 2018 performance-based stock options, the company ultimately achieved net income results of $18.7 million. For each of Mr. Darling, Ms. Cheung, Dr. Ahn, and Mr. Hague, 50% of the overall targeted award was associated with net income results. For Mr. Finnerty, 60% of the overall targeted award was associated with net income results. With respect to specified individual business milestones, approximately 50% of the aggregate shares associated with such milestones were associated with activities linked(3) to the approval or potential commercial launch of Cingal, each of which was mooted by the results of the second Cingal Phase III trial publicly announced in June 2018. An additional 30% were linked to financial metrics directly impacted by the voluntary, non-safety related recall of certain HYAFF-based products,extent not otherwise included, Amag Pharmaceuticals, Inc., Avid Biosciences, Inc., Vericel Corporation, Conformis, Inc., Axogen, Inc., CyroLife, Inc., and the remainder was associated with business development activities, systems implementation, and employee turnover rate. Dr. Ahn was the only individual who met a specified personal milestone, which was associated with 10% of his targeted award (and 1.8% of the overall group’s targeted shares) and required that he formulate a business development strategic plan. Please see the table below for share amounts earned with respect to performance awards:Glaukos Corporation.

Name Stock Option Target % Achieved Stock Options Granted
Joseph G. Darling 14,300 53.2% 7,609
Sylvia Cheung 14,300 53.2% 7,609
Edward Ahn, Ph.D. 8,900 63.2% 5,625
Thomas Finnerty 4,500 63.9% 2,873
Richard Hague 7,100 53.2% 3,777

Other Compensation Matters

Employment and Executive Retention Agreements Effective at December 31, ~~2019~~2020

~~Effective April 9, 2019,~~Dr. Blanchard entered into an employment agreement with us (more fully described in the ~~employment agreements~~section captioned “The Death of Mr. Darling and ~~Ms. Cheung were amended,~~the Appointment of Dr. Blanchard”) and ~~the Company~~we entered into ~~“Executive Retention Agreements”~~executive retention agreements with each of the other ~~NEOs (excepting Mr. Loerop, who executed his agreement upon joining the Company).~~NEOs. While the NEOs remain employed at-will, these agreements are intended to provide market-level severance compensation to be competitive with our peer group of comparable companies and to promote retention. We believe that these agreements are fair to the executives and to our stockholders because they provide relatively modest severance in exchange for the restrictive covenants that help protect our company. These restrictive covenants include standard non-competition, non-solicitation, non-disparagement, and confidentiality restrictions. The agreements are discussed in connection with the Potential Payments Upon Termination or Change in Control table on page 4857 below.

Each agreement ~~also~~ provides for severance benefits that may be triggered by an involuntary termination of employment by us without “cause” or by the executive for “good reason” (as defined in each agreement)., or a qualifying termination. The level of severance benefits depends on whether the involuntary termination occurs during or outside of a change in control protected period that runs from three months before until 12 months after a change in ~~control.~~control (as defined in each agreement). In addition, the agreements provide for full vesting of outstanding equity awards upon a qualifying termination occurring during the period from three months before until 12 months after a change in control for awards granted after January 29, 2019. ~~Awards~~Equity awards granted prior to January 29, 2019 will continue to vest in full upon the occurrence of a change in control in accordance with the award terms. Except as described in this paragraph and for certain equity grants made to Dr. Blanchard upon her appointment as our President and Chief Executive Officer, none of the equity grants made to our NEOs provide for accelerated vesting upon termination of their employment by us without “cause” or by the executive for “good reason.” If “golden parachute” excise taxes would be triggered by payments due in connection with termination during a change in control protected period, the agreements provide for a cut-back in the payments to avoid the excise tax, if the cut-back would result in a greater after-tax benefit to the executive.

For the purposes of these agreements, “cause” is generally defined, subject to slight variation, as (a) neglect of duties, (b) willful misconduct or gross negligence, (c) embezzlement, fraud or violation of company policies, (d) disclosure of a trade secret or other confidential information, (e) ~~inducement of a customer to break a contract, (f) inducement of an inventor or potential investor to break a contract to invest or decline to invest in the company, (g)~~ conviction of a felony associated with financial impropriety, ~~or (h)~~(f) failure to perform in a material respect without proper ~~cause.~~cause, or (g) willful failure to cooperate with a bona fide internal or external investigation. “Good reason” is generally defined as (a) a material diminution in responsibilities, (b) a material diminution in compensation (except as part of an across-the-board diminution to all executive employees), (c) a material change to the geographic location where the executive is expected to provide services, or (d) material breach of the agreement by the company. “Change in control” is generally defined as (a) a person becoming the beneficial owner of more than 50% of the company’s voting securities (except as a result of an acquisition of securities directly from the company), (b) a majority of the members of the board being replaced in a twelve month period or at two consecutive annual stockholder meetings, whichever is longer, or (c) an acquisition of control of the company or substantially all of its assets.

The following summarizes the cash and health benefits (i.e., company payment of premiums under the company’s health plans) severance ~~benefits~~ provided to the NEOs as of December 31, ~~2019:~~2020:

Trigger	Type of Severance	~~Mr. Darling~~Dr. Blanchard	~~Ms. Cheung~~	Other NEOs
Termination without cause or with good reason, not in connection with a change in control	Cash severance	~~1.5x~~18 months’ salary ~~plus target bonus~~	~~12 months of salary plus target bonus~~	12 months’ salary
	Health benefits	18 months at active employee rates	~~12 months at active employee rates~~	12 months at active employee rates
Termination without cause or with good reason, within 3 months before or 12 months after a change in control	Cash severance	2x the sum of 12 months’ salary plus target bonus	~~1.5x salary plus target bonus~~	12 months’ salary plus target bonus
	Health benefits	~~24 months at active employee rates~~	18 months at active employee rates	12 months at active employee rates

In addition, in accordance with the terms of ~~Mr. Darling’s~~Dr. Blanchard’s employment agreement, if ~~Mr. Darling’s~~Dr. Blanchard’s employment is terminated “without cause” or ~~Mr. Darling~~Dr. Blanchard terminates ~~his~~her employment with us for “good ~~reason,” all~~reason” not due to disability prior to December 31, 2021, she would be entitled to pro rata vesting of ~~his outstanding equity awards will immediately vest~~the time-vesting restricted stock unit grant and ~~become non-forfeitable. All outstanding awards remain exercisable until eighteen months after~~ the ~~date~~time-vesting stock option grant awarded to her on April 26, 2020 in conjunction with the commencement of ~~his termination or, if earlier, the original ten-year expiration date.~~her employment as President and Chief Executive Officer.

The Death of Mr. Darling and the Appointment of Dr. Blanchard

Mr. Darling unexpectedly passed away on January 29, 2020. At the time of his passing, the Compensation Committee had previously determined ~~his bonus for his excellent service to the company in 2019 at 150% of target, or $764,363. In addition, the Compensation Committee had also determined~~ that Mr. Darling’s base salary would be increased to $650,000 for fiscal year 2020. Mr. Darling’s bonus and salary through January 29, 2020 were paid to his estate. In 2020, the company also paid $100,000 to Mr. Darling’s estate for the housing allowance contained in his employment agreement and continued to pay the company portion of COBRA premiums at the active employee rate under our health plans for Mr. Darling’s family. In accordance with the terms of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended, and Mr. Darling’s employment agreement with ~~the Company,~~us, all of Mr. Darling’s unvested stock option, restricted stock, and restricted stock unit awards were forfeited as of the date of his passing. Vested, but unexercised, stock options ~~will remain~~remained exercisable for one year.

4148

Following Mr. Darling’s passing, ~~our~~the Board of Directors briefly activated an interim Office of the President to provide leadership and oversight of day-to-day affairs before appointing Dr. Blanchard as our interim Chief Executive Officer, effective February 10, ~~2020.~~2020, pursuant to the terms of a letter agreement executed between her and the company. Dr. Blanchard was later appointed our President and Chief Executive Officer effective April 26, 2020. In connection with Dr. Blanchard’s transition to President and Chief Executive Officer, ~~the Company~~we and Dr. Blanchard entered into an employment agreement effective as of April 23, 2020 (the “Agreement”). The Agreement has an initial term of April 26, 2020 through December 31, 2021, which automatically renews for successive 1-year periods unless either party elects nonrenewal in accordance with the Agreement. The Agreement provides for an annual base salary of $625,000 and a target annual bonus opportunity equal to 85% percent of annual base salary. In addition, the Agreement provides for the following equity awards: (i) a time-based restricted stock unit grant covering 73,726 shares, eligible to vest in equal annual installments over three years; (ii) a performance-based restricted stock unit grant covering 80,620 shares at target, eligible to vest asup to 150% of the target shares on February 25, 2023 pursuant to ~~the Company’s~~our 2020 performance measures (as described above) for performance-based restricted stock units; (iii) a time-based stock option grant covering 104,638 shares, eligible to vest in equal annual installments over three years; and (iv) a performance-based stock option grant covering 104,638 shares at target, eligible to vest asup to 150% of the target shares based on ~~the Company’s~~our total shareholder return relative to a comparison group of companies set forth in the Agreement through December 31, 2022. In each case, vesting generally requires Dr. Blanchard’s continued employment through the relevant vesting date. The Agreement provides for (i) reimbursement of reasonable business expenses, (ii) ~~reimbursement~~the payment of up to $10,000 in legal fees incurred by Dr. Blanchard in connection with the Agreement, (iii) participation in ~~the Company’s~~our benefit plans, and (iv) 30 paid vacation days per year. Under the Agreement, if Dr. Blanchard’s employment is terminated due to death, disability (as defined in the Agreement), by ~~the Company~~us without “cause” (as defined in the Agreement and including ~~the Company’s~~our nonrenewal of the term of the Agreement), or by Dr. Blanchard for “good reason” (as defined in the Agreement), Dr. Blanchard would become entitled to (i) 18 months of base salary, (ii) continued payment of ~~Company~~company premiums under ~~the Company’s~~our benefit plans for 18 months and (iii) if such termination is not due to disability and occurs prior to December 31, 2021, pro rata vesting of the time-based restricted stock unit grant and the time-based option grant described above. Notwithstanding the foregoing, if such a termination without cause or for good reason occurs within 3 months prior to or 12 months after a change in control (as defined in the Agreement), Dr. Blanchard would become entitled to (i) 2 times the sum of her base salary and her target annual bonus, (ii) continued payment of ~~Company~~company premiums under ~~the Company’s~~our benefit plans for 18 months and (iii) vesting of her equity ~~awards~~awards. The performance-based restricted stock unit grant and each other award with a performance metric-based vesting condition (other than a total stockholder return-based vesting condition) would vest based on ~~assumptions set forth~~the greater of assumed target performance or actual performance measured through the date of termination. For the total stockholder return-based option grant (and any other award with a total stockholder return-based vesting condition), the applicable performance period would be shortened to end as of immediately prior to the change in ~~the Agreement.~~control and performance would be measured at such time. Any such severance benefits under the Agreement are contingent on Dr. Blanchard entering into and not revoking a general release of claims in favor of ~~the Company, its~~our company, our affiliates, and ~~its~~our service providers. Finally, the Agreement contains customary covenants related to non-competition and non-solicitation for 12 months following termination of employment, as well as customary covenants related to confidentiality, inventions and intellectual property rights.

In addition to the Agreement, the company entered into a letter agreement with Dr. Blanchard in connection with her appointment as our interim Chief Executive Officer under which she was employed at will and the company (i) paid her base salary compensation at an annualized rate of $600,000, which resulted in base salary payments of $115,385, (ii) paid her a cash retention bonus of $127,500, (iii) provided additional monthly payments of $3,448.28 in lieu of her participation in the company’s health plans, (iv) granted her 4,231 restricted stock units on February 25, 2020, and (v) provided for the payment of up to $3,000 in legal fees incurred by Dr. Blanchard in connection with the letter agreement. The letter agreement was executed on February 25, 2020 and covered the period from her appointment as interim Chief Executive Officer on February 10, 2020 through her appointment as our President and Chief Executive Officer on April 26, 2020.

Other Compensation

The NEOs are eligible to participate in our health and welfare programs, 401(k) plan, and other benefit programs on the same basis as other employees.

Deductibility of Executive Compensation and Accounting Considerations

Section 162(m) of the Internal Revenue Code generally limits our annual corporate tax deduction for compensation paid to each of our “covered employees” to $1 million. “Covered employees” include anyone who served as chief executive officer or chief financial officer during any part of a year and the next three most highly compensated named executive officers for that year. In addition, once a person is considered a “covered employee,” that person remains a covered employee in all subsequent years (including after the person leaves our service or changes roles). The American Rescue Plan Act of 2021 updated Section 162(m) ~~limits~~of the ~~deductibility~~Internal Revenue Code, effective in 2026, to expand the number of “covered employees” subject to the $1 million deduction limit to include the next five highest compensated employees of the company; however this new group of employees will not retain the perpetual “covered employee” status and will be determined annually. Consequently, we generally will not be entitled to a U.S. tax deduction for compensation paid in any year to our named executive officers and our other “covered employees” in excess of $1 ~~million paid to any~~million. While considering tax deductibility as only one ~~NEO~~of several considerations in ~~any calendar year. Under~~determining compensation, we believe that the tax ~~rules in effect before 2018,~~deduction limitation should not compromise our ability to structure compensation programs that ~~qualified as “performance-based” under Section 162(m) was deductible without regard~~provide benefits to ~~this $1 million limit. In 2017~~the Company that outweigh the potential benefit of a tax deduction and, prior years, the Compensation Committee granted stock options under our equity incentive plans that were intended to qualify for this performance-based compensation exception. However, the Tax Cuts and Jobs Act, which was signed into law December 22, 2017, eliminated this performance-based compensation exception effective January 1, 2018, subject to a special rule that “grandfathers” certain awards and arrangements that were in effect on or before November 2, 2017. As a result,therefore, may approve compensation that is ~~paid on or after January 1, 2018 may~~ not ~~be fully~~ deductible ~~depending~~for tax purposes.

We follow the Financial Accounting Standard Board’s Accounting Standards Codification Topic 718 for our stock-based compensation awards, which requires us to measure the compensation expense for all share-based awards based on the ~~application~~grant date “fair value” of these awards. This calculation is performed for accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of the ~~special grandfather rules. Moreover,~~awards may realize no value from their awards.

We have not provided or committed to provide any NEO with a gross-up or other reimbursement for tax amounts the executive might pay pursuant to Section 280G or Section 409A of the Internal Revenue Code. Section 280G and ~~after January 1, 2018, compensation awarded~~related sections of the Internal Revenue Code provide that an executive officer and certain persons who hold significant stockholder interests and certain other service providers could be subject to significant additional taxes if they receive payments or benefits in ~~excess of $1 million to~~connection with a change in control that exceeds certain limits, and that we or our ~~NEOs generally will not be deductible. While~~successor could lose a deduction on the ~~Tax Cuts and Jobs Act will limit the deductibility of compensation paid~~amounts subject to the ~~NEOs,~~additional tax. Section 409A of the ~~Compensation Committee will—consistent with its past practice—design compensation programs that are intended to be~~Internal Revenue Code also imposes additional significant taxes on the individual in the ~~best long-term interests~~event that an executive officer, director or service provider of certain types receives “deferred compensation” that does not meet the requirements of Section 409A of the Company and its stockholders, with deductibility of compensation being one of a variety of considerations taken into account. The company takes into account certain requirements of GAAP in determining NEO compensation as one of a variety of considerations taken into account.Internal Revenue Code.

Role of Management in Determining Compensation

The Compensation Committee, which is comprised entirely of independent ~~members of our Board of Directors,~~directors, is responsible for establishing and implementing our executive compensation philosophy and for ensuring that the total compensation paid to our NEOs and other executives is fair, competitive and motivates high performance. The Compensation Committee is solely responsible for compensation decisions regarding our CEO. When making compensation recommendations for NEOs other than the CEO, the Compensation Committee expects to seek and consider the advice and counsel of the CEO, given ~~his or~~ her direct day-to-day working relationship with those executives. Taking this feedback into consideration, the Compensation Committee will engage in discussions and ~~makes~~make final determinations related to compensation paid to the NEOs.

Risk Considerations in Our Compensation ~~Programs.~~Programs

The Compensation Committee believes that risks arising from our policies and practices for compensating employees are not reasonably likely to have a material adverse effect on our company.

Compensation Clawback

All awards, amounts or benefits received or outstanding under the ~~company’s 2017 Omnibus Incentive~~ Plan by the NEOs are subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar action in accordance with the terms of any clawback or similar policy or any applicable law related to such actions, as may be in effect from time to time.

Prohibition on Hedging, Pledging, and Short Sales

~~The Company’s insider trading policy~~Our Insider Trading Policy prohibits the NEOs from hedging or pledging of ~~the Company’s~~our stock.

Stock Retention Guidelines

~~The Company’s~~Our stock retention guidelines generally require each NEO to beneficially own certain amounts of our common stock. Generally, these guidelines require the Chief Executive Officer to beneficially own, at a minimum, either (a) 50,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common stock having a market value equal to three times the amount of his or her base ~~salary and they~~salary. They require any other NEO to beneficially own, at a minimum, either (a) 10,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common stock having a market value equal to the amount of his or her base salary. Any individual initially elected as an executive officer ~~after September 30, 2014~~ has five years to achieve compliance. Each NEO is currently in compliance or within the five-year grace period. See the section captioned “Director and Executive Officer Stock Retention Guidelines” elsewhere in this Proxy Statement for additional information.

Compensation Committee Report

The Compensation Committee of the Board of Directors of Anika Therapeutics, Inc. has reviewed and discussed with the management of Anika Therapeutics, Inc. the section entitled “Compensation Discussion and Analysis” contained in this Proxy Statement. Based on its review and discussions with management, the Compensation Committee recommended to the Board that the section entitled “Compensation Discussion and Analysis” be included in this Proxy Statement for the ~~2020~~2021 Annual Meeting of Stockholders. This report is submitted by the following independent directors who comprise the Compensation Committee:

Joseph L. Bower, ~~Chairperson~~Chair

John B. Henneman, III

Raymond J. Land

Glenn R. Larsen

~~Jeffery S. Thompson~~

~~Susan N. Vogt~~

THE FOREGOING REPORT SHOULD NOT BE DEEMED INCORPORATED BY REFERENCE INTO ANY FILING UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES EXCHANGE ACT OF 1934 BY ANY GENERAL STATEMENT INCORPORATING BY REFERENCE THIS PROXY STATEMENT, EXCEPT TO THE EXTENT THAT ANIKA THERAPEUTICS, INC. SPECIFICALLY INCORPORATES THIS INFORMATION BY REFERENCE, AND SHALL NOT OTHERWISE BE DEEMED FILED UNDER EITHER OF SUCH ACTS.

4451

Executive and Director Compensation

Summary Compensation Table

The following table summarizes the compensation information in respect of our NEOs for the year ended December 31, ~~2019.~~2020.

Name and Principal Position Year Salary⁽¹⁾ Bonus⁽²⁾ Option
Awards⁽³⁾ Stock
Awards⁽³⁾ All Other
Compensation⁽⁴⁾ Total
Joseph G. Darling⁽⁵⁾ 2019 $ 599,500 $ 764,363 $ - $ 4,098,780 $ 127,539 ⁽¹⁰⁾ $ 5,590,182
President and Chief 2018 $ 523,462 ⁽⁵⁾ $ 412,500 $ 728,335 $ 399,998 ⁽⁹⁾ $ 105,892 ⁽¹¹⁾ $ 2,170,187
Executive Officer 2017 $ 181,987 $ 93,990 $ 750,281 ⁽⁸⁾ $ 749,960 ⁽⁸⁾ $ 5,993 ⁽¹²⁾ $ 1,782,212
Sylvia Cheung 2019 $ 392,094 $ 220,553 $ - $ 585,540 $ 20,680 $ 1,218,867
Chief Financial Officer 2018 $ 371,653 $ 167,244 $ 728,335 $ - $ 19,970 $ 1,287,202
2017 $ 359,085 $ 185,827 $ 709,054 $ - $ 18,720 $ 1,272,686
Thomas Finnerty 2019 $ 341,550 $ 184,437 $ - $ 585,540 $ 24,352 $ 1,135,879
EVP of Human Resources 2018 $ 330,000 $ 118,800 $ 285,831 $ - $ 24,002 $ 758,633
2017 $ 44,423 $ - $ 301,451 $ 367,812 $ 2,508 $ 716,194
James Loerop⁽⁶⁾ 2019 $ 165,865 ⁽⁶⁾ $ 202,500 $ 377,772 $ 732,060 $ 1,429 ⁽¹³⁾ $ 1,479,626
EVP of Business Development $ - $ - $ - $ - $ -
and Strategic Planning $ - $ - $ - $ - $ -
Edward S. Ahn, Ph.D.⁽⁷⁾ 2019 $ 202,628 ⁽⁷⁾ $ - $ - $ 292,770 $ 184,044 ⁽¹⁴⁾ $ 679,442
Chief Technology and 2018 $ 357,660 $ 80,474 $ 455,126 $ - $ 20,330 $ 913,590
Strategy Officer 2017 $ 347,243 $ 125,007 $ 599,331 $ - $ 19,080 $ 1,090,662

Name and Principal Position	Year		Salary ($) ⁽¹⁾			Bonus ($)⁽²⁾			Stock Awards ($)⁽³⁾			Option Awards ($) ⁽³⁾			All Other Compensation ($) ⁽⁴⁾			Total ($)
Cheryl R. Blanchard, Ph.D.		2020	$	548,077	⁽⁵⁾	$	458,510	⁽⁶⁾	$	5,335,439	⁽⁷⁾	$	3,659,450	⁽⁸⁾	$	27,958	⁽⁹⁾	$	10,029,434
President and Chief		2019	$	-		$	-		$	-		$	-		$	-		$	-
Executive Officer		2018	$	-		$	-		$	-		$	-		$	-		$	-
Michael L. Levitz⁽¹⁰⁾		2020	$	173,077		$	73,601		$	799,971		$	799,993		$	11,318		$	1,857,960
EVP, Chief Financial Officer		2019	$	-		$	-		$	-		$	-		$	-		$	-
and Treasurer		2018	$	-		$	-		$	-		$	-		$	-		$	-
David Colleran⁽¹¹⁾		2020	$	344,077		$	143,931		$	645,900		$	553,445		$	18,263		$	1,705,616
EVP, General Counsel		2019	$	-		$	-		$	-		$	-		$	-		$	-
and Secretary		2018	$	-		$	-		$	-		$	-		$	-		$	-
Thomas Finnerty		2020	$	353,505		$	143,169		$	626,367		$	-		$	20,746	⁽¹²⁾	$	1,143,787
EVP, Human Resources		2019	$	341,550		$	184,437		$	585,540		$	-		$	24,352		$	1,135,879
		2018	$	330,000		$	118,800		$	-		$	285,831		$	24,002		$	758,633
James Loerop		2020	$	381,563		$	171,703		$	464,449		$	-		$	22,156		$	1,039,871
EVP, Business Development		2019	$	165,865		$	202,500		$	732,060		$	377,772		$	1,429		$	1,479,626
and Strategic Planning		2018	$	-		$	-		$	-		$	-		$	-		$	-
Joseph G. Darling⁽¹³⁾		2020	$	80,752		$	-		$	-		$	-		$	208,001	⁽¹⁴⁾	$	288,753
President and Chief		2019	$	599,500		$	764,363		$	4,098,780		$	-		$	127,539		$	5,590,182
Executive Officer		2018	$	523,462		$	412,500		$	399,998		$	728,335		$	105,892		$	2,170,187
Sylvia Cheung⁽¹⁵⁾		2020	$	294,252		$	-		$	924,637		$	-		$	89,644	⁽¹⁶⁾	$	1,308,534
Chief Financial Officer, Treasurer		2019	$	392,094		$	220,553		$	585,540		$	-		$	20,680		$	1,218,867
and Assistant Secretary		2018	$	371,653		$	167,244		$	-		$	728,335		$	19,970		$	1,287,202

(1)	The amounts in this column represent the annual base salary approved for the executive by the Board of Directors, prorated based on employment dates during the indicated year.
(2)	The amounts in this column represent discretionary cash bonuses earned in the indicated year, but paid in ~~January or~~ February of the following year, and have been prorated based on employment dates during the indicated year. See the section in the Compensation Discussion and Analysis titled “Annual Cash Bonus” for additional details regarding the cash bonuses earned for 2020.
(3)	The amounts in this column reflect the grant date fair value computed with respect to the ~~equity~~stock and option awards issued during the indicated year calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718, or ASC ~~Topic~~ 718. See the information appearing in Note 1314 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, ~~2018~~2020 for certain assumptions made in the valuation of stock and option awards. ~~The~~Unless otherwise noted, the Board granted equity awards on February 25, 2020, February 26, 2019, and January 24, 2018, ~~and January 27, 2017,~~ respectively. ~~Awards~~Time-vesting awards granted in ~~2018, 2016,~~2020 and ~~2015~~2019 vest ratably over 3 years beginning one year from the date of grant, while time-vesting awards granted in 2018 vest ratably over 4 years beginning one year from the date of ~~grant, while awards granted in 2019 and 2017 vest ratably over 3 years beginning one year from the date of~~ grant. For 2020 and 2019 performance-based restricted stock units, ~~and 2018 performance-based stock options,~~ the fair value on the date of grant was determined at the ~~“target”~~probable outcome level of "target," or 100% attainment ~~level.~~level, pursuant to ASC 718. If the grant date fair value of the 2020 performance-based restricted stock units had been determined at the "maximum," or 150%, attainment level, the fair value on the date of grant for the awards would have been $4,039,062 for Dr. Blanchard, $599,978 for Mr. Levitz, $484,425 for Mr. Colleran, $396,273 for Messrs. Finnerty and Loerop, and $639,150 for Ms. Cheung. These values represent incremental increases over the amounts set forth in this column for 2020 of $1,346,354 for Dr. Blanchard, $199,993 for Mr. Levitz, $161,475 for Mr. Colleran, $132,091 for Messrs. Finnerty and Loerop, and $213,050 for Ms. Cheung. If the grant date fair value of the 2019 performance-based restricted stock units had been determined at the ~~“maximum”~~"maximum," or 135%, attainment level, the grant date fair value of the awards would have been valued at ~~$2,766,677 for Mr. Darling,~~ $395,240 for ~~Ms. Cheung and~~ Mr. Finnerty, $494,141 for Mr. Loerop, $2,766,677 for Mr. Darling, and ~~$197,620~~$395,240 for ~~Dr. Ahn.~~Ms. Cheung. These values ~~would~~ represent incremental increases over the amounts set forth in this column for 2019 of $102,470 for Mr. Finnerty, $128,111 for Mr. Loerop, $717,287 for Mr. Darling, and $102,470 ~~$128,111, and $51,235, respectively. Please see~~for Ms. Cheung. See the ~~table~~section in the ~~section captioned “Option Grants~~Compensation Discussion and ~~Plan Awards in 2019”~~Analysis titled “Equity-Based Grants” and "The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional ~~information.~~details regarding the stock and option awards issued in 2020.
(4)	Unless otherwise noted, these amounts constitute ~~group term life insurance premiums and~~ matching contributions to our Employee Savings and Retirement Plan (401(k) ~~plan).~~Plan) and group term life insurance premiums. Matching contributions to the 401(k) Plan in the indicated year were as follows: $18,093 to Dr. Blanchard, $10,903 to Mr. Levitz, $17,349 to Mr. Colleran, $15,669 to Mr. Finnerty, $18,940 to Mr. Loerop, $4,842 to Mr. Darling, and $19,950 to Ms. Cheung.
(5)	~~Mr. Darling was hired~~This amount represents $115,385 in salary and $10,345 in lieu of participation in the company’s health plans paid to Dr. Blanchard during her service as ~~our President on July 27, 2017~~the interim Chief Executive Officer from February 10, 2020 to April 25, 2020, and ~~his 2017~~$432,692 in Dr. Blanchard's prorated 2020 base salary ~~represents his prorated salary for 2017. On March 9, 2018, Mr. Darling was appointed~~upon her appointment on April 26, 2020 as ~~our~~ President and Chief Executive ~~Officer,~~Officer. See the section in Compensation Discussion and ~~he became one~~Analysis titled "The Death of ~~our directors. On this date,~~ Mr. ~~Darling’s base salary was increased from $440,000 to $550,000. Mr. Darling’s 2018 salary is comprised~~Darling and the Appointment of ~~his base salary as President~~Dr. Blanchard" for additional details.

(6)	This amount reflects the discretionary prorated ~~from January 1, 2018 to March 8, 2018~~cash bonus earned for the indicated year of $331,010 and ~~his base salary as~~a cash retention bonus of $127,500 provided under the terms of the interim Chief Executive Officer letter agreement entered into between the company and ~~President prorated from March 9, 2018 to December 31, 2018.~~Dr. Blanchard. See the section in the Compensation Discussion and Analysis titled “Annual Cash Bonus” for additional details regarding the cash bonus earned for 2020.
~~(6)~~(7)	In addition to the time-vesting and performance-based restricted stock units granted to her under her employment agreement (see the section in the Compensation Discussion and Analysis titled “The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional details regarding such awards), this amount includes the grant date fair value of the restricted stock unit award granted to Dr. Blanchard by the Board on February 10, 2020 in connection with her appointment as interim Chief Executive Officer. This award vests ratably on annual basis over 3 years beginning one year from the date of grant.
(8)	This amount includes the performance-based stock option award made by the Board to Dr. Blanchard on February 25, 2020. The 2020 performance-based stock option award fair value on the date of grant was determined at the "target," or 100% attainment level, pursuant to ASC 718. If the fair value of the 2020 performance-based stock option award had been determined at the "maximum," or 150%, attainment level, the award would have been valued at $5,242,364. The value represents an additional incremental increase over the amounts set forth in this column of $2,948,699. See the section in the Compensation Discussion and Analysis titled “Equity-Based Grants” and "The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional details regarding the option award.
(9)	This amount includes $6,868 in fees earned as an independent director prior to her appointment as our interim Chief Executive Officer.
(10)	As noted elsewhere in this proxy statement, Mr. ~~Loerop~~Levitz was hired as our Executive Vice President, ~~of Business Development~~Chief Financial Officer and ~~Strategic Planning~~Treasurer on ~~July 8, 2019~~August 10, 2020, and his ~~2019~~2020 base salary represents his prorated salary for ~~2017.~~ 2020.
~~(7)~~(11)	As noted elsewhere in this proxy statement, ~~Dr. Ahn’s employment~~Mr. Colleran was hired as ~~Chief Technology~~our Executive Vice President, General Counsel and ~~Strategy Officer ended effective July 5, 2019,~~Secretary on March 4, 2020, and his ~~2019~~2020 base salary represents his prorated salary for 2020.
(12)	This amount includes a $142 company service award.
(13)	As noted elsewhere in this proxy statement, Mr. Darling passed away unexpectedly on January 29, 2020, and his 2020 base salary represents the salary he earned ~~prior to the end of his employment.~~
~~(8)~~	~~Upon the commencement of Mr. Darling’s employment with the company, his employment agreement provided for two new hire equity grants with a total grant date value of $1,500,000, provided 50%~~ as ~~stock options~~President and ~~50% as shares of restricted stock, each vesting annually over three years following grant.~~
~~(9)~~	~~Upon the appointment of Mr. Darling as our~~ Chief Executive Officer ~~on March 8, 2018,,~~prior to his amended employment agreement provided for a one-time equity grant with a total grant date value of $400,000, provided 25% as shares of restricted stock vesting upon grant and 75% as shares of restricted stock vesting annually over three years following the grant.
~~(10)~~	This amount includes $100,000 of unallocated housing allowance and $3,187 for attorney fees associated with negotiation and drafting of the second amendment to Mr. Darling’s employment agreement reimbursed by the Company.
~~(11)~~	This amount includes $56,859 of relocation expenses and $25,031 of related tax gross-up payments provided to Mr. Darling in 2018 in accordance with the terms of the Employment Agreement Amendment we entered with Mr. Darling on March 9, 2018.
~~(12)~~	~~This amount includes $3,982 of relocation expense provided to Mr. Darling in 2017 in accordance with the terms of the Employment Agreement we entered with Mr. Darling on July 27, 2017.~~
~~(13)~~	~~Mr. Loerop did not receive any matching contributions to our Employee Savings and Retirement Plan (401(k) plan).~~death.
(14)	This amount includes ~~payment~~payments of ~~$2,461~~$82,211 for accrued vacation time, $100,000 in housing allowance, and ~~$161,360~~$20,400 in ~~severance payments~~continued COBRA healthcare premiums for Mr. Darling's family following Mr. Darling's death in January 2020. See the section in the Compensation Discussion and Analysis titled "The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional details.
(15)	As noted elsewhere in this proxy statement, Ms. Cheung resigned as Chief Financial Officer, Treasurer and Assistant Secretary of the company on August 10, 2020, and her 2020 base salary represents the salary she earned prior to the end of her employment.
(16)	This amount includes a $991 company service award and $67,956 for accrued vacation time pursuant to ~~Dr. Ahn’s Separation Agreement with us dated July 8, 2019.~~Ms. Cheung's resignation on August 10, 2020.

~~Option~~ Grants ~~and Plan~~of Plan-Based Awards in ~~2019~~2020

The following table sets forth each grant of equity awards under the Plan made to the NEOs during the year ended December 31, ~~2019.~~2020. All such equity awards vest over a three-year period commencing on the first anniversary of the grant date, except for performance-based equity awards which vest on the performance measurement date.

		Estimated future payouts under equity incentive plan awards							Stock Awards: Number of shares of stock or		All Other Option Awards: Number of shares underlying		Exercise Price or Base of Equity		Grant Date Fair Value of			Estimated future payouts under equity incentive plan awards							All other stock awards: Number of shares of		All other option awards: Number of securities		Exercise or base price of option		Grant date fair value of stock and
Name	Grant Date	Threshold		Target		Maximum			units		awards		Awards⁽¹⁾		Awards⁽²⁾		Grant Date	Threshold (#)		Target (#)		Maximum (#)			stock or units (#)		underlying options (#)		awards ($/Sh) ⁽¹⁾		option awards ($)⁽²⁾
Joseph G. Darling	February 26, 2019		4,725		63,000		85,050	⁽³⁾		-		-	$	32.53	$	2,049,390
Cheryl R. Blanchard, Ph.D.																	February 25, 2020									4,231			$	42.61	$	180,283
	February 26, 2019									63,000			$	32.53	$	2,049,390	April 26, 2020		8,062		80,620		120,930	⁽³⁾					$	33.40	$	2,692,708
Sylvia Cheung	February 26, 2019		675		9,000		12,150	⁽³⁾		-		-	$	32.53	$	292,770
																	April 26, 2020		52,319		104,638		156,957	⁽⁴⁾					$	33.40	$	2,293,665
																	April 26, 2020									73,726			$	33.40	$	2,462,448
																	April 26, 2020											104,638	$	33.40	$	1,365,785
Michael L. Levitz																	August 10, 2020		1,157		11,577		17,366	⁽³⁾		-		-	$	34.55	$	399,985
																	August 10, 2020									11,577		-	$	34.55	$	399,985
																	August 10, 2020											57,145	$	34.55	$	799,993
David Colleran																	March 4, 2020		750		7,500		11,250	⁽³⁾		-		-	$	43.06	$	322,950
																	March 4, 2020									7,500		-	$	43.06	$	322,950
	February 26, 2019									9,000		-	$	32.53	$	292,770	March 4, 2020											35,000	$	43.06	$	553,445
Thomas Finnerty	February 26, 2019		675		9,000		12,150	⁽³⁾		-		-	$	32.53	$	292,770	February 25, 2020		620		6,200		9,300	⁽³⁾		-		-	$	42.61	$	264,182
	February 26, 2019									9,000		-	$	32.53	$	292,770	February 25, 2020									8,500		-	$	42.61	$	362,185
James Loerop	July 8, 2019		675		9,000		12,150	⁽³⁾		-		-	$	40.67	$	366,030	February 25, 2020		620		6,200		9,300	⁽³⁾		-		-	$	42.61	$	264,182
	July 8, 2019									9,000		-	$	40.67	$	366,030	February 25, 2020									4,700		-	$	42.61	$	200,267
Joseph G. Darling⁽⁵⁾																			-		-		-			-		-			$	-
Sylvia Cheung⁽⁶⁾																	February 25, 2020		1,000		10,000		15,000	⁽³⁾		-		-	$	42.61	$	426,100
	July 8, 2019									-		27,000	$	40.67	$	377,772	February 25, 2020									11,700		-	$	42.61	$	498,537
Edward S. Ahn, Ph.D.	February 26, 2019		338		4,500		6,075	⁽³⁾		-		-	$	32.53	$	146,385
	February 26, 2019									4,500		-	$	32.53	$	146,385

(1)	The exercise price or base price of each award equals the grant date closing stock price, as reported on the NASDAQ stock exchange. With the exception of the February 25, 2020 grant to Dr. Blanchard, all other grants made to the NEOs with a grant date of February 25, 2020 were approved by the Compensation Committee on February 3, 2020.
(2)	This column represents the full grant date fair value of stock options and restricted stock unit awards under ASC 718 granted to each of the NEOs in the fiscal year ended December 31, ~~2019.~~2020. Generally, the full grant date fair value is the amount that we will expense in our financial statements over the ~~award’s~~award's vesting period. For time-vesting restricted stock units and performance-based restricted stock units, fair value was calculated using the closing price of our common stock on the grant date. For stock options, except as otherwise noted, the fair value was calculated using the Black-Scholes value on the grant date. See the information appearing in Note 1314 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020 for certain assumptions made in the valuation of these awards.
(3)	These amounts represent performance-based restricted stock units granted by the Board on February ~~26, 2019,~~25, 2020, except for Dr. Blanchard, Mr. ~~Loerop, who’s award was~~Levitz and Mr. Colleran, whose awards were granted on ~~July 8, 2019~~April 26, 2020, August 10, 2020 and March 4, 2020, respectively, in connection with the commencement of ~~his~~their employment. The ~~“Threshold”~~"Threshold" is equal to ~~7.5%~~10% of the ~~target,~~Target, and the ~~“Maximum”~~"Maximum" is equal to ~~135%~~150% of the ~~target.~~Target. The performance measurement date for these awards ~~shall be~~is generally the date on which the Compensation Committee of the Board of Directors reviews the ~~Company’s~~Company's financial and business achievements for the fiscal year ending December 31, ~~2021,~~2022, including the ~~Company’s~~Company's audited financial statements for such period, and determines and specifies, at the Compensation ~~Committee’s~~Committee's sole discretion, the percentage of the shares that have been earned by each individual NEO. See the section in the Compensation Discussion and Analysis titled “Equity-Based Grants” and "The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional details regarding the restricted stock units issued in 2020.
(4)	This amount represents the full grant date fair value of performance-based stock options under ASC 718 granted to Dr. Blanchard on April 26, 2020. For these performance-based stock options, fair value was calculated using the Monte Carlo value on the grant date. The "Threshold" is equal to 50% of the Target, and the "Maximum" is equal to 150% of the Target. The performance measurement date for this award is generally the date on which the Compensation Committee of the Board of Directors reviews the Company's Total Shareholder Return (as defined in the grant agreement) against the Comparison Group (as defined in the grant agreement), and determines and specifies, at the Compensation Committee's sole discretion, the percentage of the shares that have been earned by Dr. Blanchard. See the information appearing in Note 14 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, 2020 for certain assumptions made in the valuation of this award. See the section in the Compensation Discussion and Analysis titled “Equity-Based Grants” and "The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional details regarding the option award.
(5)	As noted elsewhere in this proxy statement, Mr. Darling passed away unexpectedly on January 29, 2020, and, therefore, no awards were granted to him in 2020.
(6)	As noted elsewhere in this proxy statement, Ms. Cheung resigned from the company, effective August 10, 2020, on which date her awards were forfeited.

4654

Outstanding Equity Awards at December 31, ~~2019~~2020

The following table provides information on the holdings of outstanding stock options and unvested stock awards held by the NEOs as of December 31, ~~2019.~~2020.

Option Awards Stock Awards
Equity Incentive Plan Awards

Name Number of Number of Option Option Number Market Number of Market or Payout
Securities Securities Exercise Expiration of Value of Unearned and Value of Unearned
Underlying Underlying Price Date Unvested Unvested Unvested Shares, and Unvested
Exercisable Unexercisable Shares or Shares or Units, or Other Shares, Units,
Options⁽¹⁾ Options⁽¹⁾ Units of Stock⁽¹⁾ Units of Stock⁽²⁾ Rights or Other Rights
Joesph G. Darling - - - 126,000 (*) $ 6,533,100 - $ -
- - - 3,738 $ 193,815 - $ -
7,252 21,757 $ 61.47 1/24/2028 - $ - - $ -
27,739 13,870 $ 51.70 7/27/2027 4,835 $ 250,695 - $ -
  Total 34,991 35,627 134,573 $ 6,977,610

Sylvia Cheung - - - 18,000 (*) $ 933,300 - $ -
7,252 21,757 $ 61.47 1/24/2028 - $ - - $ -
24,192 12,096 (*) $ 50.13 1/27/2027 - $ - - $ -
22,350 7,450 $ 38.11 2/4/2026 1,975 $ 102,404 - $ -
21,624 - $ 39.69 2/3/2025 - $ - - $ -
13,800 - $ 32.02 1/27/2024 - $ - - $ -
45,000 - $ 10.87 1/29/2023 - $ - - $ -
15,000 - $ 9.10 1/25/2022 - $ - - $ -
20,000 - (*) $ 6.99 6/7/2021 - $ - - $ -
25,000 - $ 6.98 1/18/2021 - $ - - $ -
  Total 194,218 41,303 $ 19,975 $ 1,035,704

Thomas Finnerty 18,000 (*) $ 933,300 - $ -
2,393 7,180 $ 61.47 1/24/2028 - $ - - $ -
11,333 5,667 (*) $ 54.09 10/30/2027 2,267 $ 117,544 - $ -
  Total 13,726 12,847 20,267 $ 1,050,844

James Loerop - 27,000 (*) $ 40.67 7/8/2029 18,000 (*) $ 933,300 - $ -
  Total - 27,000 18,000 $ 933,300

Edward S. Ahn, Ph.D.⁽³⁾ - - $ - - $ - - $ -
  Total - - - $ -

	Option Awards										Stock Awards
Name	Number of securities underlying unexercised options (#) exercisable⁽¹⁾		Number of securities underlying unexercised options (#) unexercisable⁽¹⁾		Equity incentive plan awards: number of securities underlying unexercised unearned options (#)			Option exercise price ($)		Option expiration date	Number of shares or units of stock that have not vested (#)⁽¹⁾		Market value of shares or units of stock that have not vested (#)⁽²⁾		Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)⁽³⁾			Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($)⁽²⁾
Cheryl R. Blanchard, Ph.D.		-		-		8,062	⁽⁴⁾	$	33.40	4/26/2030
		-		104,638				$	33.40	4/26/2030
												73,726	$	3,336,839		8,062		$	364,886

Michael L. Levitz		-		57,145				$	34.55	8/10/2030
												11,577	$	523,975		1,157		$	52,366

David Colleran		-		35,000				$	43.06	3/4/2030
												7,500	$	339,450		750		$	33,945

Thomas Finnerty												14,500	$	656,270		9,620	⁽⁵⁾	$	435,401
		4,787		4,786				$	61.47	1/24/2028
		17,000		-				$	54.09	10/30/2027

James Loerop		9,000		18,000				$	40.67	7/8/2029
												10,700	$	484,282		9,620	⁽⁵⁾	$	435,401

Joseph G. Darling⁽⁶⁾		14,505		-				$	61.47	1/24/2028
		27,739		-				$	51.70	7/27/2027

Sylvia Cheung⁽⁷⁾

(1)	Vesting of equity awards commences on the first anniversary of the grant date and continues on each subsequent grant date anniversary until the equity award is fully vested, except as otherwise noted below. Except ~~for those equity awards~~as otherwise noted, ~~by an asterisk (*), which are subject to a three-year vesting period, all~~ equity awards are subject to a ~~four-year~~three-year vesting period, in each case subject to the ~~holder’s~~holder's continued employment with us. The expiration date of each equity award is ten years after its grant date. Mr. Finnerty’s stock option award expiring October 30, 2017 is subject to a four-year vesting period.
(2)	Based on the closing price of our common stock on the NASDAQ stock exchange on December 31, ~~2019~~2020 ($~~51.85)~~45.26) per share.
(3)	Except as otherwise noted, these amounts represent performance-based restricted stock units granted at Target in 2020. The performance measurement date for these awards and the date on which the shares underlying the award will vest (if any) is generally the date on which the Compensation Committee of the Board of Directors reviews the Company's financial and business achievements for the fiscal year ending December 31, 2022, including the Company's audited financial statements for such period, and determines and specifies, at the Compensation Committee's sole discretion, the percentage of the shares that have been earned by each individual NEO. See the section in the Compensation Discussion and Analysis titled “Equity-Based Grants” and "The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional details regarding the restricted stock units issued in 2020.
(4)	This amount includes performance-based stock options granted at Threshold in 2020. The performance measurement date for this award and the date on which the shares underlying the awards will vest (if any) is generally the date on which the Compensation Committee of the Board of Directors reviews the Company's Total Shareholder Return (as defined in the grant agreement) against the Comparison Group (as defined in the grant agreement), and determines and specifies, at the Compensation Committee's sole discretion, the percentage of the shares that have been earned by Dr. Blanchard. See the section in the Compensation Discussion and Analysis titled “Equity-Based Grants” and "The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional details regarding the option award.
(5)	These amounts include performance-based restricted stock units granted at Target in 2019. The performance measurement date and the date on which the shares underlying the award will vest (if any) is generally the date on which the Compensation Committee of the Board of Directors reviews the Company's financial and business achievements for the fiscal year ending December 31, 2021, including the Company's audited financial statements for such period, and determines and specifies, at the Compensation Committee's sole discretion, the percentage of the shares that have been earned by each individual NEO.
(6)	As noted elsewhere in this proxy statement, ~~Dr. Ahn’s employment as Chief Technology~~Mr. Darling passed away unexpectedly on January 29, 2020. Under the terms of his grant agreements, all vested and ~~Strategy Officer ended effective July 5, 2019, and he had no outstanding~~unexercised options remain exercisable for 12 months upon death of the option holder. All unvested equity awards aswere forfeited upon Mr. Darling's death.
(7)	As noted elsewhere in this proxy statement, Ms. Cheung resigned from the company on August 10, 2020. All unvested equity awards were forfeited upon termination. All vested options remained exercisable for 3 months from the date of ~~December 31, 2019.~~resignation, at which time any remaining unexercised options were cancelled.

4755

~~2019 Equity Award~~2020 Option Exercises and Stock Vested

The following table provides information regarding options ~~and SAR’s~~ exercised and stock awards vested for the NEOs during the year ended December 31, ~~2019.~~2020.

Option and SARs Awards Stock Awards
Name Number of
Shares
Acquired on
Exercise Value
Realized on
Exercise Number of
Shares
Acquired on
Vesting Value
Realized on
Vesting
Joseph G. Darling - $ - 6,705 $ 327,394
Sylvia Cheung 31,319 ⁽¹⁾ $ 1,894,173 3,644 $ 138,619
Thomas Finnerty - $ - 2,266 $ 157,872
James Loerop - $ - - $ -
Edward Ahn 85,867 $ 939,910 1,975 $ 75,248

	Option Awards				Stock Awards
Name	Number of shares acquired on exercise (#)		Value realized on exercise ($)		Number of shares acquired on vesting (#)			Value realized on vesting ($)
Cheryl R. Blanchard, Ph.D.		-	$	-		8,073	⁽¹⁾	$	303,640
Michael L. Levitz		-	$	-		-		$	-
David Colleran		-	$	-		-		$	-
Thomas Finnerty		-	$	-		5,267		$	200,700
James Loerop		-	$	-		3,000		$	105,900
Joseph G. Darling		-	$	-		-		$	-
Sylvia Cheung		118,800	$	1,013,288		4,975		$	206,915

(1)

~~On November 6, 2019, Ms. Cheung exercised 35,000 Stock Appreciation Rights (SARs) previously~~Includes 3,842 restricted stock units granted to Dr. Blanchard as an independent director on ~~January~~February 26, ~~2010, of which 3,681 shares were utilized to cover the exercise price of the SARs.~~2019.

Potential Payments Upon Termination or Change in Control

Our President and Chief Executive Officer, Chief Financial Officer, and our other NEOs have certain termination or change in control benefits described in the Compensation Discussion and Analysis sections captioned “Other Compensation Matters –Employment and Executive Retention Agreements Effective at December 31, 2020” and “Other Compensation Matters – The Death of Mr. Darling and the Appointment of Dr. Blanchard.” The following table provides estimates of the potential payments and other post-termination benefits these individuals would receive assuming a change in control occurred and/or their employment was terminated as of December 31, ~~2019:~~2020:

Name Termination
Without Cause Termination
Upon Change in
Control^{(1) (2)} Change in Control
Without
Termination or
Death or
Disability^{(1) (3)}
Joseph G. Darling Salary Continuation $ 899,250 $ 1,199,000 $ -
Additional Cash Payment 764,363 1,019,150 -
Equity Awards Vesting 6,983,851 6,983,851 -
Health Care Benefits 30,232 37,208 -
$ 8,677,696 $ 9,239,210 $ -

Sylvia Cheung Salary Continuation $ 371,653 $ 557,480 $ -
Additional Cash Payment 167,244 250,866 -
Equity Awards Vesting - 6,548,473 -
Health Care Benefits 20,154 30,232 -
$ 559,051 $ 7,387,050 $ -

Thomas Finnerty Salary Continuation $ 330,000 $ 330,000 $ -
Additional Cash Payment - 148,500 -
Equity Awards Vesting - 1,050,844 -
Health Care Benefits 20,154 20,154 -
$ 350,154 $ 1,549,498 $ -

James Loerop Salary Continuation $ 375,000 $ 375,000 $ -
Additional Cash Payment - 168,750 -
Equity Awards Vesting - 1,235,160 -
Health Care Benefits 15,629 15,629 -
$ 390,629 $ 1,794,539 $ -

Edward S. Ahn, Ph.D.⁽⁴⁾ Salary Continuation $ - $ - $ -
Additional Cash Payment - - -
Equity Awards Vesting - - -
Health Care Benefits - - -
$ - $ - $ -

Name		Termination without cause or for good reason			Termination upon change in control without cause or for good reason ⁽¹⁾⁽²⁾			Change in control without termination or death or disability ⁽¹⁾⁽²⁾
Cheryl R. Blanchard, Ph.D.	Salary Continuation	$	937,500		$	1,250,000		$	-
	Additional Cash Payment	$	-		$	1,062,500		$	-
	Equity Awards Vesting	$	1,040,981	⁽³⁾	$	9,467,713	⁽⁴⁾	$	-
	Health Care Benefits	$	30,232		$	30,232		$	-
		$	2,008,712		$	11,810,445		$	-

Michael L. Levitz	Salary Continuation	$	450,000		$	450,000		$	-
	Additional Cash Payment	$	-		$	202,500		$	-
	Equity Awards Vesting	$	-		$	1,659,973		$	-
	Health Care Benefits	$	20,154		$	20,154		$	-
		$	470,154		$	2,332,627		$	-

David Colleran	Salary Continuation	$	420,000		$	420,000		$	-
	Additional Cash Payment	$	-		$	189,000		$	-
	Equity Awards Vesting	$	-		$	755,900		$	-
	Health Care Benefits	$	20,154		$	20,154		$	-
		$	440,154		$	1,385,054		$	-

Thomas Finnerty	Salary Continuation	$	353,505		$	353,505		$	-
	Additional Cash Payment	$	-		$	159,077		$	-
	Equity Awards Vesting	$	-		$	1,344,222		$	-
	Health Care Benefits	$	15,629		$	15,629		$	-
		$	369,134		$	1,872,433		$	-

James Loerop	Salary Continuation	$	381,563		$	381,563		$	-
	Additional Cash Payment	$	-		$	171,703		$	-
	Equity Awards Vesting	$	-		$	1,213,544		$	-
	Health Care Benefits	$	20,154		$	20,154		$	-
		$	401,717		$	1,786,965		$	-


Joseph G. Darling⁽⁵⁾	Salary Continuation	$	-		$	-		$	-
	Additional Cash Payment	$	-		$	-		$	-
	Equity Awards Vesting	$	-		$	-		$	-
	Health Care Benefits	$	-		$	-		$	-
		$	-		$	-		$	-


Sylvia Cheung⁽⁶⁾	Salary Continuation	$	-		$	-		$	-
	Additional Cash Payment	$	-		$	-		$	-
	Equity Awards Vesting	$	-		$	-		$	-
	Health Care Benefits	$	-		$	-		$	-
		$	-		$	-		$	-

(1)

Termination for the purposes of this column is limited to termination without cause or termination for good reason within a period three months prior to or twelve months after a change in control. The indicated values for the accelerated vesting of stock options reflect the number of equity award shares that would vest on an accelerated basis, multiplied by the excess, if any, of the ~~$51.85~~$45.26 closing price for our common stock as reported by NASDAQ on December 31, ~~2019~~2020, over the applicable exercise price for each ~~option or SAR.~~option. This calculation assumes equity awards with an exercise price higher than the closing price of our common stock on December 31, ~~2019~~2020 will not be exercised.

(2)	~~According to~~The indicated values for the ~~terms~~accelerated vesting of the Employment Agreements with our Chief Executive Officer and President and our Chief Financial Officer, all payments otherwise due to Ms. Cheung or Mr. Darling would have been subject to a modified economic cutback.performance-based restricted stock units are included at Target.
(3)	According to the terms of ~~Mr. Darling’s~~Dr. Blanchard's employment agreement as in place at December 31, ~~2019,~~2020, if ~~Mr. Darling’s~~Dr. Blanchard’s employment is terminated “without cause” or ~~Mr. Darling~~Dr. Blanchard terminates ~~his~~her employment with us for “good reason” ~~(each~~not due to disability prior to December 31, 2021, she would be entitled to pro rata vesting of the time-vesting restricted stock unit grant and the time-vesting stock option grant awarded to her on April 26, 2020 in conjunction with the commencement of her employment as ~~defined~~President and Chief Executive Officer.
(4)	Includes the 2020 grant at Target of performance-based restricted stock units and the 2020 grant at Target of performance-based stock options. If the stock options were valued at Maximum, the equity awards vesting value would be $10,088,216. If the stock options were valued at Threshold, the equity awards vesting value would be $8,847,210. See the section in the Compensation Discussion and Analysis titled “Equity-Based Grants” and "The Death of Mr. Darling and the Appointment of Dr. Blanchard" for additional details regarding the equity grants to Dr. Blanchard in 2020 and her employment ~~agreement), his initial, new-hire grant of restricted award shall vest and become non-forfeitable~~agreement with ~~respect to~~ the ~~shares eligible to vest as of the next applicable vesting date after the date of termination.~~company.
~~(4)~~(5)	As noted elsewhere in this proxy statement, ~~Dr. Ahn’s employment with~~Mr. Darling passed away unexpectedly on January 29, 2020.
(6)	As noted elsewhere in this proxy statement, Ms. Cheung resigned from the company ~~ended July 5, 2019.~~
~~(5)~~	~~This table reflects the terms of the current agreements with the NEOs as discussed~~ on ~~page 40 in the Compensation Discussion and Analysis as the result of amendments to employment agreements and agreements executed during 2019.~~August 10, 2020.

CEO Pay Ratio

As required by applicable SEC rules, we are providing the following information about the relationship of the annual total compensation of our employees and the annual total compensation of ~~Mr. Darling,~~Dr. Blanchard, our year-end Chief Executive Officer or CEO.

For ~~2019,~~2020, our last completed fiscal year:

the median of the annual total compensation of all our employees (other than our CEO) was ~~$97,018;~~$105,864; and

the annual total compensation of our CEO, for the purposes of this disclosure, was ~~$ 5,590,182.~~$10,029,434.

Based on this information, for ~~2019~~2020 the ratio of the annual total compensation of ~~Mr. Darling,~~Dr. Blanchard, our year-end Chief Executive Officer, to the median of the annual total compensation of all our employees was 5895 to 1.

We took the following steps to identify the median of the annual total compensation of all our employees, as well as to determine the annual total compensation of our median employee and our CEO.

	1.	We determined that, as of December 31, ~~2019,~~2020, our employee population consisted of ~~153~~277 individuals. This population consisted of our full-time ~~part-time, and temporary~~ employees employed with us as of the determination date.

	2.	To identify the “median employee” from our employee population, we aggregated for each applicable employee, other than our CEO, (a) annual base salary (or hourly rate multiplied by estimated work schedule, for hourly employees), (b) the bonus amount earned for ~~2019,~~2020, which was paid out in early ~~2020,~~2021, and (c) the grant date fair value of equity granted in ~~2019.~~2020. Once aggregated, we ranked this compensation measure for our employees from lowest to highest and selected the median employee. Due to anomalous compensation characteristics of our median employee as a new hire, we substituted our median employee with another employee with compensation closest to our estimate used to identify the median employee.

For the annual total compensation of our median employee, we identified and calculated the elements of that employee’s compensation for ~~2019~~2020 in accordance with the requirements of Item 402(c)(2)(x), resulting in annual total compensation of ~~$97,018.~~$105,864.

The pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. The SEC rules for identifying the median-compensated employee and calculating the pay ratio based on that employee’s annual total compensation allow companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. Therefore, the pay ratio reported by other companies may not be comparable to the pay ratio reported above, as other companies have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their own pay ratios.

4958

Director Compensation

Cash Compensation

For ~~2019,~~2020, each of our non-employee directors was entitled to annual retainers per the following schedule, with such amounts to be prorated based on the actual number of days served if a director’s service to us commenced after January 1, 2020 and/or ended prior to the end of ~~2019:~~2020:

	Compensation Element	~~2019~~2020 Cash Compensation
	Board of Directors
	~~Lead Director~~Board Chair Retainer	$~~75,000~~80,000
	Other Directors Retainer	$50,000
	Audit Committee
	Committee Chair Retainer	$20,000
	Other Committee Members Retainer	$10,000
	Compensation Committee
	Committee Chair Retainer	$15,000
	Other Committee Members Retainer	$7,500
	Governance and Nominating Committee
	Committee Chair Retainer	$10,000
	Other Committee Members Retainer	$5,000

Equity Compensation

The Board of Directors approved a grant of ~~3,842~~4,107 restricted stock units to each non-employee director, valued at ~~$124,980~~$174,999 under ~~our equity compensation plan,~~the Plan, based on the fair market value of our common stock on February ~~26, 2019,~~25, 2020, the date of grant for ~~the existing~~our then-current directors. ~~The~~These restricted stock units granted to each then-current non-employee director in ~~2019~~2020 vested in one installment one year from the date of grant. On September 3, 2020, Messrs. Henneman and Richard joined the Board of Directors as non-employee directors, and they were each granted 9,310 restricted stock units, valued at $349,963 based on the fair market value of our common stock as of that day. The restricted stock units granted to Messrs. Henneman and Richard vest in three equal annual installments immediately prior to the company’s Annual Meetings of Stockholders in 2021, 2022, and 2023. Each non-employee director is eligible for an annual equity award grant with a value and vesting provisions as may be determined by the Board based on their review of our compensation policies and general compensation trends.

The following table summarizes the compensation we paid to non-employee directors for ~~2019.~~2020.

Aggregate Number of Shares
Outstanding
Name Fees Earned or
Paid in Cash ($) Stock
Awards ($)⁽¹⁾ Option
Awards ($) Total ($) Options Restricted
Stock Units
Cheryl R. Blanchard 62,500 124,980 - 187,480 - 3,842
Joseph L. Bower 100,000 124,980 - 224,980 - 3,842
Raymond J. Land 75,000 124,980 - 199,980 - 3,842
Glenn R. Larsen, Ph.D. 62,500 124,980 - 187,480 - 3,842
Jeffery S. Thompson ⁽²⁾ 76,389 124,980 - 201,369 - 3,842
Susan N. Vogt 60,000 124,980 - 184,980 - 3,842
Steven E. Wheeler⁽³⁾ 7,313 - - 7,313 - -


Name	Fees earned or paid in cash ($)		Stock awards ($) ^{(1) (2)}			Total ($)
Joseph L. Bower		92,033		174,999			267,032
John B. Henneman, III⁽³⁾		20,261		349,963	⁽⁴⁾		370,224
Raymond J. Land		75,810		174,999			250,809
Glenn R. Larsen, Ph.D.		62,500		174,999			237,499
Stephen O. Richard⁽⁵⁾		19,451		349,963	⁽⁴⁾		369,414
Jeffery S. Thompson		78,310		174,999			253,309
Susan N. Vogt		70,316		174,999			245,316

(1)

AnExcept as otherwise noted, an amount of ~~3,842~~4,107 restricted stock units were awarded per director on February ~~26, 2019,~~25, 2020, based on the closing price of ~~$32.53~~$42.61 per share, and which ~~vest~~vested in their totality on February ~~26, 2020.~~25, 2021. The amounts in this column reflect the grant date fair value computed with respect to the restricted stock units made during ~~the indicated year~~2020 in accordance with ASC Topic 718. See the information appearing in Note 1314 to our consolidated financial statements included as part of our Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020 for certain assumptions made in the valuation of these restricted stock unit awards.

(2)	~~Mr.~~The aggregate number of shares outstanding for each director as of December 31, 2020 were: 4,107 for each of Messrs. Bower, Land, Thompson, ~~joined,~~Dr. Larsen and ~~became the chair~~Ms. Vogt, and, 9,310 for each of ~~the Governance~~Messrs. Henneman and ~~Nominating Company effective February 8, 2019.~~Richard.
(3)	Mr. ~~Wheeler retired from~~Henneman joined our Board of Directors and became a Compensation Committee member and a Governance and Nominating Committee member on September 3, 2020.
(4)	An amount of 9,310 restricted stock units were awarded to each of Messrs. Henneman and Richard upon their appointments to the Board of Directors ~~effective February 8, 2019.~~on September 3, 2020, based on the closing price of $37.59 per share. Such awards vest ratably over 3 years beginning on the date of the company's annual meeting in 2021, and vest on the date of each annual meeting thereafter.
(5)	Mr. Richard joined our Board of Directors and became an Audit Committee member on September 3, 2020.

5059

Director and Executive Officer Stock Retention Guidelines

Effective October 6, 2015, the Board of Directors adopted stock retention guidelines that generally require each of our directors and executive officers to beneficially own certain amounts of our common stock. We believe that ownership of shares of common stock by directors and executive officers helps align the financial interests of these individuals with the interests of stockholders, promotes sound corporate governance, and evidences a commitment to our company. These stock retention guidelines supersede the director stock retention guidelines previously adopted by the Board on April 22, 2015.

Generally, these guidelines require each director to beneficially own, at a minimum, either (a) 3,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common stock having a market value equal to three times the amount of our annual Board retainer for the non-lead or non-chairman directors. The minimum shareholding requirement became effective immediately, except that any director ~~initially elected after January 1, 2015~~ has three years from the date of their initial election to achieve compliance. Compliance by each director will be reviewed annually by the Board’s Governance and Nominating Committee, which is authorized to approve exceptions upon a showing of serious hardship. A non-complying director must retain at least 75% of the shares (net of shares sold or offset to pay the exercise price and taxes) ~~he or she~~the director subsequently acquires through exercise of equity grants, until ~~he or she~~the director complies with the guidelines. As of December 31, 2020, each of the following directors had met his or her minimum shareholding requirement: Joseph Bower, Raymond Land, Jeffery Thompson, and Susan Vogt. John Henneman and Stephen Richard are within the three-year phase-in period for directors to meet their required ownership threshold, such phase-in period to be completed on September 3, 2023.

Generally, ~~these~~the stock retention guidelines require the Chief Executive Officer to beneficially own, at a minimum, either (a) 50,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common stock having a market value equal to three times the amount of his or her base ~~salary and they~~salary. The guidelines require any other executive officer to beneficially own, at a minimum, either (a) 10,000 outstanding shares of common stock or (b) a number of shares (or vested share equivalents) of common stock having a market value equal to the amount of his or her base salary. The minimum shareholding requirement became effective immediately upon adoption of the stock retention guidelines, except that any individual ~~initially elected as an executive officer after September 30, 2014~~ has five years after initial election to achieve compliance. Compliance by each executive officer ~~will be~~is reviewed annually by the ~~Board’s~~ Governance and Nominating Committee, which is authorized to approve exceptions upon a showing of serious hardship. A non-complying executive officer must retain at least 75% of the shares (net of shares sold or offset to pay the exercise price and taxes) he or she subsequently acquires through exercise of equity grants, until he or she complies with the guidelines. Each of our executive officers is within the five-year phase-in period to meet his or her required shareholding requirement, such period to be completed on April 26, 2025 for Cheryl R. Blanchard, our President and Chief Executive Officer; August 10, 2025 for Michael L. Levitz, our Executive Vice President, Chief Financial Officer and Treasurer; March 4, 2025 for David Colleran, our Executive Vice President, General Counsel, and Secretary; October 30, 2022 for Thomas Finnerty, our Executive Vice President, Human Resources; and July 8, 2024 for James Loerop, our Executive Vice President, Business Development and Strategic Planning.

The stock retention guidelines were most recently reviewed and verified by the Governance and Nominating Committee on March 10, 2021.

Compensation Committee Interlocks and Insider Participation

The Compensation Committee as of December 31, ~~2019~~2020 consisted of Dr. Joseph L. Bower, John Henneman, Raymond Land, and Dr. ~~Blanchard, Dr. Larsen, and Mr. Thompson.~~Glenn Larsen. None of these individuals is or formerly was an officer or employee of our company, nor have they engaged in any transactions involving our company that would require disclosure as a transaction with a related person. There are no Compensation Committee interlocks between our company and any other entity involving our or such entity’s executive officers or board members. When Dr. Blanchard became our interim Chief Executive Officer on February 10, 2020, she relinquished her role on the Compensation Committee.

During the fiscal year ended December 31, ~~2019,~~2020, none of our executive officers served as: (1) a member of the Compensation Committee (or other committee of the Board of Directors performing equivalent functions or, in the absence of any such committee, the entire Board) of another entity, one of whose executive officers served on the Compensation ~~Committee;~~Committee, with the exception of Dr. Blanchard who relinquished her role when she became our interim Chief Executive Officer, as described above; (2) a director of another entity, one of whose executive officers served on the Compensation Committee; or (3) a member of the compensation committee (or other committee of the Board performing equivalent functions or, in the absence of any such committee, the entire Board) of another entity, one of whose executive officers served as a director on the Board.

Equity Compensation Plan Information

The following table sets forth information concerning our equity compensation plan as of December 31, ~~2019.~~2020.

Equity Compensation Plan Information
Plan category Number of securities to be issued
upon exercise of outstanding
options, stock appreciation rights,
performance shares and restricted
stock units⁽¹⁾ Weighted Average exercise
price of outstanding options,
stock appreciation rights,
and performance shares Number of securities remaining
available for future issuance under
equity compensation plans
Equity compensation plans approved by security holders 967,250 $ 41.65 1,728,869
Equity compensation plans not approved by security holders N/A N/A N/A
Total 967,250 $ 41.65 1,728,869

~~(1)~~

~~Excludes 12,816 shares of unvested restricted stock awards as of December 31, 2019.~~

Equity Compensation Plan Information

Plan category

Number of securities to be issued upon
exercise of outstanding options, stock
appreciation rights, performance shares
and restricted stock units (1)

Weighted Average exercise price
of outstanding options, stock
appreciation rights, and
performance shares

Number of securities remaining
available for future issuance under
equity compensation plans

Equity compensation plans approved by security holders

1,308,355

$41.50

1,618,173

Equity compensation plans not approved by security holders

N/A

Total

1,308,355

$41.50

1,618,173

5261

Proposal 2: Amendment of 2017 Omnibus Incentive Plan

History of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan (as amended June 16, 2020)

On March 31, 2017, the Board of Directors, upon the recommendation of the Compensation Committee, adopted the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, or the Original Plan, for officers, employees, non-employee directors and other key persons of Anika Therapeutics, Inc. and its subsidiaries, subject to the approval of our stockholders. Our stockholders approved the Original Plan at the 2017 Annual Meeting of Stockholders. On ~~April~~March 19, 2019, the Board, upon the recommendation of the Compensation Committee, approved the amendment of the Original Plan (or the First Amended Plan) to increase the number of shares of common stock reserved by 1,500,000, from 1,200,000 to 2,700,000 shares, subject to the approval of the amendment by our stockholders. Additionally, the Board approved certain clarifying amendments to the sections governing minimum vesting and tax withholding to facilitate plan administration. Our stockholders approved the First Amended Plan on June 18, 2019.

On April 23, 2020, the Board, upon the approval of the Compensation Committee, approved the amendment of the First Amended Plan (or the Second Amended Plan) to increase the number of shares of common stock reserved by 800,000, from 2,700,000 to 3,500,000 shares, subject to the approval of the amendment by our stockholders. The Board also approved an amendment to the First Amended Plan to allow for all 3,500,000 authorized under the plan to be issued as Incentive Stock Options under Section 422 of the Internal Revenue Code of 1986, or the Code. No other provisions of the First Amended Plan ~~are~~were proposed to be amended. Our stockholders approved the Second Amended Plan on June 16, 2020.

On March 17, 2021, the Board, upon the recommendation of the Compensation Committee, approved the amendment of the Second Amended Plan to increase the number of shares of common stock reserved by 1,100,000 from 3,500,000 to 4,600,000 shares, subject to the approval of the amendment by our stockholders. The Board also approved an amendment to the Second Amended Plan to allow for all 4,600,000 shares authorized under the plan to be issued as Incentive Stock Options under the Code.

Plan Amendment to Provide Adequate Shares to Attract and Retain Talent to Execute Strategic Plan and Drive Shareholder Value

The Board recommends that stockholders approve the amendment to the ~~First~~Second Amended ~~Plan.~~Plan (the Third Amended Plan). The overall purposes of ~~our Omnibus Incentive~~the Third Amended Plan ~~as amended (or the Second Amended Plan),~~ continue to be to enhance our ability to attract and retain highly qualified officers, non-employee directors, key employees and consultants, and to motivate those service providers to serve us and to expend maximum effort to improve our business results and earnings, by providing to those service providers an opportunity to acquire or increase a direct proprietary interest in our operations and future success.

In addition, since our ~~overall number~~appointment of ~~employees has increased substantially~~Dr. Blanchard as President and Chief Executive Officer following our ~~recent~~early 2020 acquisitions of Parcus Medical ~~LLC~~ and Arthrosurface, ~~Incorporated,~~we have established new strategic priorities that will guide the next phase of our transformation into a global, commercial joint preservation company. One of our significant focuses and strategic priorities is investing in our people and strengthening our employee value proposition to help us drive better outcomes for our customers and the patients that they treat, which will in turn help us create value for our stockholders. Equity-based compensation is a critical component of our ability to both attract and retain talent in a very competitive Life Sciences sector, especially near our corporate headquarters and major operating location outside of Boston, MA. Under Dr. Blanchard’s leadership, we have hired experienced senior talent as part of our transformation, and we ~~expect~~will continue to recruit top talent throughout the organization. It is critical that we have the ability to issue equity to these individuals to help attract them to the company, retain their services, and align their interests to those of stockholders and the creation of long-term stockholder value.

As we realign our company with our new strategic plan and priorities, our stock price has not appreciated in the short term, an effect that was exacerbated by market-wide impacts due to the COVID-19 pandemic. The lack of appreciation thus far in our share price, combined with our growth through acquisitions and new hires, has impacted the pool of shares we have available under the Second Amended Plan. In order to continue to attract and retain employees and align their interests with those of our stockholders, we are seeking stockholder approval to make an additional 1,100,000 shares available for issuance under the Third Amended Plan, which would increase the number of available shares under the Plan from 758,748 shares as of April 20, 2021 to 1,858,748 shares in total, pending stockholder approval. The 1,100,000 shares requested reflects our estimate of the number of shares we would grant under the Third Amended Plan over the course of ~~equity awards~~the next year based on our current share price, recent burn rate history, and new-hire and annual grant practices. If the proposed Third Amended Plan is not approved by our stockholders, we currently anticipate that we will ~~increase accordingly. The~~exhaust the 758,748 shares that remain available for issuance under the Second Amended Plan ~~also will continue~~by early 2022, and we would not be able to ~~allow us~~maintain our competitive annual equity grant practices to ~~promote greater ownership in our company by~~key employees during the ~~service providers in order~~2022 annual compensation cycle due to ~~align the service providers’ interests more closely with the interests~~lack of ~~our stockholders. Stockholder approval of the amendment will also enable us to continue to grant awards that are designed to qualify for special tax treatment under the Code.~~shares available.

In the opinion of ~~our~~the Board, our future success depends in large part on our ability to maintain a competitive position in attracting, retaining, and motivating key employees with experience and ability. ~~Our~~The Board believes that approval of the ~~Second~~Third Amended Plan, including the authorization of the additional shares for issuance thereunder, is appropriate and in the best interests of our stockholders given our current expectations on hiring, the highly competitive environment in which we recruit and retain employees, and our historical burn rate. Our Compensation Committee will carefully consider all proposed grants under the ~~Second~~Third Amended Plan. ~~If the proposed Second Amended Plan is not approved by~~Nevertheless, we are in a transition period and are seeking shareholder approval only for an amount of additional shares necessary to align to one annual grant cycle to ensure that we are able to appropriately incentivize our key employees. We expect to roll out shortly a comprehensive strategic plan to deliver superior value to our stockholders and other stakeholders and look forward to engaging with our stockholders regarding it once we ~~currently~~do so. Our compensation programs will be a part of, and tie directly into, this comprehensive strategic plan, and we anticipate ~~that we will exhaust~~seeking shareholder approval at next year’s annual meeting for the ~~765,109~~additional shares ~~that remain available for issuance under~~needed to fund an equity incentive program designed to align closely with the ~~First Amended Plan by early to mid-2021 and such shares may be exhausted sooner depending on the pace~~goals of our ~~hiring to support our growth. The inability to make competitive equity awards to attract and retain talented employees in a highly competitive market could have an adverse impact on our business.~~comprehensive strategic plan.

Shares Subject to the Plan

The following table summarizes information regarding awards outstanding and shares of our ~~Common Stock~~common stock remaining available for grant under the ~~First~~Second Amended Plan as of ~~the~~ April ~~28, 2020:~~20, 2021:

Stock Options Outstanding	~~1,076,569~~1,247,393
Weighted Average Exercise Price of Stock Options Outstanding	$~~39.92~~39.36
Weighted Average Remaining Term of Stock Options Outstanding	~~7.70 years~~8.9
Full Value Awards Outstanding (RSAs, RSUs and PSUs)	~~422,470~~621,026
Shares Available for Grant under the ~~First~~Second Amended Plan*	~~765,109~~758,748

* The ~~Second~~Third Amended Plan will continue to employ a “fungible” plan design that assigns a higher cost to “full-value” awards (all awards other than stock options and stock appreciation rights) by reducing the share pool on a greater than one-for-one basis when full-value shares are granted. Consistent with the First and Second Amended ~~Plan,~~Plans, we have maintained a fungible rate of 2.0 common shares per full-value award in the Third Amended Plan.

The number of shares remaining available for grant under the ~~First~~Second Amended Plan as noted in the previous table differs from those reported as of December 31, ~~2019~~2020 because that information does not take into account year-to-date grants ~~during 2020~~ for ~~the 2019 performance year or for~~our annual grant cycle and grants to new-hires who started after January 1, ~~2020.~~2021. Information regarding the number of shares remaining available for grant as required by SEC disclosure rules are discussed in detail under “Equity Compensation Plan Information” on page ~~52.~~61. In addition, the company has historically made equity grants to directors in the first quarter of each year to align to the annual grant cycle that we utilize for employees. In 2021, we have augmented this approach to align the annual grant cycle for directors to our annual meeting cycle. As a result, we expect to make our annual equity grant to directors immediately following the annual meeting, and shares granted to our directors in 2021 will further reduce the shares available for grant under the Second Amended Plan.

Historic Equity Usage

As part of our ongoing review of our compensation plans, we calculate our annual “burn rate” to help us determine, among other things, the expected remaining life of our equity incentive plans based on the current number of outstanding shares. Burn rate is calculated by dividing the aggregate number of stock options and full-value awards (as adjusted by the fungible rate) granted during the year by our basic weighted average common shares outstanding during the year. The following table provides detailed information regarding the activity related to our equity incentive plans and weighted average ordinary shares outstanding for the three fiscal years ending on December 31, ~~2019:~~2020:

Award Type FY 2017 FY 2018 FY 2019
Stock Options Granted 440,688 199,970 254,517
Stock Settled Restricted Stock/RSUs Granted 67,567 160,070 626,014
Basic Weighted. Avg. Common Shares Outstanding 14,575,000 14,442,000 14,121,000
Annual Burn Rate 3.49% 2.49% 6.24%
Three Year Avg. Burn Rate (FY 2017-2019) 4.07%

Award Type	FY 2018	FY 2019	FY 2020
Stock Options Granted	199,970	254,517	598,815
Stock Settled Restricted Stock/RSUs Granted	160,070	712,464	924,499
Basic Weighted. Avg. Common Shares Outstanding	14,442,000	14,121,000	14,222,000
Annual Burn Rate	2.49%	6.85%	10.71%
Three Year Avg. Burn Rate (FY 2018-2020)			6.68%

Based on the current range of our stock price, our current compensation practices, our anticipated future awards, as well as our three-year burn rate experience, we are requesting an additional ~~800,000~~1,100,000 shares to be added to the ~~2,700,000~~3,500,000 shares already authorized under the ~~First~~Second Amended Plan. We believe this request for additional shares, ~~in conjunction~~together with ~~what is~~the shares currently available, will be sufficient for us to grant equity awards for approximately one and a half years. We expect that 1,100,000 shares approximates our share usage in a single annual compensation cycle based on our stock price and compensation philosophy and policies. Our actual share usage will vary ~~based~~depending on a number of factors, including the number of employees receiving equity awards, ~~our~~the prevailing price per share of our common ~~share,~~stock, the methodology used to value and determine the size of equity awards, and the mix of award types provided to participants. We believe that our requested number of common shares will give us the necessary flexibility we need to respond to these changes and other unanticipated circumstances that may arise during the life of the ~~Second~~Third Amended Plan. As stated above, we anticipate that we will be seeking stockholder approval at next year’s annual meeting for an additional number of shares to fund an equity program in line with our comprehensive strategic plan. As of April 20, 2021, the closing price of a share of common stock on the NASDAQ Global Select Market was $40.60.

A copy of the ~~Second~~Third Amended Plan marked to show the amendment approved by the Board on ~~April 23, 2020~~March 17, 2021 is attached as Appendix A to this proxy statement and is incorporated herein by reference. The following discussion summarizes certain features and effects of the ~~First~~Second Amended Plan as proposed to be amended herein, which we refer to below as the ~~Second~~Third Amended Plan, and it is qualified in its entirety by reference to the terms of ~~Second~~Third Amended Plan set forth in Appendix A.A.

Key Features of the ~~Second~~Third Amended Plan

The following is a summary of key features of the ~~Second~~Third Amended Plan, which are intended to protect the interests of our stockholders:

	·	Limitation on terms of stock options and stock appreciation rights. The maximum term of each stock option and Stock Appreciation Right, or SAR, is 10 years.

	·	Minimum vesting requirement. The ~~Second~~Third Amended Plan includes minimum vesting requirements ~~which was~~that were updated in the First Amended Plan to reflect current administrative practices. Equity-based awards generally cannot vest earlier than one year after grant. Certain limited exceptions are permitted.

	·	No repricing or grant of discounted stock options. The ~~Second~~Third Amended Plan does not permit the repricing of options or SARs either by amending an existing award or by substituting a new award at a lower ~~price.~~price without stockholder approval. The ~~Second~~Third Amended Plan prohibits the granting of stock options or SARs with an exercise price less than the fair market value of the common stock on the date of grant.

	·	No transferability. Awards generally may not be transferred, except by will or the laws of descent and distribution, unless approved by the plan administrator.

	·	No single-trigger vesting on a change in control. In the event of a change in control of our company, the plan administrator may provide for accelerated vesting of outstanding awards, but there is no automatic acceleration of awards upon a change in control.

	·	No dividends on options, SARs or unvested share awards. The ~~Second~~Third Amended Plan prohibits the payment of dividends or dividend equivalents on stock options and SARs, or on any other awards that have not vested.

	·	Multiple award types. The ~~Second~~Third Amended Plan permits the issuance of incentive stock options, non-qualified stock options, SARs, restricted stock units, restricted stock awards, and other types of share and cash-based awards, subject to the share limits of the ~~Second~~Third Amended Plan. This gives us the flexibility to grant different type of awards as compensation tools to motivate our workforce.

	·	Independent oversight. The ~~Second~~Third Amended Plan is administered by the Compensation Committee, which is comprised of independent members of the Board of Directors.

	·	Director limits. The ~~Second~~Third Amended Plan contains annual limits on the value of awards that may be granted to non-employee directors.

Summary of the ~~Second~~Third Amended Plan

The following description of certain features of the ~~Second~~Third Amended Plan is intended to be a summary ~~only.~~only, and it is qualified in its entirety by reference to the terms of the Third Amended Plan set forth in Appendix A.

Plan Administration

As with the ~~First~~Second Amended Plan, the ~~Second~~Third Amended Plan may be administered by the Board of Directors or the Compensation Committee. The Board or Compensation Committee so acting is referred to below as the Administrator. The Administrator, in its discretion, selects the individuals to whom awards may be granted, the time or times at which such awards are granted and the terms and conditions of such awards. In addition, the Administrator may not reprice outstanding options or cancel stock options or SARs for cash without prior stockholder approval, other than to appropriately reflect changes in our capital structure. The Administrator may delegate to the Chief Executive Officer the authority to grant stock options to employees who are not subject to the reporting and other provisions of Section 16 of the Exchange Act, ~~and not subject to Section 162(m) of the Code,~~ subject to certain limitations and guidelines.

Eligibility

As with the ~~First~~Second Amended Plan, all full-time and part-time officers, employees, non-employee directors, and other key persons of our company and subsidiaries are eligible to participate in the ~~Second~~Third Amended Plan, subject to the discretion of the Administrator. The number of individuals potentially eligible to participate in the ~~Second~~Third Amended Plan is currently approximately ~~278~~281 persons, including 5 executive officers and 57 non-employee directors. The Administrator will use its discretion to select individuals to participate in the ~~Second~~Third Amended Plan who are responsible for, or contribute to, our management, growth, or profitability.

Plan Limits

The number of shares of common stock authorized for issuance under the ~~Second~~Third Amended Plan is ~~3,500,000~~4,600,000 shares comprised of the ~~2,700,000~~3,500,000 shares approved under the ~~First~~Second Amended Plan and ~~800,000~~1,100,000 additional shares if the amendment to the ~~First~~Second Amended Plan is approved by the stockholders. These additional shares represent ~~5.6%~~7.7% of the fully diluted common stock outstanding as of April 20, ~~2020.~~2021. In addition, any shares subject to outstanding awards under the ~~First~~Second Amended Plan that subsequently expire, terminate, or are surrendered or forfeited for any reason without issuance of shares will automatically become available for issuance under the ~~Second~~Third Amended Plan. In addition, under the ~~Second~~Third Amended Plan, up to ~~3,500,000~~4,600,000 shares may be granted as incentive stock options under Code Section ~~422 of the Code.~~422. The shares of common stock issuable under the ~~Second~~Third Amended Plan will consist of authorized and unissued shares, treasury shares, or shares purchased on the open market or otherwise.

The ~~Second~~Third Amended Plan makes no changes to the share counting and share recycling provisions under the ~~First~~Second Amended Plan. For purposes of determining the number of shares available for issuance under the ~~Second~~Third Amended Plan, the grant of any “full value award” (i.e., a restricted stock award, deferred stock award, unrestricted stock award, or performance share) shall be deemed an award of two shares for each share subject to such full value award. For purposes of determining the number of shares available for issuance under the ~~Second~~Third Amended Plan, the grant of any option or SAR shall be deemed an award of one share for each share subject to such option or SAR.

If any award expires, terminates, is settled in cash, or is surrendered or forfeited, the shares subject to such awards will not count against the aggregate number of shares of common stock available for grant under the ~~Second~~Third Amended Plan. Additionally, awards granted in assumption of or in substitution for awards previously granted by an acquired company will not count against the shares available for grant. Shares issuable upon exercise, vesting, or settlement or an award, or shares surrendered or tendered to pay the exercise price or taxes required to be withheld with respect to an award, shall not be available again for the grant of awards.

The ~~Second~~Third Amended Plan makes no changes to the individual award limits included in the ~~First~~Second Amended Plan, although these award limits are no longer needed as the result of changes in the federal tax laws effective in 2018. The maximum award of stock options or SARs granted to any one individual will not exceed 400,000 shares of common stock (subject to adjustment for stock splits and similar events) for any calendar-year period. If any award of restricted stock, restricted stock units, deferred stock or performance shares granted to an individual is intended to qualify as "performance based compensation" under Section 162(m) of the Code, then the maximum award shall not exceed 400,000 shares of common stock (subject to adjustment for stock splits and similar events) to any one such individual in any calendar year. If any cash-based award is intended to qualify as “performance-based compensation” under Section 162(m) of the Code, then the maximum award to be paid in cash in any calendar year may not exceed $1,000,000.

Awards to Non-Employee Directors

As under the ~~First~~Second Amended Plan, the maximum value of plan awards granted during any calendar year to any non-employee director, taken together with any cash fees paid to such non-employee director during the calendar year and the value of awards granted to the non-employee director under any other equity compensation plan of our company or an affiliate during the calendar year, may not exceed the following in total value (calculating the value of any equity compensation plan awards based on the grant date fair market value for financial reporting purposes): ~~(i)~~(a) $500,000 for the Chair ~~or Lead Director~~ of the ~~Board~~Board; and ~~(ii)~~(b) $425,000 for each non-employee director other than the Chair ~~or Lead Director~~ of the Board. However, awards granted to non-employee directors upon their initial election to the Board of Directors or the board of directors of an affiliate will not be counted towards this limit.

Tax Withholding

Participants under the ~~Second~~Third Amended Plan are responsible for the payment of any federal, state, or local taxes that we are required by law to withhold upon any option or SAR exercise or vesting or payment of other awards. Subject to approval by the Administrator, participants may elect to have the tax withholding obligations satisfied either by authorizing us to withhold shares of common stock to be issued pursuant to an option exercise or other award, or by transferring to us shares of common stock having a value equal to the amount of such taxes. Such share withholding may be made at up to maximum statutory tax rates.

Change of Control Provisions

As under the ~~First~~Second Amended Plan, the ~~Second~~Third Amended Plan provides that upon the effectiveness of a “change in control” as defined in the ~~Second~~Third Amended Plan, the Administrator may take any one or more of the following actions, with or without the consent of a participant: ~~(1)~~(a) accelerate the vesting or settlement of awards on the terms and conditions determined by the Administrator (including upon a participant’s separation from service following the change in control)~~, (2)~~; (b) permit the assumption or substitution of outstanding awards by the acquiror in the change in control, and cancel any awards that are not assumed or substituted ~~for, and/~~for; or ~~(3)~~(c) cancel outstanding vested awards in exchange for cash, the stock of the acquiror, or other property having a fair market value equal to the consideration paid for shares in the change in control (reduced by the exercise price of an award, if necessary).

Adjustments for Stock Dividends, Mergers, etc.

As under the ~~First~~Second Amended Plan, subject to any required action by our stockholders, in the event of any change in our common stock effected without receipt of consideration by us, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares, or similar change in our capital structure, or in the event of payment of a dividend or distribution to our stockholders in a form other than our common stock (excepting normal cash dividends) that has a material effect on the fair market value of our common stock, appropriate and proportionate adjustments will be made in the number and class of shares subject to the ~~Second~~Third Amended Plan and to any outstanding awards, and in the option exercise price, SAR exercise price, or purchase price per share of any outstanding awards in order to prevent dilution or enlargement of participant rights under the ~~Second~~Third Amended Plan. If a majority of our common shares are exchanged for, converted into, or otherwise become shares of another corporation, the Administrator may unilaterally amend outstanding awards under the ~~Second~~Third Amended Plan to provide that such awards are for new shares. In the event of any such amendment, the number of shares subject to, and the option exercise price, SAR exercise price, or purchase price per share of, the outstanding awards will be adjusted in a fair and equitable manner as determined by the Administrator. The Administrator may also make such adjustments in the terms of any award to reflect, or related to, such changes in our capital structure or distributions as it deems appropriate.

No Repricing

Without stockholder approval, the ~~Compensation Committee~~Administrator is not authorized to (a) lower the exercise or grant price of a stock option or SAR after it is granted, except in connection with certain adjustments to our corporate or capital structure permitted by the ~~Second~~Third Amended Plan, such as stock splits, (b) take any other action that is treated as a repricing under generally accepted accounting principles or (c) cancel a stock option or SAR at a time when its exercise or grant price exceeds the fair market value of the underlying stock, in exchange for cash, another stock option or SAR, restricted stock, restricted stock units or other equity award, unless the cancellation and exchange occur in connection with a change in capitalization or other similar change. These provisions are unchanged from the ~~First~~Second Amended Plan.

Minimum Vesting Provisions

Equity-based awards granted under the ~~Second~~Third Amended Plan will have a one-year minimum vesting requirement. This requirement does not apply to (1) substitute awards resulting from acquisitions, (2) shares delivered in lieu of fully vested cash awards, or (3) awards to non-employee directors that vest on the earlier of the one-year anniversary of the date of grant or the next annual meeting of stockholders (but not sooner than 50 weeks after the grant date). Also, the Compensation Committee may grant equity-based awards without regard to the minimum vesting requirement with respect to a maximum of five percent of the available share reserve authorized for issuance under the ~~Second~~Third Amended Plan. In addition, the minimum vesting requirement does not apply to the ~~Compensation Committee’s~~Administrator’s discretion to provide for accelerated exercisability or vesting of any award, including in cases of retirement, death, disability or a change in control, in the terms of the award or otherwise.

Amendments and Termination

Unless earlier terminated by the Board of Directors, the ~~Second~~Third Amended Plan will terminate, and no further awards may be granted, 10 years after the date on which the Original Plan was approved by stockholders. The Board may amend, suspend, or terminate the ~~Second~~Third Amended Plan at any time, except that, if required by applicable law, regulation, or stock exchange rule, stockholder approval will be required for any amendment. The amendment, suspension, or termination of the ~~Second~~Third Amended Plan or the amendment of an outstanding award generally may not, without a participant’s consent, materially impair the participant’s rights under an outstanding award.

Transferability

Awards are not transferable other than by will or the laws of descent and distribution, except that in certain instances transfers may be made to or for the benefit of designated family members of the participant for no value.

Types of Awards

The ~~Second~~Third Amended Plan makes no changes to the types of awards as authorized under the ~~First~~Second Amended Plan, which are summarized below.

Stock Options

Options granted under the ~~Second~~Third Amended Plan may be either incentive stock options, which must comply with Code Section 422, ~~of the Code,~~ or non-qualified stock options. Incentive stock options may be granted only to employees of ~~Anika Therapeutics~~our company or any subsidiary. Options granted under the ~~Second~~Third Amended Plan will be non-qualified stock options if they ~~(1)~~(a) fail to qualify as incentive stock options, ~~(2)~~(b) are granted to a person not eligible to receive incentive stock options under the Code, or ~~(3)~~(c) otherwise so provide. Non-qualified stock options may be granted to persons eligible to receive incentive stock options and to non-employee directors and other key persons. The Administrator has authority to determine the terms and conditions of options at the time of grant, including quantity of shares covered, exercise price, method of exercise, vesting conditions, the term (which cannot exceed 10 years), and other conditions on exercise. Stock options must be granted with an exercise price not less than 100% of the fair market value of our common stock on the date of grant (excluding stock options granted in connection with assuming or substituting stock options in acquisition transactions). The ~~Second~~Third Amended Plan prohibits the payment of dividends or dividend equivalent rights on unvested stock options.

Stock Appreciation Rights

The Administrator may award SARs, with a term not to exceed 10 years. Upon exercise of an SAR, the holder will be entitled to receive an amount equal to the excess of the fair market value on the date of exercise of one share of common stock over the exercise price per share specified in such right times the number of shares of common stock with respect to which the SAR is exercised. This amount may be paid in cash, common stock, or a combination thereof, as determined by the Administrator. The exercise price is the fair market value of the common stock on the date of grant. The ~~Second~~Third Amended Plan prohibits the payment of dividends or dividend equivalent rights on ~~unvested~~ SARs.

Restricted Stock and Restricted Stock Unit Awards

The Administrator may grant shares of restricted stock, which are shares of common stock subject to specified restrictions, and restricted stock units or RSUs, which represent the right to receive shares of our common stock in the future. These awards may be made subject to repurchase, forfeiture, or vesting restrictions at the Administrator’s discretion. The restrictions may be based on continuous service with us or the attainment of specified performance goals, as determined by the Administrator. RSUs may be paid in stock or cash or a combination of stock and cash, as determined by the Administrator.

Other Share- and Cash-Based Awards

The Administrator may also grant awards based on shares of stock, either alone or in addition to or in conjunction with other awards. Such awards may be granted in lieu of other cash or other compensation to which a participant is entitled from ~~the Company~~us or may be used in the settlement of amounts payable under any of our other compensation plans or arrangements. The Administrator shall have the authority to determine the persons to whom and the time or times at which such Awards will be made, the number of shares to be granted pursuant to such Awards, and all other terms of such Awards. The Administrator may grant cash bonuses under the ~~Second~~Third Amended Plan. The cash bonuses may be subject to achievement of certain performance goals.

Performance Awards

At the time of grant, the Administrator may condition the grant, exercise, vesting, or settlement of any award on such performance conditions as it may specify. We refer to these awards as “performance awards.” The Administrator may select such business criteria or other performance measures as it may deem appropriate in establishing any performance conditions.

New Plan Benefits

A new plan benefits table for the ~~Second~~Third Amended Plan and the benefits or amounts that would have been received by or allocated to participants for the last completed fiscal year under the ~~Second~~Third Amended Plan if the ~~Second~~Third Amended Plan was then in effect, as described in the SEC proxy rules, are not provided because all awards made under the ~~Second~~Third Amended Plan will be made at the Administrator’s discretion, subject to the terms and conditions of the ~~Second~~Third Amended Plan. Therefore, the benefits and amounts that will be received or allocated under the ~~Second~~Third Amended Plan are not determinable at this time.

Federal Income Tax Information

The following is a brief summary of the U.S. federal income tax consequences of the ~~Second~~Third Amended Plan generally applicable to us and to participants in the ~~Second~~Third Amended Plan who are subject to U.S. federal taxes. The summary is based on the Code, applicable Treasury Regulations, and administrative and judicial interpretations thereof, each as in effect on the date of this Proxy Statement, and is, therefore, subject to future changes in the law, possibly with retroactive effect. The summary is general in nature and does not purport to be legal or tax advice. Furthermore, the summary does not address issues relating to any U.S. gift or estate tax consequences or the consequences of any state, local or foreign tax laws.

Non-qualified Stock Options

A participant generally will not recognize taxable income upon the grant or vesting of a non-qualified stock option with an exercise price at least equal to the fair market value of the common stock on the date of grant and no additional deferral feature. Upon the exercise of a non-qualified stock option, a participant generally will recognize compensation taxable as ordinary income in an amount equal to the difference between the aggregate fair market value of the exercised shares underlying the stock option on the date of exercise and the aggregate exercise price of the ~~stock option.~~exercised shares. When a participant sells the shares, the participant will have short-term or long-term capital gain or loss, as the case may be, equal to the difference between the amount the participant received from the sale and the tax basis of the shares sold. The tax basis of the shares generally will be ~~equal to the greater of~~ the fair market value of the shares on the exercise ~~date or the exercise price of the stock option.~~date.

Incentive Stock Options

A participant generally will not recognize taxable income upon the grant of an incentive stock option. If a participant exercises an incentive stock option during employment or within three months after employment ends (one year in the case of permanent and total disability), the participant will not recognize taxable income at the time of exercise for regular U.S. federal income tax purposes (although the participant generally will have taxable income for alternative minimum tax purposes at that time as if the stock option were a non-qualified stock option). If a participant sells or otherwise disposes of the shares acquired upon exercise of an incentive stock option after the later of (a) one year from the date the participant exercised the option and (b) two years from the grant date of the stock option, the participant generally will recognize long-term capital gain or loss equal to the difference between the amount the participant received in the disposition and the exercise price of the stock option. If a participant sells or otherwise disposes of shares acquired upon exercise of an incentive stock option before these holding period requirements are satisfied, the disposition will constitute a “disqualifying disposition,” and the participant generally will recognize taxable ordinary income in the year of disposition equal to the excess of the fair market value of the shares on the date of exercise over the exercise price of the stock option (or, if less, the excess of the amount realized on the disposition of the shares over the exercise price of the stock option). The balance of the participant’s gain on a disqualifying disposition, if any, will be taxed as short-term or long-term capital gain, as the case may be.

With respect to both non-qualified stock options and incentive stock options, special rules apply if a participant uses shares of common stock already held by the participant to pay the exercise price or if the shares received upon exercise of the stock option are subject to a substantial risk of forfeiture by the participant.

Stock Appreciation Rights

A participant generally will not recognize taxable income upon the grant or vesting of a SAR with a grant price at least equal to the fair market value of common stock on the date of grant and no additional deferral feature. Upon the exercise of a SAR, a participant generally will recognize compensation taxable as ordinary income in an amount equal to the difference between the aggregate fair market value of the exercised shares underlying the SAR on the date of exercise and the aggregate grant price of the ~~SAR.~~exercised shares.

Restricted Stock Awards, Restricted Stock Units, and Performance Awards

A participant generally will not have taxable income upon the grant of restricted stock, restricted stock units or performance awards. Instead, the participant will recognize ordinary income at the time of vesting or payout equal to the fair market value (on the vesting or payout date) of the shares or cash received minus any amount paid. For restricted stock only, a participant may instead elect to be taxed at the time of grant.

Other Stock or Cash-Based Awards

The U.S. federal income tax consequences of other stock or cash- based awards will depend upon the specific terms of each award.

Tax Consequences to Us

In the foregoing cases, we generally will be entitled to a deduction at the same time, and in the same amount, as a participant recognizes ordinary income, subject to limitations imposed under the Code.

Section 409A

We intend that awards granted under the ~~Second~~Third Amended Plan comply with, or otherwise be exempt from, Code Section 409A, ~~of the Code,~~ but make no representation or warranty to that effect.

Tax Withholding

We are authorized to deduct or withhold from any award granted or payment due under the ~~Second~~Third Amended Plan, or require a participant to remit to us, the amount of any withholding taxes due in respect of the award or payment and to take such other action as may be necessary to satisfy all obligations for the payment of applicable withholding taxes. We are not required to issue any shares of common stock or otherwise settle an award under the ~~Second~~Third Amended Plan until all tax withholding obligations are satisfied.

Vote Required

At the Annual Meeting, the approval of the amendment to ~~our 2017 Omnibus Incentive~~the Second Amended Plan requires the affirmative vote of the holders of a majority ~~in voting power~~ of the shares of common stock ~~of Anika Therapeutics~~ that are voting on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal.

Board Recommendation

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE AMENDMENT OF ~~OUR 2017 OMNIBUS INCENTIVE~~THE SECOND AMENDED PLAN.

6170

Proposal 3: Approval of 2021 Employee Stock Purchase Plan

On March 17, 2021, the Board of Directors, upon the recommendation of its Compensation Committee, adopted the Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan, or the ESPP, subject to stockholder approval. The Board unanimously recommends that stockholders vote to approve the ESPP. The ESPP will encourage stock ownership by all eligible employees of our company and participating subsidiaries so that they may share in our growth by acquiring or increasing their proprietary interest in our company. Stockholder approval of the ESPP is necessary in order to satisfy the stockholder approval requirements of The Nasdaq Stock Market and requirements under Section 423 of the Internal Revenue Code of 1986, as amended, or the Code.

If the ESPP is approved by the stockholders at the Annual Meeting, it will become effective immediately. If the ESPP is not approved by the stockholders, it will not become effective and employees of our company and subsidiaries will not be able to participate in the ESPP.

Summary of the ESPP

The following is a summary of the material terms of the ESPP. These sections are qualified in their entirety by the full text of the ESPP, which is included as Appendix B to this Proxy Statement. If the terms of the ESPP are amended in a manner that would require stockholder approval under the requirements of The Nasdaq Stock Market or under Code Section 423, stockholders will be asked to approve such amendment.

Purpose

The ESPP is intended to encourage stock ownership by all eligible employees of our company and participating subsidiaries so that they may share in our growth by acquiring or increasing their proprietary interest in our company. The ESPP is designed to encourage eligible employees to remain in the employ of our company and participating subsidiaries. The ESPP is intended to constitute an “employee stock purchase plan” within the meaning of Code Section 423(b), except as described below under “International Participation.”

General

As further described below, the ESPP permits eligible employees to use payroll deductions to purchase shares of common stock at a discount. The payroll deductions accumulate over “offering periods.” On the first day of each offering period, each participant in the ESPP is automatically granted an option to purchase as many whole shares of common stock as the participant will be able to purchase with the payroll deductions credited to his or her account during the offering period, subject to various limits described below. At the end of the offering period, the total payroll deductions of all participants are used to purchase common stock directly from us at the discount.

Stock Subject to the ESPP

The stock subject to options under the ESPP will be shares of our authorized but unissued common stock, or shares of common stock we reacquire, including shares purchased in the open market. The aggregate number of shares of common stock that may be issued pursuant to the ESPP is 200,000, subject to adjustment as described below. If any option granted under the ESPP expires or terminates for any reason without having been exercised in full or ceases for any reason to be exercisable in whole or in part, the unpurchased shares subject thereto will again be available under the ESPP. As of April 20, 2021, the closing price of a share of common stock on the NASDAQ Global Select Market was $40.60.

Administration

The ESPP will be administered by the Compensation Committee, or such other committee as determined by the Board of Directors, or the Administrator. The interpretation and construction by the Administrator of any provisions of the ESPP or of any option granted under it will be final, unless otherwise determined by the Board. The Administrator may from time to time adopt such rules and regulations for carrying out the ESPP as it may deem best, provided that any such rules and regulations will be applied on a uniform basis to all employees under the ESPP. No member of the Board or the Administrator will be liable for any action or determination made in good faith with respect to the ESPP or any option granted under it.

Eligibility

Except as otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, all employees of our company or any of the participating subsidiaries who are (a) so employed on the start date of any offering period and (b) have continuously been employed with our company or the participating subsidiary for at least one month prior to such start date will be eligible to participate and receive an option with respect to such offering period. All eligible employees will have the same rights and privileges under the ESPP with respect to such offering period. In no event, however, may an employee be granted an option if such employee, immediately after the option is granted, would be treated as owning stock possessing five percent or more of the total combined voting power or value of all classes of stock of our company or of any parent corporation or subsidiary corporation, as the terms “parent corporation” and “subsidiary corporation” are defined in Code Sections 424(e) and (f). For purposes of determining stock ownership under this paragraph, the rules of Code Section 424(d) will apply, and stock that the employee may purchase under outstanding options (including options not granted under the ESPP) will be treated as stock owned by the employee. Notwithstanding the foregoing, except as otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, employees who are otherwise eligible employees and who are citizens or residents of a non-U.S. jurisdiction (without regard to whether such employee is also a citizen of the United States or a resident alien) will not be considered an eligible employee if their participation is prohibited under the laws of the applicable non-U.S. jurisdiction or if complying with the laws of the applicable non-U.S. jurisdiction would cause the ESPP or an offering period to violate Code Section 423. As of April 20, 2021, 265 employees would have been eligible to participate in the ESPP.

Offering Periods; Exercise Dates; Certain Limits.

Except as otherwise determined by the Administrator, the first offering period will start on November 15, 2021 and will end on May 14, 2022, provided that if such end date is not a business day, such offering period will end on the first business day preceding such end date. Thereafter, except as otherwise determined by the Administrator: an offering period will start on each May 15 (provided that if such start date is not a business day, such start date will be the first business day following the immediately preceding exercise date (as described below) and end on the following November 14 (provided that if such end date is not a business day, such end date will be the first business day preceding such end date); and offering period will start on each November 15 (provided that if such start date is not a business day, such start date will be the first business day following the immediately preceding exercise date) and end on the following May 14 (provided that if such end date is not a business day, such end date will be the first business day preceding such end date).

The end date within each offering period will be the day on which shares of common stock are purchased by participants in an offering period, which date we refer to as exercise date. On the start date of each offering period, we will grant to each eligible employee who has then elected to be a participant in the ESPP an option to purchase shares on the relevant exercise date, at the option price hereinafter provided for, covering a maximum of 800 shares of common stock (which maximum number may be amended by the Administrator from time to time with respect to an offering period prior to the start date thereof), on condition that such employee remains an eligible employee through the exercise date. A participant will be entitled to exercise the option so granted only to the extent of the participant’s accumulated payroll deductions on the exercise date.

Notwithstanding the foregoing, the Administrator may in its discretion determine to implement offering periods of up to twenty-seven months. Those offering periods may consist of one or more exercise dates. Each eligible employee who elects to be a participant in such an offering period will be granted an option, at the option price, to purchase shares of common stock on such exercise date or dates. Each such option will cover a maximum number of shares of common stock for such offering period as determined by the Administrator prior the start date of such offering period. In no event will an offering period under the ESPP exceed twenty-seven months.

Option Price

The option price per share for each exercise date within an offering period will be 85% of the lesser of (a) the fair market value of the common stock on the start date of the offering period and (b) the fair market value of the common stock on the exercise date, in either event rounded up to the nearest cent. Prior to the start date of an offering period, the Administrator may increase, but not decrease, the option price with respect to such offering period. The foregoing limitation on the number of shares subject to an option and the option price will be subject to adjustment as described below. For purposes of the ESPP, the term “fair market value” on any date means the value of the common stock as determined below. If the common stock is listed on any established stock exchange or a national market system, including the New York Stock Exchange or the NASDAQ Stock Market, the fair market value will be the closing price of a share of common stock (or if no sales were reported on such date, the closing price on the last trading date) as quoted on such exchange or system. In the absence of an established market for the common stock, the fair market value will be determined in good faith by the Administrator and such determination will be conclusive and binding on all persons.

$25,000 Limitation

No employee will be granted an option that permits the employee’s right to purchase stock under the ESPP, and under all other Code Section 423(b) employee stock purchase plans of our company and any parent corporations or subsidiary corporations, as “parent corporation” and “subsidiary corporation” are defined in Code Section 424(e) and (f), to accrue at a rate that exceeds $25,000 of fair market value of such stock (determined on the date or dates that options on such stock were granted) for each calendar year in which such option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply, and such limitation will be administered in accordance, with Code Section 423(b)(8).

Payroll Deductions; Maximum Amount of Payroll Deductions

Except as otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, an employee may authorize payroll deductions in an amount (expressed as a whole percentage) not less than 1% but not more than 15% of the employee’s Compensation. For this purpose, “Compensation” means, unless otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, an employee’s base pay or salary from our company or participating subsidiary, including such amounts of base pay or salary as are deferred by the employee (a) under a qualified cash or deferred arrangement described in Code Section 401(k) or (b) to a plan qualified under Code Section 125. Except as otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, deductions may not be increased or decreased during an offering period.

Plan Withdrawal

Except as otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, a participant may withdraw from the ESPP and such offering period (in whole but not in part) by giving notice at least three business days prior to the end date of such offering period, in which case the entire balance of his or her unused payroll deduction account under the ESPP will be promptly refunded, without interest. Except as otherwise determined by the Administrator with respect to an offering period prior to the start date thereof, to re-enter the ESPP, an employee who has previously withdrawn must file a new authorization at least ten business days before the first day of the next offering period in which he or she wishes to participate.

Adjustments; Change in Control

Subject to any required action by the stockholders, the Administrator, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the ESPP, will, in such manner as it may deem equitable, adjust the number of shares of common stock available for issuance under the ESPP, the option price, the maximum number of shares that may be purchased during an offering period, as well as any other terms that the Administrator determines require adjustment, for: (a) any increase or decrease in the number of issued shares of common stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the common stock; (b) any other increase or decrease in the number of issued shares of common stock effected without receipt of consideration; or (c) as the Administrator may determine in its discretion, any other transaction with respect to common stock, including a corporate merger, consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation (whether partial or complete), or any similar transaction; provided that conversion of any convertible securities will not be deemed to have been “effected without receipt of consideration.” Such adjustment, if any, will be made by the Administrator and its determination will be final, binding and conclusive. Except as the Administrator determines otherwise, no issuance of shares of stock of any class, or securities convertible into shares of stock of any class, will require adjustment hereunder. Except as otherwise determined by the Administrator, in the event of a Change in Control (as defined in our 2017 Omnibus Incentive Plan, as amended from time to time), all outstanding options under the ESPP will automatically be exercised immediately before the closing of such Change in Control for whole shares as if the date of such closing is the next exercise date, subject to the maximum 800 share limitation and the $25,000 limitation described above.

Transfers

An option granted under the ESPP may not be transferred or assigned, except by will or the laws of descent and distribution, and will be exercised, during a participant’s lifetime, only by the participant.

Employee Terminations

Whenever a participant ceases to be an eligible employee because of retirement, voluntary or involuntary termination, resignation, layoff, discharge, death, or for any other reason, his or her rights under the ESPP will immediately terminate, and the entire balance of his or her payroll deduction account under the ESPP will be promptly refunded, without interest. Notwithstanding the foregoing, eligible employment will be treated as continuing intact while the participant is on military leave, sick leave, or other bona fide leave of absence (such as temporary employment by the government) if the period of such leave does not exceed three months, or if longer, so long as the participant’s right to reemployment with our company or participating subsidiary is provided either by statute or by contract. If the period of leave exceeds three months and the participant’s right to reemployment with our company or participating subsidiary is not provided either by statute or by contract, the employment relationship will be deemed to terminate on the first day immediately following such three-month period.

Termination of Plan; Amendment of ESPP

Unless terminated sooner as provided below, the ESPP will terminate on the tenth anniversary of its approval by the stockholders. The ESPP may be terminated at any time by the Board of Directors but such termination will not affect options then outstanding under the ESPP. The ESPP will terminate in any case when all or substantially all of the unissued shares of stock reserved for the purposes of the ESPP have been purchased. If at any time shares of stock reserved for the purpose of the ESPP remain available for purchase but not in sufficient number to satisfy all then unfilled purchase requirements, the available shares will be apportioned among participants in proportion to the amount of payroll deductions accumulated on behalf of each participant that would otherwise be used to purchase stock, and the ESPP will terminate. Upon such termination or any other termination of the ESPP, all payroll deductions not used to purchase stock will be refunded, without interest. The Administrator or the Board may from time to time adopt amendments to the ESPP, provided that, without the approval of the stockholders, no amendment may (a) increase the number of shares that may be issued under the ESPP, (b) change the class of employees eligible to receive options under the ESPP, if such action would be treated as the adoption of a new plan for purposes of Code Section 423(b), or (c) be made if it would be treated as the adoption of a new plan for purposes of Code Section 423(b) or would require stockholder approval under applicable exchange listing rules.

Participation Subsidiaries

The term “participating subsidiary” means any of our present or future subsidiaries, as that term is defined in Code Section 424(f), that is designated from time to time by the Board of Directors to participate in the ESPP. The Board will have the power to make such designation before or after the ESPP is approved by the stockholders. The following subsidiaries are currently designated as participating subsidiaries: Arthrosurface, Inc. and Parcus Medical, LLC.

International Participation

Notwithstanding anything to the contrary in the ESPP, to provide us with greater flexibility in structuring our equity compensation programs for our non-U.S. employees, the ESPP also permits us to grant employees of our non-U.S. subsidiary entities rights to purchase shares pursuant to other offering period rules or sub-plans adopted by the Administrator in order to achieve tax, securities law or other compliance objectives. While the ESPP is intended to be a qualified “employee stock purchase plan” within the meaning of Code Section 423, any such international sub-plans or offerings are not required to satisfy those U.S. tax code requirements and therefore may have terms that differ from the ESPP terms applicable in the U.S. However, the international sub-plans or offering periods are subject to the ESPP terms limiting the overall shares available for issuance, the maximum payroll deduction rate, maximum purchase price discount and the maximum offering period length.

Stockholder Status

Neither the granting of an option to an employee nor the deductions from his or her pay will constitute such employee a stockholder of the shares covered by an option until such shares have been actually purchased by the employee. A participant will have no interest or voting right in shares covered by the participant’s option until such shares are actually purchased on the participant’s behalf in accordance with the applicable provisions of the ESPP. Except as set described above, no adjustment will be made for dividends, distributions or other rights for which the record date is prior to the date of such purchase.

Governing Law

The validity and construction of the ESPP will be governed by the laws of Delaware, without giving effect to the principles of conflicts of law thereof.

Plan Benefits

Benefits under the ESPP will depend on participants’ elections to participate and the fair market value of common stock at various future dates. As a result, it is not possible as of the date of this proxy statement to determine future benefits that will be received by executive officers and other employees. Each participant is limited to the $25,000 annual purchase restriction described above as well as the 800 share per-offering period limit described above.

Employees as General Creditors

We will accumulate and hold for each participant’s account the amounts deducted from the participant’s pay. No interest will be paid on these amounts. We may use payroll deductions that we receive or hold under the ESPP for any corporate purpose, and we will not be obligated to segregate such payroll deductions or hold them exclusively for the benefit of participants. All payroll deductions that we receive or hold may be subject to the claims of our general creditors. Participants will have the status of general unsecured creditors of our company. Any amounts payable to participants pursuant to the ESPP will be unfunded and unsecured obligations for all purposes, including Title I of the Employee Retirement Income Security Act of 1974, as amended.

Form S-8

We anticipate filing a registration statement on Form S-8 with the SEC to register shares of common stock under the ESPP as soon as practicable, subject to and effective upon stockholder approval of the ESPP.

Certain U.S. Federal Income Tax Consequences

The following brief summary of the effect of U.S. federal income taxation upon a participant and our company with respect to shares of common stock purchased under the ESPP does not purport to be complete and does not discuss the tax consequences of a participant’s death or the income tax laws of any state or non-U.S. jurisdiction in which the participant may reside. The ESPP, and the right of U.S. participants to make purchases thereunder, is intended to qualify under the provisions of Code Sections 421 and 423. Under these provisions, no income will be taxable to a participant until shares purchased under the ESPP are sold or otherwise disposed of. Upon sale or other disposition of shares, the participant generally will be subject to tax in an amount that depends upon whether the sale occurs before or after expiration of the holding periods described in the following sentence. If the shares are sold or otherwise disposed of more than two years from the first day of the applicable offering period and one year from the applicable exercise date, the participant will recognize ordinary income measured as the lesser of (a) the excess of the fair market value of the shares at the time of such sale or disposition over the option price and (b) the excess of the fair market value of a share on the first day of the applicable offering period over the option price. Any additional gain will be treated as long term capital gain. If the shares are sold or otherwise disposed of before the expiration of either of these holding periods, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased over the option price. Any additional gain or loss on such sale or disposition will be long- or short-term capital gain or loss, depending on how long the shares been held from the date of purchase. We generally are not entitled to a deduction for amounts taxed as ordinary income or capital gain to a participant, except to the extent of ordinary income recognized by participants upon a sale or disposition of shares prior to the expiration of the holding periods described above.

Vote Required

At the Annual Meeting, the approval of the 2021 Employee Stock Purchase Plan requires the affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal.

Board Recommendation

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT OUR STOCKHOLDERS APPROVE THE 2021 EMPLOYEE STOCK PURCHASE PLAN.

Audit Committee Report

The Audit Committee of the Board of Directors consists entirely of members who meet the independence requirements of the listing standards of NASDAQ and the rules and regulations of the SEC, as determined by the ~~Board of Directors.~~Board. The Audit Committee is responsible for providing independent, objective oversight of the financial reporting processes and internal controls of Anika Therapeutics, Inc., or Anika. The Audit Committee operates under a written charter approved by the ~~Board of Directors.~~Board. A copy of the current charter is available on the investor relations portion of Anika’s website athttps://ir.anikatherapeutics.com/corporate-governance.

Management is responsible for Anika’s system of internal control and financial reporting processes, for the preparation of consolidated financial statements in accordance with U.S. generally accepted accounting principles and for the annual report on Anika’s internal control over financial reporting. The independent auditor is responsible for performing an independent audit of Anika’s consolidated financial statements in accordance with the standards of the Public Company Accounting Oversight Board, or PCAOB, and for issuing a report on the financial statements and the effectiveness of Anika’s internal control over financial reporting. The Audit Committee’s responsibility is to monitor and oversee these processes. In performing its functions, the Audit Committee acts only in an oversight capacity and necessarily relies on the work and assurances of management, the internal audit group, and the independent auditor. Audit Committee members do not serve as professional accountants or auditors for Anika, and their functions are not intended to duplicate or certify the activities of Anika’s management or independent auditor.

Consistent with its monitoring and oversight responsibilities, the Audit Committee met with management and Deloitte & Touche LLP, or Deloitte, Anika’s independent auditor, to review and discuss the December 31, ~~2019~~2020 audited consolidated financial statements. Management represented that Anika had prepared the consolidated financial statements in accordance with U.S. generally accepted accounting principles. The Audit Committee discussed with Deloitte the matters required by the PCAOB in accordance with Auditing Standard No. 1301, “Communications with Audit Committees.”

The Audit Committee received from Deloitte the written communication that is required by PCAOB Rule 3526, “Communication with Audit Committees Concerning Independence,” and the Audit Committee discussed with Deloitte that firm’s independence. The Audit Committee also considered whether Deloitte’s provision of non-audit services and the audit and non-audit fees paid to Deloitte were compatible with maintaining that firm’s independence. On the basis of these reviews, the Audit Committee determined that Deloitte has the requisite independence.

Management completed the documentation, testing, and evaluation of Anika’s system of internal control over financial reporting as of December 31, ~~2019~~2020 as required by Section 404 of the Sarbanes-Oxley Act of 2002. The Audit Committee received periodic updates from management and Deloitte at Audit Committee meetings throughout the year and provided oversight of the process. Prior to filing Anika’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2019,~~2020, or the Form 10-K, with the Securities and Exchange Commission, the Audit Committee also reviewed management’s report on the effectiveness of Anika’s internal control over financial reporting contained in the Form 10-K, as well as the Report of Independent Registered Public Accounting Firm provided by Deloitte and also included in the Form 10-K. Deloitte’s report included in the Form 10-K related to its audit of Anika’s consolidated financial statements and the effectiveness of Anika’s internal control over financial reporting.

Based upon the Audit Committee’s discussions with management and Deloitte and the Audit Committee’s review of the information provided by, and the representations of, management and Deloitte, the Audit Committee recommended to the Board ~~of Directors~~ that the audited consolidated financial statements as of and for the year ended December 31, ~~2019~~2020 be included in the Annual Report. The Audit Committee selected Deloitte as Anika’s independent auditor for the fiscal year ending December 31, ~~2020,~~2021 and recommended that the selection be submitted for ratification by the stockholders of Anika.

6277

This report is submitted by the following independent directors who comprise the Audit Committee:

Raymond J. Land, ~~Chairperson~~Chair

~~Joseph L. Bower~~

~~Jeffery S. Thompson~~Stephen O. Richard

Susan N. Vogt

THE FOREGOING REPORT SHOULD NOT BE DEEMED INCORPORATED BY REFERENCE INTO ANY FILING UNDER THE SECURITIES ACT OF 1933 OR THE SECURITIES EXCHANGE ACT OF 1934 BY ANY GENERAL STATEMENT INCORPORATING BY REFERENCE THIS PROXY STATEMENT, EXCEPT TO THE EXTENT THAT ANIKA SPECIFICALLY INCORPORATES THIS INFORMATION BY REFERENCE, AND SHALL NOT OTHERWISE BE DEEMED FILED UNDER SUCH ACTS.

6378

Proposal 3:4: Ratification of Appointment of Independent Auditor for ~~2020~~2021

Appointment of Independent Auditor by Audit Committee

The Audit Committee annually evaluates the performance of our independent auditor, including the senior audit engagement team, and determines whether to reengage the current independent auditor or consider other audit firms. The Audit Committee’s initial appointment of Deloitte & Touche LLP, or Deloitte, as independent auditor ~~for~~of our consolidated financial statements for 2017, was ratified by a vote of stockholders at our 2017 Annual Meeting of Stockholders. The Audit Committee again appointed Deloitte as our independent auditor for the years ended December 31, 2018, 2019, and ~~2019,~~2020, which were ratified by votes of our stockholders at our ~~2018~~2019 and ~~2019~~2020 Annual Meetings of Stockholders.

This year the Audit Committee has again approved the retention of Deloitte as our independent auditor to report on our consolidated financial statements and the effectiveness of our internal control over financial reporting for the year ending December 31, ~~2020.~~2021. Factors considered by the Audit Committee in deciding whether to retain Deloitte included:

Deloitte’s global capabilities;

Deloitte’s technical expertise and knowledge of our global operations and industry;

the quality and candor of Deloitte’s communications with the Audit Committee and management;

the quality and efficiency of the services provided by Deloitte, including input from management on Deloitte’s performance;

Deloitte’s objectivity and professional skepticism;

external data on audit quality and performance, including recent PCAOB reports on Deloitte and its peer firms;

Deloitte’s use of technology to aid in audit efficiency;

Deloitte’s independence, how effectively Deloitte demonstrated its independent judgment, and the controls and processes in place that help ensure Deloitte’s independence; and

the appropriateness of Deloitte’s fees.

Proposed Ratification of Independent Auditor

The Audit Committee is responsible for the appointment, retention, termination, compensation, and oversight of the work of our independent registered public accounting firm for the purpose of preparing or issuing an audit report or related work. Although ratification of the appointment of our independent auditor is not required by our bylaws or otherwise, the Board of Directors is submitting the appointment of Deloitte to our stockholders for ratification because we value the views of our stockholders.

The Audit Committee considers Deloitte to be well qualified. In the absence of contrary specification, the Proxy Committee will vote proxies received in response to this solicitation in favor of ratification of the appointment. In the event that stockholders fail to ratify the appointment of Deloitte, the Audit Committee will reconsider the appointment of Deloitte. Even if the appointment is ratified, the ratification is not binding and the Audit Committee may in its discretion select a different independent auditor at any time during the year if it determines that such a change would be in the best interests of our company and stockholders.

Representatives of Deloitte are expected to be present at the Annual Meeting. They will have an opportunity to make a statement, if they desire, and will be available to respond to appropriate questions.

6479

Vote Required

At the Annual Meeting, the ratification of our independent auditor for ~~2020~~2021 requires the affirmative vote of the holders of a majority ~~in voting power~~ of the shares of common stock ~~of Anika Therapeutics~~ that are voting on the matter. Abstentions will not be treated as votes cast and will have no effect on the vote. Because this proposal is considered a routine matter, discretionary votes by brokers will be counted.

Board Recommendation

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE RATIFICATION OF THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS OUR INDEPENDENT AUDITOR FOR THE YEAR ENDING DECEMBER 31, ~~2020.~~2021.

Fees Paid to Our Independent Auditor

The following table summarizes the fees that we paid or accrued for audit and other services provided by Deloitte, our independent auditor, for the years ended December 31, ~~2019~~2020 and ~~2018.~~2019.

Fee Category 2019 2018
Audit fees $ 697,022 $ 728,929
Audit-related fees - -
Tax fees 127,783 21,000
All other fees 3,790 -
Total fees $ 828,595 $ 749,929

Fee Category	2020		2019
Audit fees	$	1,314,815	$	697,022
Audit-related fees		-		-
Tax fees		196,269		127,783
All other fees		5,685		3,790
Total fees	$	1,516,769	$	828,595

For purposes of the preceding table:

Audit fees consist of fees for the audit of our consolidated financial statements, the review of the interim financial statements included in our Quarterly Reports on Form 10-Q, and other professional services provided in connection with statutory and regulatory filings or engagements for those ~~years.~~years, inclusive of fees related to work performed with respect to our acquisitions of Arthrosurface and Parcus Medical in early 2020. In addition, Audit fees include: fees for comfort letters, consents, assistance with and review of documents filed with the SEC, Section 404 attest services, other attest services that generally only the principal independent auditor can provide, work done by tax professionals in connection with the audit or quarterly review, and accounting consultations billed as audit services, as well as other accounting and financial reporting consultation research work necessary to comply with the standards of the PCAOB.

Audit-related fees consist of the aggregate fees billed by the principal accountant in each of the last two fiscal years for assurance and related services reasonably related to the performance of the audit or review.

Tax fees consist of fees for tax compliance, tax advice, and tax planning services for those years.

All other fees consist of the aggregate fees billed by the principal accountant in each of the last two fiscal years for products and services other than the services reported herein.

In considering the nature of the services provided by a principal independent auditor, the Audit Committee determined that such services are compatible with the provision of independent audit services. The Audit Committee discussed these services with the independent auditor and management to determine that they are permitted under the rules and regulations concerning auditor independence promulgated by the SEC to implement the Sarbanes-Oxley Act of 2002, as well as the American Institute of Certified Public Accountants. In accordance with its charter, the Audit Committee has procedures for pre-approving audit and non-audit services to be provided by the independent auditor. These procedures are designed to ensure the continued independence of the independent auditor. More specifically, the use of the independent auditor to perform either audit or non-audit services is prohibited unless specifically approved in advance by the Audit Committee. As a result of this approval process, the Audit Committee has pre-approved specific categories of services and associated fee budgets. All services outside of the specified categories and all amounts exceeding the approved fee budgets are approved by the Chair of the Audit Committee, who has been delegated the authority to review and approve audit and non-audit related services during the year. A listing of the audit and non-audit services and associated fees approved by the Chair outside the scope of the services and fees initially approved by the full Audit Committee is reported to the full Audit Committee no later than its next meeting. The Audit Committee also regularly receives updates from Deloitte and management about the services actually performed and the associated fees and expenses actually incurred.

In addition, the Audit Committee evaluates other known potential engagements of the independent auditor, including the scope of audit-related services, tax services, and other services proposed to be performed and the proposed fees, and approves or rejects each service, taking into account whether the services are permissible under applicable law and the possible impact of each non-audit service on the independent auditor’s independence from management. All such services were approved by the Audit Committee pursuant to Rule 2-01 of Regulation S-X under the Exchange Act to the extent that rule was applicable. Since May 2003 each new engagement of a principal independent auditor has been approved in advance by the Audit Committee.

6681

Proposal 4:5: Advisory Vote on Executive Compensation

In accordance with Section 14A of the Exchange Act, we are providing our stockholders with the opportunity to vote on a non-binding, advisory resolution to approve the compensation of our NEOs for the year ended December 31, ~~2019,~~2020, which is described in the section titled “Compensation Discussion and Analysis” in this Proxy Statement. At our 2017 Annual Meeting of Stockholders, we asked our stockholders to indicate if we should hold a “say-on-pay” vote every one, two or three years. Consistent with the recommendation of the Board of Directors, our stockholders indicated by advisory vote their preference to hold a “say-on-pay” vote annually. After consideration of the 2017 voting results, and based upon its prior recommendation, the Board elected to hold a stockholder “say-on-pay” vote annually.

As described in the section titled “Compensation Discussion and Analysis” of this Proxy Statement, our executive compensation program is designed to attract and retain highly qualified executive officers and motivate them to provide a high level of performance for the benefit of ~~Anika Therapeutics~~our company and ~~our~~ stockholders. Stockholders are urged to read the section titled “Compensation Discussion and Analysis,” which more thoroughly discusses how our compensation policies and procedures implement our compensation philosophy and objectives. The Compensation Committee and the Board ~~of Directors~~ believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving our objectives. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our NEOs and the policies and practices described in this Proxy Statement.

Accordingly, the following resolution is submitted for a stockholder vote at the Annual Meeting:

“RESOLVED:

That the stockholders of Anika Therapeutics, Inc. approve, on an advisory basis, the compensation paid to the named executive officers of Anika Therapeutics, Inc. as disclosed pursuant to Item 402 of Regulation S-K under the Securities Exchange Act of 1934, including the Compensation Discussion and Analysis, compensation tables, and narrative discussion set forth in the Proxy Statement for the ~~2020~~2021 Annual Meeting of Stockholders.”

This vote is advisory and will not be binding upon us, the Compensation Committee or the Board. However, the Board and its Compensation Committee value the opinions of our stockholders and to the extent there is any significant vote against the NEO compensation as disclosed in this Proxy Statement, we will consider our stockholders’ concerns, and the Compensation Committee will evaluate whether any actions are necessary to address those concerns.

Vote Required

At the Annual Meeting, approval of our ~~2019~~2020 executive compensation requires the affirmative vote of the holders of a majority ~~in voting power~~ of the shares of common stock ~~of Anika Therapeutics, Inc.~~ that are voting on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal. While this vote is required by law, it will not be binding on us, the Compensation Committee, or the Board of Directors, nor will it create or imply any change in the fiduciary duties of, or impose any additional fiduciary duty on, our company, the Compensation Committee or the Board. However, the Compensation Committee and the Board will take into account the outcome of the vote when considering future executive compensation decisions.

Board Recommendation

THE BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS VOTE TO APPROVE THE OVERALL COMPENSATION OF THE NAMED EXECUTIVE OFFICERS BY VOTING “FOR” THIS RESOLUTION.

6782

Other Matters

The Board of Directors does not know of any other matters that will come before the Annual Meeting. However, if any other matters are properly presented at the Annual Meeting, it is the intention of the persons named in the accompanying proxy card to vote, or otherwise act, in accordance with their judgment on such matters.

Solicitation Expenses

All costs of solicitation of proxies will be borne by us. In addition to solicitation by mail, our directors, officers, and employees, without additional remuneration, may solicit proxies in person or by telephone, e-mail, and facsimile. We will reimburse banks, brokerage firms, and other custodians, nominees, trustees, and fiduciaries for reasonable out-of-pocket expenses incurred by them in sending proxy materials to and soliciting proxies from beneficial holders of our shares. We ~~may retain a proxy solicitation firm~~have retained Innisfree M&A Incorporated to assist in the solicitation of proxies for a fee of $25,000, plus reimbursement of expenses.

Stockholder Proposals

In order for stockholder proposals for the ~~2021~~2022 Annual Meeting of Stockholders to be eligible for inclusion in the proxy statement and form of proxy card for that meeting, we must receive the proposals before December ~~23, 2020.~~31, 2021. These proposals must also comply with the rules of the SEC governing the form and content of proposals in order to be included in our proxy statement and form of proxy, and proposals should be directed to: Secretary, Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730. All proposals will need to comply with Rule 14a-8 of the Exchange Act, which sets forth the requirements for the inclusion of stockholder proposals in our sponsored proxy materials.

Our bylaws and Policy and Procedures for Stockholder Nominations to the Board set forth the procedures you must follow in order to nominate a director for election or make a proposal at an annual meeting of our stockholders, other than proposals intended to be included in our sponsored proxy materials. In addition to any other applicable requirements, in order for business to be properly brought before the ~~2021~~2022 Annual Meeting by a stockholder, the stockholder must have given us timely notice thereof in proper written form, including all required information, at our corporate headquarters, 32 Wiggins Avenue, Bedford, Massachusetts 01730, directed to the attention of the Secretary, between February 16, ~~2021~~2022 and March 18, ~~2021.~~2022. The proposal must also comply with the other requirements contained in the bylaws, including supporting documentation and other information. Proxies solicited by the Board of Directors will confer discretionary voting authority with respect to these proposals, subject to SEC rules governing the exercise of this authority. We have posted ~~a copy~~copies of our bylaws and our Policy and Procedures for Stockholders to the Board in the investor relations section of our website at https://~~www.anikatherapeutics.com~~ir.anikatherapeutics.com/investor-relations under “Corporate Governance.”

The chair of the meeting has the power and duty to ~~(i) to~~(a) determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in our bylaws and ~~(ii) to~~(b) declare that a proposed nomination shall be disregarded or that proposed business shall not be transacted if such proposed nomination or business was not made or proposed in compliance our bylaws. Additionally, unless otherwise required by law, if the stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or proposed business, such nomination shall be disregarded and such proposed business shall not be transacted, notwithstanding that proxies in respect of such vote may have been received by ~~Anika Therapeutics.~~us.

6883

Householding

SEC rules permit us to deliver a single copy of our ~~2019~~2020 Annual Report to Stockholders and this Proxy Statement, or one Notice of Internet Availability of Proxy Materials, to two or more stockholders who share an address, unless we have received contrary instructions from one or more of the security holders. This delivery method, which is known as “householding,” can reduce our expenses for printing and mailing. Any stockholder of record at a shared address to which a single copy of the documents was delivered may request a separate copy of the ~~2019~~2020 Annual Report to Stockholders and this Proxy Statement, or a separate Notice of Internet Availability of Proxy Materials, as applicable, by sending us a written request made to Anika Therapeutics, Inc., 32 Wiggins Avenue, Bedford, Massachusetts 01730, Attention: Secretary or by calling (781) 457-9000. Stockholders of record who wish to receive separate copies of these documents in the future may also contact us as stated above. Stockholders of record who share an address and are receiving multiple copies of our annual reports to stockholders and Proxy Statements, or of our Notices of Internet Availability of Proxy Materials, may contact us as stated above to request delivery of a single copy of such documents. Stockholders who hold their shares in “street name” and who wish to obtain copies of these proxy materials should follow the instructions on their voting instruction forms or contact the holders of record. STOCKHOLDERS MAY OBTAIN, WITHOUT CHARGE, A COPY OF OUR ANNUAL REPORT ON FORM 10-K, INCLUDING THE FINANCIAL STATEMENTS CONTAINED THEREIN, FILED WITH THE SEC FOR THE YEAR ENDED DECEMBER 31, ~~2019,~~2020, BY WRITING TO OUR SECRETARY AT ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD, MASSACHUSETTS 01730.

6984

Appendix A

ANIKA THERAPEUTICS, INC.

2017 OMNIBUS INCENTIVE PLAN

(Marked to Show ~~2020~~2021 Amendment)

Anika Therapeutics, Inc. sets forth herein the terms of its 2017 Omnibus Incentive Plan.

PURPOSE

The Plan is intended to enhance the ability of the Company and its Affiliates to attract and retain highly qualified officers, Non-employee Directors, employees, consultants and advisors, and to motivate such individuals to serve the Company and its Affiliates and to expend maximum effort to improve the business results and earnings of the Company, by providing to such persons an opportunity to acquire or increase a direct proprietary interest in the operations and future success of the Company. To this end, the Plan provides for the grant of stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units (“RSUs”), unrestricted stock, other share-based awards and cash awards. Any of these awards may, but need not, be made as performance incentives to reward attainment of performance goals in accordance with the terms hereof. Upon the Plan becoming effective, no further awards shall be made under the Prior Plan.

DEFINITIONS

For purposes of interpreting the Plan and related documents (including Award Agreements), the following definitions shall apply:

“Acquiror” shall have the meaning set forth inSection 15.2.1.

“Affiliate” means any company or other trade or business that “controls,” is “controlled by” or is “under common control with” the Company within the meaning of Rule 405 of Regulation C under the Securities Act, including any Subsidiary.

“Annual Incentive Award” means a cash-based Performance Award with a performance period that is the Company’s fiscal year or other 12-month (or shorter) performance period as specified under the terms of the Award as approved by the Board.

“Award” means a grant under the Plan of an Option, SAR, Restricted Stock, RSU, Other Share-based Award or cash award.

“Award Agreement” means a written agreement between the Company and a Participant, or notice from the Company or an Affiliate to a Participant that evidences and sets out the terms of an Award.

“Board” means the Board of Directors of the Company.

“Business Combination” shall have the meaning set forth inSection 15.2.2.

“Cause” shall be defined as that term is defined in the Participant’s offer letter or other applicable employment agreement; or, if there is no such definition, “Cause” means, as determined by the Company in its sole discretion and unless otherwise provided in the applicable Award Agreement: (i) any material breach by the Participant of any agreement between the Participant and the Company; (ii) the conviction of or plea of nolo contendere by the Participant to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Participant of the Participant’s duties to the Company. A Separation from Service for Cause shall be deemed to include a determination by the Company in its sole discretion following a Participant’s Separation from Service that circumstances existing prior to such Separation from Service would have entitled the Company or an Affiliate to have terminated the Participant’s service for Cause. All rights a Participant has or may have under the Plan shall be suspended automatically during the pendency of any investigation by the Company, or during any negotiations between the Company and the Participant, regarding any actual or alleged act or omission by the Participant of the type described in the applicable definition of Cause.

70A-1

“Change in Control” shall have the meaning set forth inSection 15.2.2.

“Code” means the Internal Revenue Code of 1986.

“Committee” means the Compensation Committee of the Board, or such other committee as determined by the Board. The Compensation Committee of the Board may designate a subcommittee of its members to serve as the Committee (to the extent the Board has not designated another person, committee or entity as the Committee). The Board will cause the Committee to satisfy the applicable requirements of any securities exchange on which the Common Stock may then be listed. For purposes of Awards to Covered Employees intended to qualify as Performance-Based Compensation, to the extent required by Section 162(m), Committee means all of the members of the Compensation Committee who are “outside directors” within the meaning of Section 162(m). For purposes of Awards to Participants who are subject to Section 16 of the Exchange Act, Committee means all of the members of the Compensation Committee who are “non-employee directors” within the meaning of Rule 16b-3 adopted under the Exchange Act.

“Company” means Anika Therapeutics, Inc., a Massachusetts corporation, or any successor corporation.

“Common Stock” means the common stock of the Company.

“Consultant” means a consultant or advisor that provides bona fide services to the Company or any Affiliate and who qualifies as a consultant or advisor under Form S-8.

“Covered Employee” means a Participant who is a “covered employee” within the meaning of Section 162(m) as qualified bySection 12.4.

“Disability” shall be defined as that term is defined in the Participant’s offer letter or other applicable employment agreement; or, if there is no such definition, “Disability” means, as determined by the Company in its sole discretion and unless otherwise provided in the applicable Award Agreement, the Participant is unable to perform each of the essential duties of such Participant’s position by reason of a medically determinable physical or mental impairment which is potentially permanent in character or which can be expected to last for a continuous period of not less than 12 months;provided,however, that, with respect to rules regarding expiration of an Incentive Stock Option following termination of the Participant’s employment, “Disability” means “permanent and total disability” as set forth in Code Section 22(e)(3).

“Effective Date” means June 13, 2017, the date the Plan was approved by the Stockholders.

“Exchange Act” means the Securities Exchange Act of 1934.

“Fair Market Value” means, as of any date, the value of the Common Stock as determined below. If the Common Stock is listed on any established stock exchange or a national market system, including without limitation, the New York Stock Exchange or the NASDAQ Stock Market, the Fair Market Value shall be the closing price of a share of Common Stock (or if no sales were reported the closing price on the date immediately preceding such date) as quoted on such exchange or system on the day of determination. In the absence of an established market for the Common Stock, the Fair Market Value shall be determined in good faith by the Board and such determination shall be conclusive and binding on all persons.

“Family Member” means a person who is a spouse, former spouse, child, stepchild, grandchild, parent, stepparent, grandparent, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother, sister, brother-in-law or sister-in-law, including adoptive relationships, of the applicable individual, any person sharing the applicable individual’s household (other than a tenant or employee), a trust in which any one or more of these persons have more than 50% of the beneficial interest, a foundation in which any one or more of these persons (or the applicable individual) control the management of assets, and any other entity in which one or more of these persons (or the applicable individual) own more than 50% of the voting interests.

71A-2

“Grant Date” means the latest to occur of (i) the date as of which the Board approves an Award, (ii) the date on which the recipient of an Award first becomes eligible to receive an Award underSection 6or (iii) such other date as may be specified by the Board in the Award Agreement.

“Incentive Stock Option” means an “incentive stock option” within the meaning of Code Section 422.

“Incumbent Directors”shall have the meaning set forth inSection 15.2.2.

“New Shares” shall have the meaning set forth inSection 15.1.

“Non-employee Director” means a member of the Board or the board of directors of an Affiliate, in each case who is not an officer or employee of the Company or any Affiliate.

“Nonqualified Stock Option” means an Option that is not an Incentive Stock Option.

“Option” means an option to purchase one or more Shares pursuant to the Plan.

“Option Price” means the exercise price for each Share subject to an Option.

“Other Share-based Awards” means Awards consisting of Share units, or other Awards, valued in whole or in part by reference to, or otherwise based on, Shares.

“Participant” shall mean a person who, as a Service Provider, has been granted an Award under the Plan;provided,however, that in the case of the death or Disability of a Participant, the term “Participant” refers to the Participant’s estate or other legal representative acting in a fiduciary capacity on behalf of the Participant under applicable state law and court supervision.

“Performance Award” means an Award made subject to the attainment of performance goals (as described inSection 12) over a performance period established by the Committee, and includes an Annual Incentive Award.

“Performance-Based Compensation” means “performance-based compensation” under Section 162(m).

“Plan” means this Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan.

“Policy” shall have the meaning set forth inSection 3.2.2.

“Prior Plan” means the Anika Therapeutics, Inc. Second Amended and Restated 2003 Stock Option and Incentive Plan, as amended.

“Purchase Price” means the purchase price for each Share pursuant to a grant of Restricted Stock.

“Restricted Stock” means restricted Shares, awarded to a Participant pursuant toSection 10.

“Restricted Stock Unit” or “RSU” means a bookkeeping entry representing the equivalent of Shares, awarded to a Participant pursuant toSection 10.

“SAR Exercise Price” means the per Share exercise price of a SAR granted to a Participant underSection 9.

“SEC” means the United States Securities and Exchange Commission.

72A-3

“Section 162(m)” means Code Section 162(m).

“Section 409A” means Code Section 409A.

“Securities Act” means the Securities Act of 1933.

“Separation from Service” means the termination of the applicable Participant’s employment with, and performance of services for, the Company and each Affiliate. A Participant employed by, or performing services for, an Affiliate or a division of the Company or an Affiliate shall not be deemed to incur a Separation from Service if such Affiliate or division ceases to be an Affiliate or division of the Company, as the case may be, and the Participant immediately thereafter becomes an employee of (or service provider to), or member of the board of directors of, the Company or an Affiliate or a successor company or an affiliate or subsidiary thereof. Approved temporary absences from employment because of illness, vacation or leave of absence and transfers among the Company and its Affiliates shall not be considered Separations from Service. Notwithstanding the foregoing, with respect to any Award that constitutes nonqualified deferred compensation under Section 409A, “Separation from Service” shall mean a “separation from service” as defined under Section 409A.

“Service Period” shall have the meaning set forth inSection 10.1.

“Service Provider” means an employee, officer, Non-employee Director or Consultant of the Company or an Affiliate.

“Share” means a share of Common Stock.

“Stock Appreciation Right” or “SAR” means a right granted to a Participant pursuant toSection 9.

“Stockholders” means the stockholders of the Company.

“Subsidiary” means any “subsidiary corporation” of the Company within the meaning of Code Section 424(f).

“Substitute Award” means any Award granted in assumption of or in substitution for an award of a company or business acquired by the Company or an Affiliate or with which the Company or an Affiliate combines.

“Ten Percent Stockholder” means an individual who owns more than 10% of the total combined voting power of all classes of outstanding stock of the Company, its parent or any of its Subsidiaries. In determining stock ownership, the attribution rules of Code Section 424(d) shall be applied.

“Termination Date” means the date that is 10 years after the Effective Date, unless the Plan is earlier terminated by the Board underSection 5.2.

“Voting Securities” shall have the meaning set forth inSection 15.2.2.

ADMINISTRATION OF THE PLAN

3.1. General

The Board shall have such powers and authorities related to the administration of the Plan as are consistent with the Company’s certificate of incorporation and bylaws and applicable law. The Board shall have the power and authority to delegate its responsibilities hereunder to the Committee, which shall have full authority to act in accordance with its charter, and with respect to the power and authority of the Board to act hereunder, all references to the Board shall be deemed to include a reference to the Committee, unless such power or authority is specifically reserved by the Board. Except as specifically provided inSection 14 or as otherwise may be required by applicable law, regulatory requirement or the certificate of incorporation or the bylaws of the Company, the Board shall have full power and authority to take all actions and to make all determinations required or provided for under the Plan, any Award or any Award Agreement, and shall have

full power and authority to take all such other actions and make all such other determinations not inconsistent with the specific terms and provisions of the Plan that the Board deems to be necessary or appropriate to the administration of the Plan. The Committee shall administer the Plan;provided,however, the Board shall retain the right to exercise the authority of the Committee to the extent consistent with applicable law and the applicable requirements of any securities exchange on which the Common Stock may then be listed. All actions, determinations and decisions by the Board or the Committee under the Plan or any Award Agreement, or with respect to any Award, shall be in the sole discretion of the Board and shall be final, binding and conclusive on all persons. Without limitation, the Board shall have full and final power and authority, subject to the other terms of the Plan, to:

(i)

designate Participants;

A-4

(ii)

determine the type or types of Awards to be made to Participants;

(iii)

determine the number of Shares to be subject to an Award;

(iv)

establish the terms of each Award (including the Option Price of any Option, the nature and duration of any restriction or condition (or provision for lapse thereof) relating to the vesting, exercise, transfer or forfeiture of an Award or the Shares subject thereto and any terms or conditions that may be necessary to qualify Options as Incentive Stock Options);

(v)

subject to applicable law, delegate its authority and duties to the Chief Executive Officer with respect to the granting of Options to individuals who are not Covered Employees or “insiders” within the meaning of Section 16 of the Exchange Act. Any such delegation by the Board shall include a limitation as to the amount of Options that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Board may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Board’ delegate or delegates that were consistent with the terms of the Plan.;

(vi)

prescribe the form of each Award Agreement; and

(vii)

amend, modify or supplement the terms of any outstanding Award including the authority, in order to effectuate the purposes of the Plan, to modify Awards to foreign nationals or individuals who are employed outside the United States to recognize differences in local law, tax policy or custom.

3.2. Separation from Service for Cause; Clawbacks

3.2.1. Separation from Service for Cause

The Company may annul an Award if the Participant incurs a Separation from Service for Cause.

3.2.2. Clawbacks

All awards, amounts or benefits received or outstanding under the Plan shall be subject to clawback, cancellation, recoupment, rescission, payback, reduction or other similar action in accordance with the terms of any Company clawback or similar policy (the “Policy”) or any applicable law related to such actions, as may be in effect from time to time. A Participant’s acceptance of an Award shall be deemed to constitute the Participant’s acknowledgement of and consent to the Company’s application, implementation and enforcement of any applicable Policy that may apply to the Participant, whether adopted prior to or following the Effective Date, and any provision of applicable law relating to clawback, cancellation, recoupment, rescission, payback or reduction of compensation, and the Participant’s agreement that the Company may take such actions as may be necessary to effectuate any such policy or applicable law, without further consideration or action.

74A-5

3.3. Deferral Arrangement

The Board may permit or require the deferral of any Award payment into a deferred compensation arrangement, subject to such rules and procedures as it may establish and in accordance with Section 409A, which may include provisions for the payment or crediting of interest or dividend equivalents as provided inSection 17.10, including converting such credits into deferred Share units.

3.4. No Liability

No member of the Board or of the Committee shall be liable for any action or determination made in good faith with respect to the Plan, any Award or Award Agreement.

3.5. Book Entry

Notwithstanding any other provision of the Plan to the contrary, the Company may elect to satisfy any requirement under the Plan for the delivery of stock certificates through the use of book entry.

3.6. No Repricing

Notwithstanding any provision herein to the contrary, the repricing of Options or SARs is prohibited without prior approval of the Stockholders. For this purpose, a “repricing” means any of the following (or any other action that has the same effect as any of the following): (i) changing the terms or conditions of an Option or SAR to lower its Option Price or SAR Exercise Price; (ii) any other action that is treated as a “repricing” under generally accepted accounting principles; and (iii) repurchasing for cash or canceling an Option or SAR at a time when its Option Price or SAR Exercise Price is greater than the Fair Market Value of the underlying Shares in exchange for another Award, unless the cancellation and exchange occurs in connection with a change in capitalization or similar change underSection 15. A cancellation and exchange under clause (iii) would be considered a “repricing” regardless of whether it is treated as a “repricing” under generally accepted accounting principles and regardless of whether it is voluntary on the part of the Participant.

STOCK SUBJECT TO THE PLAN

4.1. Authorized Number of Shares

Subject to adjustment underSection 15, the total number of Shares authorized to be awarded under the Plan shall not exceed~~3,500,000 shares~~4,600,000~~~~the sum of (A) 1,200,000 shares, plus (B) effective upon approval of the Company’s stockholders at the Company’s 2019 Annual Meeting of Stockholders, 1,500,000 shares~~3,500,000~~. shares. The grant of any full value Award (i.e., an Award other than an Option or a SAR) shall be deemed, for purposes of determining the number of Shares available for issuance under thisSection 4.1, as an Award of two (2) Shares for each Share actually subject to the Award. The grant of an Option or SAR shall be deemed, for purposes of determining the number of Shares available for issuance under thisSection 4.1, as an Award for one (1) Share for each such Share actually subject to the Award. Any Shares returned to the Plan pursuant toSection 4.2 shall be returned to the reserved pool of Shares under the Plan in the same manner. In addition, Shares underlying any outstanding award granted under a Prior Plan that, following the Effective Date, expires, or is terminated, surrendered or forfeited for any reason without issuance of Shares shall be available for the grant of new Awards. As provided inSection 1, no new awards shall be granted under the Prior Plan following the Effective Date. Shares issued under the Plan may consist in whole or in part of authorized but unissued Shares, treasury Shares or Shares purchased on the open market or otherwise.

4.2. Share Counting

4.2.1. Any Award settled in cash shall not be counted as issued Shares for any purpose under the Plan.

4.2.2. If any Award expires, or is terminated, surrendered or forfeited, in whole or in part, the unissued Shares covered by such Award shall again be available for the grant of Awards.

75A-6

4.2.3. If Shares issued pursuant to the Plan are repurchased by, or are surrendered or forfeited to the Company at no more than cost, such Shares shall again be available for the grant of Awards.

4.2.4. If Shares issuable upon exercise, vesting or settlement of an Award, or Shares owned by a Participant (which are not subject to any pledge or other security interest), are surrendered or tendered to the Company in payment of the Option Price or Purchase Price of an Award or any taxes required to be withheld in respect of an Award, in each case, in accordance with the terms of the Plan and any applicable Award Agreement, such surrendered or tendered Shares shall not be available again for the grant of Awards.

4.2.5. Substitute Awards shall not be counted against the number of Shares available for the grant of Awards.

4.3. Award Limits

4.3.1. Incentive Stock Options

Subject to adjustment underSection 15,~~3,500,000~~4,600,000~~~~1,200,000~~3,500,000~~ Shares available for issuance under the Plan shall be available for issuance as Incentive Stock Options.

4.3.2. Individual Award Limits for Section 162(m) -- Share-Based Awards

Subject to adjustment underSection 15, the maximum number of each type of Award (other than cash-based Performance Awards) granted to any Participant in any calendar year shall not exceed the following number of Shares: (i) Options and SARs: 400,000 Shares; and (ii) all share-based Performance Awards (including Restricted Stock, RSUs and Other Share-based Awards that are Performance Awards): 400,000 Shares.

4.3.3. Individual Award Limits for Section 162(m) -- Cash-Based Awards

The maximum amount of cash-based Performance Awards intended to qualify as Performance-Based Compensation granted to any Participant in any calendar year shall not exceed the following: (i) Annual Incentive Awards: $1,000,000; and (ii) all other cash-based Performance Awards: $1.000,000.

4.3.4. Director Awards

The maximum value of Awards granted during any calendar year to any Non-employee Director, taken together with any cash fees paid to such Non-employee Director during the calendar year and the value of awards granted to the Non-employee Director under any other equity compensation plan of the Company or an Affiliate during the calendar year, shall not exceed the following in total value (calculating the value of any Awards or other equity compensation plan awards based on the fair market value as of grant date for financial reporting purposes): (i) $500,000 for the non-employee Chair or Lead Director of the Board and (ii) $425,000 for each Non-employee Director other than the Chair or Lead Director of the Board;provided, however, that awards granted to Non-employee Directors upon their initial election to the Board or the board of directors of an Affiliate shall not be counted towards the limit under thisSection 4.3.4.

EFFECTIVE DATE, DURATION AND AMENDMENTS

5.1. Term

The Plan shall be effective as of the Effective Date,provided that it has been approved by the Stockholders. The Plan shall terminate automatically on the 10-year anniversary of the Effective Date and may be terminated on any earlier date as provided inSection 5.2.

76A-7

5.2. Amendment and Termination of the Plan

The Board may, at any time and from time to time, amend, suspend or terminate the Plan as to any Awards which have not been made. An amendment shall be contingent on approval of the Stockholders to the extent stated by the Board, required by applicable law or required by applicable securities exchange listing requirements. No Awards shall be made after the Termination Date. The applicable terms of the Plan, and any terms applicable to Awards granted prior to the Termination Date, shall survive the termination of the Plan and continue to apply to such Awards. No amendment, suspension or termination of the Plan shall, without the consent of the Participant, materially impair rights or obligations under any Award theretofore awarded.

AWARD ELIGIBILITY AND LIMITATIONS

6.1. Service Providers

Subject to thisSection 6, Awards may be made to any Service Provider as the Board may determine and designate from time to time.

6.2. Successive Awards

An eligible person may receive more than one Award, subject to such restrictions as are provided herein.

6.3. Stand-Alone, Additional, Tandem, and Substitute Awards

Awards may be granted either alone or in addition to, in tandem with, or in substitution or exchange for, any other Award or any award granted under another plan of the Company, any Affiliate or any business entity to be acquired by the Company or an Affiliate, or any other right of a Participant to receive payment from the Company or any Affiliate. Such additional, tandem or substitute or exchange Awards may be granted at any time. If an Award is granted in substitution or exchange for another award, the Board shall have the right to require the surrender of such other award in consideration for the grant of the new Award. Subject to the requirements of applicable law, the Board may make Awards in substitution or exchange for any other award under another plan of the Company, any Affiliate or any business entity to be acquired by the Company or an Affiliate. In addition, Awards may be granted in lieu of cash compensation, including in lieu of cash amounts payable under other plans of the Company or any Affiliate, in which the value of Shares subject to the Award is equivalent in value to the cash compensation (for example, RSUs or Restricted Stock).

6.4. Minimum Vesting

Notwithstanding any other provision of the Plan to the contrary, Share-based Awards granted under the Plan shall vest no earlier than the first anniversary of the date the Award is granted, excluding, for this purpose, any (i) Substitute Awards, (ii) Shares delivered in lieu of fully vested cash Awards, and (iii) Awards to Non-employee Directors that vest on the earlier of the one year anniversary of the date of grant or the next annual meeting of stockholders (provided that such vesting period under this clause (iii) may not be less than 50 weeks after grant; provided, that, the Board may grant Share-based Awards without regard to the foregoing minimum vesting requirement with respect to a maximum of five percent (5%) of the available share reserve authorized for issuance under the Plan pursuant to Section 4.1 (subject to adjustment under Section 15); and, provided further, for the avoidance of doubt, that the foregoing restriction does not apply to the Committee’s discretion to provide for accelerated exercisability or vesting of any Award, including in cases of retirement, death, disability or a Change in Control, in the terms of the Award or otherwise.

AWARD AGREEMENT

The grant of any Award may be contingent upon the Participant executing an appropriate Award Agreement, in such form or forms as the Board shall from time to time determine. Without limiting the foregoing, an Award Agreement may be provided in the form of a notice which provides that acceptance of the Award constitutes acceptance of all terms of the Plan and the notice. Award Agreements granted from time to time or at the same time need not contain similar provisions but shall be consistent with the terms of the Plan. Each Award Agreement evidencing an Award of Options shall specify whether such Options are intended to be Nonqualified Stock Options or Incentive Stock Options, and in the absence of such specification such options shall be deemed Nonqualified Stock Options.

77A-8

TERMS AND CONDITIONS OF OPTIONS

8.1. Option Price

The Option Price of each Option shall be fixed by the Board and stated in the related Award Agreement. The Option Price of each Option (except those that constitute Substitute Awards) shall be at least the Fair Market Value on the Grant Date;provided,however, that in the event that a Participant is a Ten Percent Stockholder as of the Grant Date, the Option Price of an Option granted to such Participant that is intended to be an Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the Grant Date. In no case shall the Option Price of any Option be less than the par value of a Share.

8.2. Vesting

Subject toSection 8.3, each Option shall become exercisable at such times and under such conditions (including performance requirements) as stated in the Award Agreement.

8.3. Term

Each Option shall terminate, and all rights to purchase Shares thereunder shall cease, upon the expiration of the Option term stated in the Award Agreement not to exceed 10 years from the Grant Date, or under such circumstances and on such date prior thereto as is set forth in the Plan or as may be fixed by the Board and stated in the related Award Agreement;provided,however, that in the event that the Participant is a Ten Percent Stockholder, an Option granted to such Participant that is intended to be an Incentive Stock Option at the Grant Date shall not be exercisable after the expiration of five years from its Grant Date.

8.4. Limitations on Exercise of Option

Notwithstanding any other provision of the Plan, in no event may any Option be exercised, in whole or in part, (i) prior to the date the Plan is approved by the Stockholders as provided herein or (ii) after the occurrence of an event which results in termination of the Option.

8.5. Method of Exercise

An Option that is exercisable may be exercised by the Participant’s delivery of a notice of exercise to the Company, setting forth the number of Shares with respect to which the Option is to be exercised, accompanied by full payment for the Shares. To be effective, notice of exercise must be made in accordance with procedures established by the Company from time to time.

8.6. Rights of Holders of Options

Unless otherwise provided in the applicable Award Agreement, an individual holding or exercising an Option shall have none of the rights of a Stockholder (for example, the right to direct the voting of the subject Shares) until the Shares covered thereby are fully paid and issued to him or her. An individual holding an Option shall not have the right to receive cash or dividend payments or distributions attributable to the subject Shares until the Option has been exercised and the Shares covered thereby are fully paid and issued to him or her. Except as provided inSection 15 or the related Award Agreement, no adjustment shall be made for dividends, distributions or other rights for which the record date is prior to the date of such issuance.

78A-9

8.7. Delivery of Stock Certificates

Subject toSection 3.5, promptly after the exercise of an Option by a Participant and the payment in full of the Option Price, such Participant shall be entitled to the issuance of a stock certificate which evidences, or electronic notice of a book entry which records, his or her ownership of the Shares subject to the Option.

8.8. Limitations on Incentive Stock Options

An Option shall constitute an Incentive Stock Option only (i) if the Participant of such Option is an employee of the Company or any Subsidiary of the Company; (ii) to the extent specifically provided in the related Award Agreement; and (iii) to the extent that the aggregate Fair Market Value (determined at the time the Option is granted) of the Shares with respect to which all Incentive Stock Options held by such Participant become exercisable for the first time during any calendar year (under the Plan and all other plans of the Participant’s employer and its Affiliates) does not exceed $100,000. This limitation shall be applied by taking Options into account in the order in which they were granted. No Option shall be treated as an Incentive Stock Option unless the Plan has been approved by the Stockholders in a manner intended to comply with the stockholder approval requirements of Code Section 422(b)(1);provided,however,that any Option intended to be an Incentive Stock Option shall not fail to be effective solely on account of a failure to obtain such approval, but rather such Option shall be treated as a Nonqualified Stock Option unless and until such stockholder approval is obtained.

TERMS AND CONDITIONS OF STOCK APPRECIATION RIGHTS (SARs)

9.1. Right to Payment

A SAR shall confer on the Participant a right to receive, upon exercise thereof, the excess of (i) the Fair Market Value on the date of exercise over (ii) the SAR Exercise Price, as determined by the Board. The Award Agreement for a SAR (except those that constitute Substitute Awards) shall specify the SAR Exercise Price, which shall be fixed on the Grant Date as not less than the Fair Market Value on that date. SARs may be granted alone or in conjunction with all or part of an Option or at any subsequent time during the term of such Option or in conjunction with all or part of any other Award. A SAR granted in tandem with an outstanding Option following the Grant Date of such Option shall have a grant price that is equal to the Option Price;provided,however, that the SAR’s grant price may not be less than the Fair Market Value on the Grant Date of the SAR to the extent required by Section 409A.

9.2. Other Terms

The Board shall determine at the Grant Date or thereafter, the time or times at which and the circumstances under which a SAR may be exercised in whole or in part (including based on achievement of performance goals or future service requirements), the time or times at which SARs shall cease to be or become exercisable following Separation from Service or upon other conditions, the method of exercise, whether or not a SAR shall be in tandem or in combination with any other Award and any other terms of any SAR.

9.3. Term of SARs

The term of a SAR granted under the Plan shall be determined by the Board;provided,however, that such term shall not exceed 10 years.

9.4. Payment of SAR Amount

Upon exercise of a SAR, a Participant shall be entitled to receive payment from the Company (in cash or Shares, as set forth in the Award Agreement) in an amount determined by multiplying:

(i)

the difference between the Fair Market Value on the date of exercise over the SAR Exercise Price; by

(ii)

the number of Shares with respect to which the SAR is exercised.

79A-10

10.

TERMS AND CONDITIONS OF RESTRICTED STOCK AND RESTRICTED STOCK UNITS (RSUs)

10.1. Restrictions (applicable to Restricted Stock and RSUs)

At the time of grant, the Board may establish a period of time (a “Service Period”) and any additional restrictions including the satisfaction of corporate or individual performance objectives applicable to an Award of Restricted Stock or RSUs. Each Award of Restricted Stock or RSUs may be subject to a different Service Period and additional restrictions. Neither Restricted Stock nor RSUs may be sold, transferred, assigned, pledged or otherwise encumbered or disposed of during the Service Period or prior to the satisfaction of any other applicable restrictions.

10.2. Delivery of Shares (applicable to Restricted Stock and RSUs)

Subject toSection 3.5, upon the expiration or termination of any Service Period and the satisfaction of any other conditions prescribed by the Board, the restrictions applicable to Shares of Restricted Stock or RSUs settled in Shares shall lapse, and, unless otherwise provided in the applicable Award Agreement, a stock certificate for such Shares shall be delivered, free of all such restrictions, to the Participant or the Participant’s beneficiary or estate, as the case may be.

10.3. Rights of Holders of Restricted Stock (applicable to Restricted Stock, not RSUs)

Unless otherwise provided in the applicable Award Agreement, holders of Restricted Stock shall have rights as Stockholders, including voting and dividend rights;provided,however, any dividends with respect to the Restricted Stock shall be withheld by the Company for the Participant’s account, and interest may be credited on the amount of the dividends withheld at a rate and subject to such terms as determined by the Committee. The dividends so withheld by the Committee and attributable to any particular share of Restricted Stock (and earnings thereon, if applicable) shall be distributed to the Participant in cash or, at the discretion of the Committee, in Shares having a Fair Market Value equal to the amount of such dividends, if applicable, upon the release of restrictions on such Share and, if such Share is forfeited, the Participant shall have no right to such dividends.

10.4. Purchase of Restricted Stock (applicable to Restricted Stock, not RSUs)

The Participant shall be required, to the extent required by applicable law, to purchase the Restricted Stock from the Company at a Purchase Price equal to the greater of (i) the aggregate par value of the Shares represented by such Restricted Stock or (ii) the Purchase Price, if any, specified in the related Award Agreement. If specified in the Award Agreement, the Purchase Price may be deemed paid by services already rendered. The Purchase Price shall be payable in a form described inSection 11 or, if so determined by the Board, in consideration for past services rendered.

10.5. Restricted Stock Certificates (applicable to Restricted Stock, not RSUs)

Subject toSection 3.5, the Company shall issue, in the name of each Participant to whom Restricted Stock has been granted, stock certificates or other evidence of ownership representing the total number of Shares of Restricted Stock granted to the Participant, as soon as reasonably practicable after the Grant Date. The Board may provide in an Award Agreement that either (i) the Secretary of the Company shall hold any stock certificates for the Participant’s benefit until such time as the Restricted Stock is forfeited to the Company or the restrictions lapse or (ii) such certificates shall be delivered to the Participant;provided,however, that such certificates shall bear a legend or legends that comply with the applicable securities laws and regulations and make appropriate reference to the restrictions imposed under the Plan and the Award Agreement.

10.6. Rights of Holders of RSUs (applicable to RSUs, not Restricted Stock)

10.6.1. Settlement of RSUs

RSUs may be settled in cash or Shares, as set forth in the Award Agreement. The Award Agreement shall also set forth whether the RSUs shall be settled (i) within the time period specified in Section 409A for short term deferrals or (ii) otherwise within the requirements of Section 409A, in which case the Award Agreement shall specify upon which events such RSUs shall be settled.

80A-11

10.6.2. Voting and Dividend Rights

Unless otherwise provided in the applicable Award Agreement, holders of RSUs shall not have rights as Stockholders, including voting or dividend or dividend equivalents rights. Dividend equivalent rights may be granted with respect to RSUs pursuant toSection 17.10.

10.6.3. Creditor’s Rights

A holder of RSUs shall have no rights other than those of a general creditor of the Company. RSUs represent an unfunded and unsecured obligation of the Company, subject to the terms of the applicable Award Agreement.

11.

FORM OF PAYMENT FOR OPTIONS AND RESTRICTED STOCK

11.1. General Rule

Payment of the Option Price for the Shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock shall be made in cash or in cash equivalents acceptable to the Company, except as provided in thisSection 11.

11.2. Surrender of Shares

To the extent the Award Agreement so provides, payment of the Option Price for Shares purchased pursuant to the exercise of an Option or the Purchase Price for Restricted Stock may be made all or in part through the tender to the Company of Shares, which Shares shall be valued, for purposes of determining the extent to which the Option Price or Purchase Price for Restricted Stock has been paid thereby, at their Fair Market Value on the date of exercise or surrender. Notwithstanding the foregoing, in the case of an Incentive Stock Option, the right to make payment in the form of already-owned Shares may be authorized only at the time of grant.

11.3. Cashless Exercise

With respect to an Option only (and not with respect to Restricted Stock), to the extent permitted by law and to the extent the Award Agreement so provides, payment of the Option Price may be made all or in part by delivery (on a form acceptable to the Company) of an irrevocable direction to a licensed securities broker acceptable to the Company to sell Shares and to deliver all or part of the sales proceeds to the Company in payment of the Option Price and any withholding taxes described inSection 17.3.

11.4. Other Forms of Payment

To the extent the Award Agreement so provides, payment of the Option Price or the Purchase Price for Restricted Stock may be made in any other form that is consistent with applicable laws, regulations and rules, including the Company’s withholding of Shares otherwise due to the exercising Participant.

12.

TERMS AND CONDITIONS OF PERFORMANCE AWARDS

12.1. Performance Conditions

The right of a Participant to exercise or receive a grant or settlement of any Award, and the timing thereof, may be subject to such performance conditions as may be specified by the Board. The Board may use such business criteria and other measures of performance as it may deem appropriate in establishing any performance conditions, and may reduce the amounts payable under any Award subject to performance conditions, except as limited underSection 12.2in the case of Performance-Based Compensation.

81A-12

12.2. Performance Awards Granted to Designated Covered Employees

If and to the extent that the Board determines that a Performance Award to be granted to a Participant who is designated by the Board as likely to be a Covered Employee should qualify as Performance-Based Compensation, the grant, exercise or settlement of such Performance Award shall be contingent upon achievement of pre-established performance goals and other terms set forth in thisSection 12.2. Notwithstanding anything herein to the contrary, the Board may provide for Performance Awards to Covered Employees that are not intended to qualify as Performance-Based Compensation.

12.2.1. Performance Goals Generally

The performance goals for Performance Awards shall consist of one or more business criteria and a targeted level or levels of performance with respect to each of such criteria, as specified by the Board consistent with thisSection 12.2. Performance goals shall be objective and shall otherwise meet the requirements of Section 162(m), including the requirement that the level or levels of performance targeted by the Board result in the achievement of performance goals being “substantially uncertain.” The Board may determine that Performance Awards shall be granted, exercised or settled upon achievement of any one performance goal or that two or more of the performance goals must be achieved as a condition to grant, exercise or settlement of the Performance Awards. Performance goals may be established on a Company-wide basis, or with respect to one or more business units, divisions, Affiliates or business segments, as applicable. To the extent consistent with the requirements of Section 162(m), the Committee may determine at the time that goals under thisSection 12are established the extent to which measurement of performance goals may exclude the impact of charges for restructuring, discontinued operations, extraordinary items, debt redemption or retirement, asset write downs, litigation or claim judgments or settlements, acquisitions or divestitures, foreign exchange gains and losses and other extraordinary, unusual or non-recurring items, and the cumulative effects of tax or accounting changes (each as defined by generally accepted accounting principles and as identified in the Company’s financial statements or other SEC filings). Performance goals may differ for Performance Awards granted to any one Participant or to different Participants.

12.2.2. Business Criteria

One or more of the following business criteria for the Company, on a consolidated basis, or specified Affiliates or business units of the Company (except with respect to the total stockholder return and earnings per share criteria), shall be used exclusively by the Board in establishing performance goals for Performance Awards: (i) cash flow; (ii) earnings per share, as adjusted for any stock split, stock dividend or other recapitalization; (iii) earnings measures; (iv) return on equity; (v) total stockholder return; (vi) share price performance, as adjusted for any stock split, stock dividend or other recapitalization; (vii) return on capital; (viii) revenue; (ix) income; (x) profit margin; (xi) return on operating revenue; (xii) brand recognition or acceptance; (xiii) customer satisfaction; (xiv) productivity; (xv) expense targets; (xvi) market share; (xvii) cost control measures; (xviii) balance sheet metrics; (xix) strategic initiatives; (xx) implementation, completion or attainment of measurable objectives with respect to recruitment or retention of personnel or employee satisfaction; (xxi) regulatory body approval for commercialization of a product; (xxii) implementation or completion of critical projects; or (xxiii) any other business criteria established by the Board;provided,however, that such business criteria shall include any derivations of business criteria listed above (e.g., income shall include pre-tax income, net income and operating income).

12.2.3. Timing for Establishing Performance Goals

Performance goals shall be established not later than 90 days after the beginning of any performance period applicable to Performance Awards, or at such other date as may be required or permitted for Performance-Based Compensation.

82A-13

12.2.4. Settlement of Performance Awards; Other Terms

Settlement of Performance Awards may be in cash, Shares, other Awards or other property. The Board may reduce the amount of a settlement otherwise to be made in connection with such Performance Awards.

12.3. Written Determinations

All determinations by the Board as to the establishment of performance goals, the amount of any Performance Award pool or potential individual Performance Awards and the achievement of performance goals relating to Performance Awards, shall be made in writing in the case of any Award intended to qualify as Performance-Based Compensation to the extent required by Section 162(m). To the extent permitted by Section 162(m), the Board may delegate any responsibility relating to Performance Awards.

12.4. Status of Section 12.2 Awards under Section 162(m)

It is the intent of the Company that Performance Awards underSection 12.2 granted to persons who are designated by the Board as likely to be Covered Employees within the meaning of Section 162(m) shall, if so designated by the Board, qualify as Performance-Based Compensation. Accordingly, the terms ofSection 12.2, including the definitions of Covered Employee and other terms used therein, shall be interpreted in a manner consistent with Section 162(m). The foregoing notwithstanding, because the Board cannot determine with certainty whether a given Participant will be a Covered Employee with respect to a fiscal year that has not yet been completed, the term Covered Employee as used herein shall mean only a person designated by the Board, at the time of grant of Performance Awards, as likely to be a Covered Employee with respect to that fiscal year. If any provision of the Plan or any agreement relating to such Performance Awards does not comply or is inconsistent with the requirements of Section 162(m), such provision shall be construed or deemed amended to the extent necessary to conform to such requirements.

13.

other SHARE-based awards

13.1. Grant of Other Share-based Awards

Other Share-based Awards may be granted either alone or in addition to or in conjunction with other Awards. Other Share-based Awards may be granted in lieu of other cash or other compensation to which a Service Provider is entitled from the Company or may be used in the settlement of amounts payable in Shares under any other compensation plan or arrangement of the Company, including any other Company incentive compensation plan. The Board shall have the authority to determine the persons to whom and the time or times at which such Awards will be made, the number of Shares to be granted pursuant to such Awards, and all other terms of such Awards. Unless the Board determines otherwise, any such Award shall be confirmed by an Award Agreement, which shall contain such provisions as the Board determines to be necessary or appropriate to carry out the intent of the Plan with respect to such Award.

13.2. Terms of Other Share-based Awards

Any Common Stock subject to Awards made under thisSection 13 may not be sold, assigned, transferred, pledged or otherwise encumbered prior to the date on which the Shares are issued, or, if later, the date on which any applicable restriction, performance or deferral period lapses.

14.

REQUIREMENTS OF LAW

14.1. General

The Company shall not be required to sell or issue any Shares under any Award if the sale or issuance of such Shares would constitute a violation by the Participant, any other individual exercising an Option or the Company of any provision of any law or regulation of any governmental authority, including any federal or state securities laws or regulations. If at any time the Board determines that the listing, registration or qualification of any Shares subject to an Award upon any securities

exchange or under any governmental regulatory body is necessary or desirable as a condition of, or in connection with, the issuance or purchase of Shares hereunder, no Shares may be issued or sold to the Participant or any other individual exercising an Option pursuant to such Award unless such listing, registration, qualification, consent or approval shall have been effected or obtained free of any conditions not acceptable to the Company, and any delay caused thereby shall in no way affect the date of termination of the Award. Specifically, in connection with the Securities Act, upon the exercise of any Option or the delivery of any Shares underlying an Award, unless a registration statement under such Act is in effect with respect to the Shares covered by such Award, the Company shall not be required to sell or issue such Shares unless the Board has received evidence satisfactory to it that the Participant or any other individual exercising an Option may acquire such Shares pursuant to an exemption from registration under the Securities Act. The Company may, but shall in no event be obligated to, register any securities covered hereby pursuant to the Securities Act. The Company shall not be obligated to take any affirmative action in order to cause the exercise of an Option or the issuance of Shares pursuant to the Plan to comply with any law or regulation of any governmental authority. As to any jurisdiction that expressly imposes the requirement that an Option shall not be exercisable until the Shares covered by such Option are registered or are exempt from registration, the exercise of such Option (under circumstances in which the laws of such jurisdiction apply) shall be deemed conditioned upon the effectiveness of such registration or the availability of such an exemption. The Committee may require the Participant to sign such additional documentation, make such representations and furnish such information as it may consider appropriate in connection with the grant of Awards or issuance or delivery of Shares in compliance with applicable laws, rules and regulations.

A-14

14.2. Rule 16b-3

During any time when the Company has a class of equity security registered under Section 12 of the Exchange Act, it is the intent of the Company that Awards and the exercise of Options will qualify for the exemption provided by Rule 16b-3 under the Exchange Act. To the extent that any provision of the Plan or action by the Board or Committee does not comply with the requirements of Rule 16b-3, it shall be deemed inoperative to the extent permitted by law and deemed advisable by the Board, and shall not affect the validity of the Plan. In the event that Rule 16b-3 is revised or replaced, the Board may modify the Plan in any respect necessary to satisfy the requirements of, or to take advantage of any features of, the revised exemption or its replacement.

15.

EFFECT OF CHANGES IN CAPITALIZATION

15.1. Adjustments for Changes in Capital Structure

Subject to any required action by the Stockholders, in the event of any change in the Common Stock effected without receipt of consideration by the Company, whether through merger, consolidation, reorganization, reincorporation, recapitalization, reclassification, stock dividend, stock split, reverse stock split, split-up, split-off, spin-off, combination of shares, exchange of shares or similar change in the capital structure of the Company, or in the event of payment of a dividend or distribution to the Stockholders in a form other than Shares (excepting normal cash dividends) that has a material effect on the Fair Market Value, appropriate and proportionate adjustments shall be made in the number and class of shares subject to the Plan and to any outstanding Awards, and in the Option Price, SAR Exercise Price or Purchase Price per Share of any outstanding Awards in order to prevent dilution or enlargement of Participants’ rights under the Plan. For purposes of the foregoing, conversion of any convertible securities of the Company shall not be treated as “effected without receipt of consideration by the Company.” If a majority of the Shares which are of the same class as the Shares that are subject to outstanding Awards are exchanged for, converted into, or otherwise become (whether or not pursuant to a Change in Control) shares of another corporation (the “New Shares”), the Board may unilaterally amend the outstanding Awards to provide that such Awards are for New Shares. In the event of any such amendment, the number of Shares subject to, and the Option Price, SAR Exercise Price or Purchase Price per Share of, the outstanding Awards shall be adjusted in a fair and equitable manner. Any fractional share resulting from an adjustment pursuant to thisSection 15.1shall be rounded down to the nearest whole number and the Option Price, SAR Exercise Price or Purchase Price per share shall be rounded up to the nearest whole cent. In no event may the exercise price of any Award be decreased to an amount less than the par value, if any, of the stock subject to the Award. The Board may also make such adjustments in the terms of any Award to reflect, or related to, such changes in the capital structure of the Company or distributions as it deems appropriate. Adjustments determined by the Board pursuant to thisSection 15.1 shall be made in accordance with Section 409A to the extent applicable.

84A-15

15.2. Change in Control

15.2.1. Consequences of a Change in Control

Subject to the requirements and limitations of Section 409A if applicable, the Board may provide for any one or more of the following in connection with a Change in Control, which such actions need not be the same for all Participants:

(a) Accelerated Vesting. The Board may provide in any Award Agreement, or in the event of a Change in Control may take such actions as it deems appropriate to provide, for the acceleration of the exercisability, vesting or settlement in connection with such Change in Control of each or any outstanding Award or portion thereof and Shares acquired pursuant thereto upon such terms, including a Participant’s Separation from Service prior to, upon, or following such Change in Control, to such extent as determined by the Board.

(b) Assumption, Continuation or Substitution. In the event of a Change in Control, the surviving, continuing, successor or purchasing corporation or other business entity or parent thereof, as the case may be (the “Acquiror”), may, without the consent of any Participant, either assume or continue the Company’s rights and obligations under each or any Award or portion thereof outstanding immediately prior to the Change in Control or substitute for each or any such outstanding Award or portion thereof a substantially equivalent award with respect to the Acquiror’s stock, as applicable. For purposes of thisSection 15.2.1, an Award denominated in Shares shall be deemed assumed if, following the Change in Control, the Award confers the right to receive, subject to the terms of the Plan and the applicable Award Agreement, for each Share subject to the Award immediately prior to the Change in Control, the consideration (whether stock, cash, other securities or property or a combination thereof) to which a Stockholder on the effective date of the Change in Control was entitled;provided, however, that if such consideration is not solely common stock of the Acquiror, the Board may, with the consent of the Acquiror, provide for the consideration to be received upon the exercise or settlement of the Award, for each Share subject to the Award, to consist solely of common stock of the Acquiror equal in Fair Market Value to the per Share consideration received by Stockholders pursuant to the Change in Control. If any portion of such consideration may be received by Stockholders pursuant to the Change in Control on a contingent or delayed basis, the Board may determine such Fair Market Value as of the time of the Change in Control on the basis of the Board’s estimate of the present value of the probable future payment of such consideration. Any Award or portion thereof which is neither assumed or continued by the Acquiror in connection with the Change in Control nor exercised or settled as of the time of consummation of the Change in Control shall terminate and cease to be outstanding effective as of the time of consummation of the Change in Control.

(c) Cash-Out of Awards. The Board may, without the consent of any Participant, determine that, upon the occurrence of a Change in Control, each or any Award or a portion thereof outstanding immediately prior to the Change in Control and not previously exercised or settled shall be canceled in exchange for a payment with respect to each vested Share (and each unvested Share, if so determined by the Board) subject to such canceled Award in (i) cash, (ii) stock of the Company or of a corporation or other business entity a party to the Change in Control or (iii) other property which, in any such case, shall be in an amount having a Fair Market Value equal to the Fair Market Value of the consideration to be paid per Share in the Change in Control, reduced by the exercise or purchase price per Share, if any, under such Award. If any portion of such consideration may be received by Stockholders pursuant to the Change in Control on a contingent or delayed basis, the Board may determine such Fair Market Value as of the time of the Change in Control on the basis of the Board’s estimate of the present value of the probable future payment of such consideration. In the event such determination is made by the Board, the amount of such payment (reduced by applicable withholding taxes, if any) shall be paid to Participants in respect of the vested portions of their canceled Awards as soon as practicable following the date of the Change in Control and in respect of the unvested portions of their canceled Awards in accordance with the vesting schedules applicable to such Awards. For avoidance of doubt, if the amount determined pursuant to thisSection 15.2.1(c)for an Option or SAR is zero or less, the affected Option or SAR may be cancelled without any payment therefore.

85A-16

15.2.2. Change in Control Defined

Unless otherwise provided in the applicable Award Agreement, a “Change in Control” means the consummation of any of the following events:

(a) the acquisition, other than from the Company, by any individual, entity or group (within the meaning of Section 13(d)(3) or Section 14(d)(2) of the Exchange Act), other than the Company or any subsidiary, affiliate (within the meaning of Rule 144 promulgated under the Securities Act) or employee benefit plan of the Company, of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of more than 50% of the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Voting Securities”); or

(b) a reorganization, merger, consolidation or recapitalization of the Company (a “Business Combination”), other than a Business Combination in which more than 50% of the combined voting power of the outstanding voting securities of the surviving or resulting entity immediately following the Business Combination is held by the persons who, immediately prior to the Business Combination, were the holders of the Voting Securities; or

(c) a complete liquidation or dissolution of the Company, or a sale of all or substantially all of the assets of the Company; or

(d) during any period of 12 consecutive months, the Incumbent Directors cease to constitute a majority of the Board; “Incumbent Directors” means individuals who were members of the Board at the beginning of such period or individuals whose election or nomination for election to the Board by the Stockholders was approved by a vote of at least a majority of the then Incumbent Directors (but excluding any individual whose initial election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors).

Notwithstanding the foregoing, if it is determined that an Award is subject to the requirements of Section 409A and payable upon a Change in Control, the Company will not be deemed to have undergone a Change in Control for purposes of the Plan unless the Company is deemed to have undergone a “change in control event” pursuant to the definition of such term in Section 409A.

15.3. Adjustments

Adjustments under thisSection 15 related to Shares or other securities of the Company shall be made by the Board. No fractional Shares or other securities shall be issued pursuant to any such adjustment, and any fractions resulting from any such adjustment shall be eliminated in each case by rounding downward to the nearest whole Share.

16.

No Limitations on Company

The making of Awards shall not affect or limit in any way the right or power of the Company to make adjustments, reclassifications, reorganizations or changes of its capital or business structure or to merge, consolidate, dissolve or liquidate, or to sell or transfer all or any part of its business or assets.

17.

TERMS APPLICABLE GENERALLY TO AWARDS

17.1. Disclaimer of Rights

No provision in the Plan or in any Award Agreement shall be construed to confer upon any individual the right to remain in the employ or service of the Company or any Affiliate, or to interfere in any way with any contractual or other right or authority of the Company or any Affiliate either to increase or decrease the compensation or other payments to any individual at any time, or to terminate any employment or other relationship between any individual and the Company or any Affiliate. In addition, notwithstanding anything contained in the Plan to the contrary, unless otherwise provided in the applicable Award Agreement, no Award shall be affected by any change of duties or position of the Participant, so long as such Participant continues to be a Service Provider. The obligation of the Company to pay any benefits pursuant to the Plan shall be interpreted as a contractual obligation to pay only those amounts described herein, in the manner and under the conditions prescribed herein. The Plan shall in no way be interpreted to require the Company to transfer any amounts to a third party trustee or otherwise hold any amounts in trust or escrow for payment to any Participant or beneficiary under the terms of the Plan.

86A-17

17.2. Nonexclusivity of the Plan

Neither the adoption of the Plan nor the submission of the Plan to the Stockholders for approval shall be construed as creating any limitations upon the right or authority of the Board or its delegate to adopt such other compensation arrangements as the Board or its delegate determines desirable.

17.3. Withholding Taxes

The Company or an Affiliate, as the case may be, shall have the right to deduct from payments of any kind otherwise due to a Participant any federal, state or local taxes of any kind required by law to be withheld (i) with respect to the vesting of or other lapse of restrictions applicable to an Award, (ii) upon the issuance of any Shares upon the exercise of an Option or SAR or (iii) otherwise due in connection with an Award. At the time of such vesting, lapse or exercise, the Participant shall pay to the Company or the Affiliate, as the case may be, any amount that the Company or the Affiliate may reasonably determine to be necessary to satisfy such withholding obligation. In addition, the Board may provide one or more Participants with the right to direct the Company to withhold, from the Shares otherwise issuable upon the exercise of an Option or Stock Appreciation Right or upon the issuance of fully-vested Shares (whether pursuant to Restricted Stock, RSUs, Other Share-based Awards, or otherwise), a portion of those Shares with an aggregate Fair Market Value equal to the percentage of the applicable withholding taxes (not to exceed one hundred percent (100%)) designated by the Participant; provided, however, that the amount of any Shares so withheld shall not exceed the amount necessary to satisfy the Company’s required tax withholding obligations using not more than the applicable maximum statutory withholding rates (or such other rates as required to avoid adverse accounting treatment as determined by the Board). The Fair Market Value of the Shares used to satisfy such withholding obligation shall be determined by the Company or the Affiliate as of the date that the amount of tax to be withheld is to be determined. A Participant who has made an election pursuant to thisSection 17.3 may satisfy his or her withholding obligation only with Shares that are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements.

17.4. Other Provisions; Legends

Each Award Agreement may contain such other terms not inconsistent with the Plan as may be determined by the Board. Any stock certificates for any Shares issued under the Plan shall be subject to such stop-transfer orders and other restrictions as the Company in its sole discretion may deem advisable under the rules, regulations and other requirements of the SEC, any securities exchange on which the Common Stock may then be listed and any applicable federal or state securities law, and the Company in its sole discretion may cause a legend or legends to be placed on such certificates to make appropriate reference to such restrictions.

17.5. Severability

If any provision of the Plan or any Award Agreement shall be determined to be illegal or unenforceable by any court of law in any jurisdiction, the remaining provisions hereof and thereof shall be severable and enforceable in accordance with their terms, and all provisions shall remain enforceable in any other jurisdiction.

17.6. Governing Law

The Plan shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts without regard to the principles of conflicts of law thereof or principles of conflicts of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction other than the Commonwealth of Massachusetts. For purposes of resolving any dispute that arises directly or indirectly in connection with the Plan, each Participant, by virtue of receiving an Award, shall be deemed to have submitted to and consented to the exclusive jurisdiction of the Commonwealth of Massachusetts and to have agreed that any related litigation shall be conducted solely in the courts of Middlesex County, Massachusetts or the United States District Court for the District of Massachusetts, where the Plan is made and to be performed, and no other courts.

87A-18

17.7. Section 409A

The Plan is intended to comply with Section 409A, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the “short-term deferral period” as defined in Section 409A shall not be treated as deferred compensation unless applicable laws require otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six-month period immediately following the Participant’s Separation from Service shall instead be paid on the first payroll date after the six-month anniversary of the Participant’s Separation from Service (or the Participant’s death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any excise tax or penalty on any Participant under Section 409A and neither the Company nor the Board shall have any liability to any Participant for such tax or penalty.

17.8. Separation from Service

The Board shall determine the effect of a Separation from Service upon Awards, and such effect shall be set forth in the applicable Award Agreement. Without limiting the foregoing, the Board may provide in the Award Agreements at the time of grant, or any time thereafter with the consent of the Participant, the actions that will be taken upon the occurrence of a Separation from Service, including accelerated vesting or termination, depending upon the circumstances surrounding the Separation from Service.

17.9. Transferability of Awards

17.9.1. Transfers in General

Except as provided inSection 17.9.2, no Award shall be assignable or transferable by the Participant to whom it is granted, other than by will or the laws of descent and distribution, and, during the lifetime of the Participant, only the Participant personally (or the Participant’s personal representative) may exercise rights under the Plan.

17.9.2. Family Transfers

If authorized in the applicable Award Agreement, a Participant may transfer, not for value, all or part of an Award (other than Incentive Stock Options) to any Family Member. For the purpose of thisSection 17.9.2, a “not for value” transfer is a transfer which is (i) a gift, (ii) a transfer under a domestic relations order in settlement of marital property rights or (iii) a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant) in exchange for an interest in that entity. Following a transfer under thisSection 17.9.2, any such Award shall continue to be subject to the same terms as were applicable immediately prior to transfer. Subsequent transfers of transferred Awards are prohibited except to Family Members of the original Participant in accordance with thisSection 17.9.2 or by will or the laws of descent and distribution.

17.10. Dividends and Dividend Equivalent Rights

If specified in the Award Agreement, the recipient of an Award may be entitled to receive, currently or on a deferred basis, dividends or dividend equivalents with respect to the Common Stock or other securities covered by an Award;provided,however, that no dividends or dividend equivalents may be paid or granted with respect to an Option or SAR or the Shares subject thereto until such Award has been exercised. The terms of a dividend equivalent right may be set forth in the Award Agreement. Dividend equivalents credited to a Participant may be paid currently or may be deemed to be reinvested in additional Shares or other securities of the Company at a price per unit equal to the Fair Market Value on the date that such dividend was paid to Stockholders. Notwithstanding the foregoing, in no event will dividends or dividend equivalents on any Award that is subject to vesting conditions (including the achievement of performance criteria) be payable before the Award has become vested.

88A-19

17.11. Data Protection

A Participant’s acceptance of an Award shall be deemed to constitute the Participant’s acknowledgement of and consent to the collection and processing of personal data relating to the Participant so that the Company and the Affiliates can fulfill their obligations and exercise their rights under the Plan and generally administer and manage the Plan. This data shall include data about participation in the Plan and Shares offered or received, purchased or sold under the Plan and other appropriate financial and other data (such as the date on which the Awards were granted) about the Participant and the Participant’s participation in the Plan.

17.12. Plan Construction

In the Plan, unless otherwise stated, the following uses apply: (i) references to a statute or law refer to the statute or law and any amendments and any successor statutes or laws, and to all valid and binding governmental regulations, court decisions and other regulatory and judicial authority issued or rendered thereunder, as amended, or their successors, as in effect at the relevant time; (ii) in computing periods from a specified date to a later specified date, the words “from” and “commencing on” (and the like) mean “from and including,” and the words “to,” “until” and “ending on” (and the like) mean “to and including”; (iii) indications of time of day shall be based upon the time applicable to the location of the principal headquarters of the Company; (iv) the words “include,” “includes” and “including” (and the like) mean “include, without limitation,” “includes, without limitation” and “including, without limitation” (and the like), respectively; (v) all references to articles and sections are to articles and sections in the Plan; (vi) all words used shall be construed to be of such gender or number as the circumstances and context require; (vii) the captions and headings of articles and sections have been inserted solely for convenience of reference and shall not be considered a part of the Plan, nor shall any of them affect the meaning or interpretation of the Plan or any of its provisions; (viii) any reference to an agreement, plan, policy, form, document or set of documents, and the rights and obligations of the parties under any such agreement, plan, policy, form, document or set of documents, shall mean such agreement, plan, policy, form, document or set of documents as amended from time to time, and any and all modifications, extensions, renewals, substitutions or replacements thereof; and (ix) all accounting terms not specifically defined shall be construed in accordance with GAAP.

	Adopted by the Board:		March 31, 2017
	Approved by the Stockholders:		June 13, 2017
	Amended by the Stockholders:		June 18, 2019
	Amended by the Stockholders:		June ~~18, 2019~~16, 2020
	Scheduled Termination Date:		June 13, 2027

89A-20

Appendix B

ANIKA THERAPEUTICS, INC.

2021 EMPLOYEE STOCK PURCHASE PLAN

Article 1 - Purpose.

This 2021 Employee Stock Purchase Plan (the “Plan”) is intended to encourage stock ownership by all eligible employees of Anika Therapeutics, Inc., a Delaware corporation (including any successor corporation, the “Company”), and its participating subsidiaries (as defined in Article 17) so that they may share in the growth of the Company by acquiring or increasing their proprietary interest in the Company. The Plan is designed to encourage eligible employees to remain in the employ of the Company and its participating subsidiaries. Except as described below in Article 2, the Plan is intended to constitute an “employee stock purchase plan” within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the “Code”).

Article 2 - Administration of the Plan.

The Plan will be administered by the Compensation Committee of the Company’s Board of Directors (the “Board”), or such other committee as determined by the Board (the “Committee”).

Notwithstanding anything to the contrary in the Plan, the Committee may establish sub-plans (which need not qualify under section 423 of the Code) and initiate separate Offering Periods (as defined in Article 5) through such sub-plans for the purpose of (i) facilitating participation in the Plan by non-U.S. employees in compliance with foreign laws and regulations without affecting the qualification of the remainder of the Plan under section 423 of the Code or (ii) qualifying the Plan for preferred tax treatment under foreign tax laws (which sub-plans, at the Committee’s discretion, may provide for allocations of the authorized shares reserved for issue under the Plan as set forth in Article 4). The rules, guidelines and forms of such sub-plans (or the Offering Periods thereunder) may take precedence over other provisions of the Plan, with the exception of the maximum Offering Period term set forth in Article 5, the maximum payroll deduction set forth in Article 8, the limitation on the decrease to the Option Price defined and described in Article 5 and the aggregate stock limit described in Article 4, but unless otherwise superseded by the terms of such sub-plan, the provisions of the Plan shall govern the operation of such sub-plan. Alternatively, notwithstanding anything to the contrary in the Plan, in order to comply with the laws of a foreign jurisdiction, the Committee shall have the power, in its discretion, to grant options in an Offering Period to citizens or residents of a non-U.S. jurisdiction (without regard to whether they are also citizens of the United States or resident aliens) that provide terms which are less favorable than the terms of options granted under the same Offering Period to employees resident in the United States, subject to compliance with section 423 of the Code.

The interpretation and construction by the Committee of any provisions of the Plan or of any option granted under it will be final, unless otherwise determined by the Board. The Committee may from time to time adopt such rules and regulations for carrying out the Plan as it may deem best, provided that any such rules and regulations will be applied on a uniform basis to all employees under the Plan. No member of the Board or the Committee will be liable for any action or determination made in good faith with respect to the Plan or any option granted under it.

B-1

Article 3 - Eligible Employees.

Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, all employees of the Company or any of its participating subsidiaries who are (i) so employed on the start date of any Offering Period and (2) have continuously been employed with the Company or such participating subsidiary for at least one month prior to such start date will be eligible to participate and receive an option with respect to such Offering Period. All such eligible employees will have the same rights and privileges hereunder with respect to such Offering Period. In no event, however, may an employee be granted an option if such employee, immediately after the option is granted, would be treated as owning stock possessing five percent or more of the total combined voting power or value of all classes of stock of the Company or of any parent corporation or subsidiary corporation, as the terms “parent corporation” and “subsidiary corporation” are defined in Section 424(e) and Section 424(f) of the Code. For purposes of determining stock ownership under this paragraph, the rules of Section 424(d) of the Code will apply, and stock which the employee may purchase under outstanding options (including options not granted under the Plan) will be treated as stock owned by the employee. Notwithstanding the foregoing, except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, employees who are otherwise eligible employees and who are citizens or residents of a non-U.S. jurisdiction (without regard to whether such employee is also a citizen of the United States or a resident alien (within the meaning of Section 7701(b)(1)(A) of the Code)) will not be considered an eligible employee if his or her participation is prohibited under the laws of the applicable non-U.S. jurisdiction or if complying with the laws of the applicable non-U.S. jurisdiction would cause the Plan or an Offering Period to violate Section 423 of the Code.

Article 4 - Stock Subject to the Plan.

The stock subject to the options under the Plan will be shares of the Company’s authorized but unissued common stock (the “Common Stock”), or shares of Common Stock reacquired by the Company, including shares purchased in the open market. The aggregate number of shares of Common Stock which may be issued pursuant to the Plan is 200,000, subject to adjustment as provided in Article 12. If any option granted under the Plan expires or terminates for any reason without having been exercised in full or ceases for any reason to be exercisable in whole or in part, the unpurchased shares subject thereto will again be available under the Plan.

Article 5 - Offering Period and Stock Options.

Except as otherwise determined by the Committee, the first Offering Period will start on November 15, 2021 and will end on May 14, 2022, provided that if such end date is not a business day (as defined below in this Article 5), such Offering Period will end on the first business day preceding such end date.

Thereafter, except as otherwise determined by the Committee:

1. An offering period (“Offering Period”) will start on each May 15 (provided that if such start date is not a business day, such start date will be the first business day following the immediately preceding Exercise Date (as defined below in this Article 5)) and end on the following November 14 (provided that if such end date is not a business day, such end date will be the first business day preceding such end date); and

2. An Offering Period will start on each November 15 (provided that if such start date is not a business day, such start date will be the first business day following the immediately preceding Exercise Date) and end on the following May 14 (provided that if such end date is not a business day, such end date will be the first business day preceding such end date).

The end date within each Offering Period will be the day on which shares of Common Stock are purchased by participants in an Offering Period (“Exercise Date”). On the start date of each Offering Period, the Company will grant to each eligible employee who has then elected to be a participant in the Plan an option to purchase shares on the relevant Exercise Date, at the Option Price hereinafter provided for, covering a maximum of 800 shares of Common Stock (which maximum number may be amended by the Committee from time to time with respect to an Offering Period prior to the start date thereof), on condition that such employee remains an eligible employee through the Exercise Date. If a participant’s accumulated payroll deductions on the end date of an Offering Period would enable the participant to purchase more than such maximum number of shares of Common Stock, the excess of the amount of the accumulated payroll deductions over the aggregate purchase price of such maximum number of shares will be promptly refunded to the participant by the Company, without interest. A participant will be entitled to exercise the option so granted only to the extent of the participant’s accumulated payroll deductions on the Exercise Date. The Option Price per share for each Exercise Date within an Offering Period will be the lesser of (i) 85% of the Fair Market Value of the Common Stock on the start date of the Offering Period and (ii) 85% of the Fair Market Value of the Common Stock on the Exercise Date, in either event rounded up to the nearest cent. Prior to the start date of an Offering Period, the Committee may increase, but not decrease, the Option Price with respect to such Offering Period. The foregoing limitation on the number of shares subject to an option hereunder and the Option Price will be subject to adjustment as provided in Article 12.

B-2

Notwithstanding the foregoing, the Committee may in its discretion determine to implement Offering Periods of up to twenty-seven months. Such Offering Periods may consist of one or more Exercise Dates. Each eligible employee who elects to be a participant in such Offering Period will be granted an option, at the Option Price, to purchase shares of Common Stock on such Exercise Date(s). Each such option will cover a maximum number of shares of Common Stock for such Offering Period as determined by the Committee prior the start date of such Offering Period. In no event will an Offering Period under the Plan exceed twenty-seven months.

Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, unless a participant files a new authorization (as described in Article 7) or withdraws from the Plan (as described in Article 10), the deductions and purchases under the authorization a participant has on file under the Plan will continue from one Offering Period to succeeding Offering Periods as long as the Plan remains in effect and the participant continues to be an eligible employee at the start date of the relevant Offering Period.

For purposes of the Plan, the term “Fair Market Value” on any date means the value of the Common Stock as determined below. If the Common Stock is listed on any established stock exchange or a national market system, including without limitation, the New York Stock Exchange or the NASDAQ Stock Market, the Fair Market Value will be the closing price of a share of Common Stock (or if no sales were reported on such date, the closing price on the last trading date) as quoted on such exchange or system. In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Committee and such determination will be conclusive and binding on all persons. For purposes of the Plan, the term “business day” means a day on which there is trading on such exchange or system and that is not a Saturday, Sunday or legal holiday in the State of Massachusetts.

No employee will be granted an option which permits the employee’s right to purchase stock under the Plan, and under all other Code Section 423(b) employee stock purchase plans of the Company and any parent corporations or subsidiary corporations, as “parent corporation” and “subsidiary corporation” are defined in Section 424(e) and Section 424(f) of the Code, to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined on the date or dates that options on such stock were granted) for each calendar year in which such option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply, and such limitation will be administered in accordance, with Section 423(b)(8) of the Code. If a participant’s accumulated payroll deductions on any Exercise Date would otherwise enable a participant to purchase Common Stock in excess of the Section 423(b)(8) limitation described in this paragraph, the excess of the amount of the accumulated payroll deductions over the aggregate purchase price of the shares actually purchased will be promptly refunded to the participant by the Company, without interest.

Article 6 - Exercise of Option.

Each eligible employee who continues to be a participant in the Plan on an Exercise Date will be deemed to have exercised his or her option on such date and will be deemed to have purchased from the Company such number of full shares of Common Stock reserved for the purpose of the Plan as the participant’s accumulated payroll deductions on such date will pay for at the Option Price, subject to the 800 maximum share limit of the option and the Section 423(b)(8) limitation described in Article 5. If the individual is not a participant on an Exercise Date, then he or she will not be entitled to exercise his or her option. Only full shares of Common Stock may be purchased under the Plan. Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, unused payroll deductions remaining in a participant’s account at the end of an Offering Period, by reason of the inability to purchase a fractional share, will be carried forward to the next Offering Period.

B-3

Article 7 - Authorization for Entering the Plan.

~~Signature [PLEASE SIGN WITHIN BOX]~~

An employee may elect to enter the Plan by filling out, signing and delivering to the Company an authorization form provided by the Company (including electronically), which will include the percentage to be deducted regularly from the employee’s pay, and any other terms or conditions as determined by the Committee in its sole discretion, and authorizing the purchase of stock for the employee in each Offering Period in accordance with the terms of the Plan.

Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, such authorization must be received by the Company (or made electronically) at least ten (10) business days before the start date of the Offering Period to which it relates and will take effect only if the employee is an eligible employee on the first business day of such Offering Period and otherwise meets the terms and conditions of the Plan.

Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, unless a participant files a new authorization or withdraws from the Plan, the deductions and purchases under the authorization the participant has on file under the Plan will continue from one Offering Period to succeeding Offering Periods as long as the Plan remains in effect.

The Company will accumulate and hold for each participant’s account the amounts deducted from his or her pay. No interest will be paid on these amounts. All payroll deductions received or held by the Company under the Plan may be used by the Company for any corporate purpose, and the Company will not be obligated to segregate such payroll deductions or hold them exclusively for the benefit of participants. All payroll deductions received or held by the Company may be subject to the claims of the Company’s general creditors. Participants will have the status of general unsecured creditors of the Company. Any amounts payable to participants pursuant to the Plan will be unfunded and unsecured obligations for all purposes, including, without limitation, Title I of the Employee Retirement Income Security Act of 1974, as amended.

Article 8 - Maximum Amount of Payroll Deductions.

Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, an employee may authorize payroll deductions in an amount (expressed as a whole percentage) not less than one percent (1%) but not more than ten percent (10%) of the employee’s Compensation. For this purpose, “Compensation” means, unless otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, an employee’s base pay or salary from the Company or participating subsidiary, including such amounts of base pay or salary as are deferred by the employee: (i) under a qualified cash or deferred arrangement described in Section 401(k) of the Code; or (ii) to a plan qualified under Section 125 of the Code. Unless otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, “Compensation” does not include overtime, bonuses, annual awards, other incentive payments, reimbursements or other expense allowances, fringe benefits (cash or non-cash), moving expenses, deferred compensation, contributions (other than contributions described in the preceding sentence) made on the employee’s behalf by the Company or a participating subsidiary under any employee benefit or welfare plan now or hereafter established, benefit plan payments, short-term disability pay, long-term disability pay, maternity pay, military pay, tuition reimbursement and adoption assistance, and any other payments not specifically referenced in the prior sentence.

B-4

Article 9 - Change in Payroll Deductions.

Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, deductions may not be increased or decreased during an Offering Period.

Article 10 - Withdrawal from the Plan.

Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, a participant may withdraw from the Plan and such Offering Period (in whole but not in part) by giving notice (in the form provided by the Company from time to time, including electronically) at least three business days prior to the end date of such Offering Period, in which case the Company will promptly refund, without interest, the entire balance of his or her unused payroll deduction account under the Plan.

Except as otherwise determined by the Committee with respect to an Offering Period prior to the start date thereof, to re-enter the Plan, an employee who has previously withdrawn must file a new authorization at least ten business days before the first day of the next Offering Period in which he or she wishes to participate. The employee’s re-entry into the Plan becomes effective at the beginning of such Offering Period, provided that he or she is an eligible employee on the first business day of the Offering Period and otherwise meets the terms and conditions of the Plan.

For the avoidance of doubt, any application of the maximum share limitation set forth in Article 5 hereof, Code Section 423(b)(8) and fractional-share limitations on the amount of stock a participant would be entitled to purchase will not constitute a withdrawal from the Plan.

Article 11 - Issuance of Stock.

Stock purchased by participants under the Plan will be evidenced in such a manner as the Company, in its discretion, deems appropriate, including, without limitation, book-entry or direct registration or the issuance of one or more stock certificates. Stock purchased under the Plan will be issued only in the name of the relevant participant.

Article 12 - Adjustments.

Subject to any required action by the stockholders of the Company, the Committee, in order to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will, in such manner as it may deem equitable, adjust the number of shares of Common Stock available for issuance under the Plan, the Option Price, the maximum number of shares that may be purchased during an Offering Period, as well as any other terms that the Committee determines require adjustment, for: (i) any increase or decrease in the number of issued shares of Common Stock resulting from a stock split, reverse stock split, stock dividend, combination or reclassification of the Common Stock; (ii) any other increase or decrease in the number of issued shares of Common Stock effected without receipt of consideration by the Company; or (iii) as the Committee may determine in its discretion, any other transaction with respect to Common Stock, including a corporate merger, consolidation, acquisition of property or stock, separation (including a spin-off or other distribution of stock or property), reorganization, liquidation (whether partial or complete) or any similar transaction; provided, however, that conversion of any convertible securities of the Company will not be deemed to have been “effected without receipt of consideration.” Such adjustment, if any, will be made by the Committee and its determination will be final, binding and conclusive. Except as the Committee determines otherwise, no issuance by the Company of shares of stock of any class, or securities convertible into shares of stock of any class, will require adjustment hereunder. Notwithstanding the foregoing, any adjustments made pursuant to this paragraph will be made only after the Committee, based on advice of counsel for the Company, determines whether such adjustments would constitute a “modification” (as that term is defined in Section 424 of the Code). If the Committee determines that such adjustments would constitute a modification, it may refrain from making such adjustments.

B-5

Except as otherwise determined by the Committee, in the event of a Change in Control (as defined in the Company’s 2017 Omnibus Incentive Plan, as amended from time to time), all outstanding options under the Plan will automatically be exercised immediately before the closing of such Change in Control as if the date of such closing is the next Exercise Date, ~~Signature (Joint Owners)~~subject to the maximum share limitation set forth in Article 5 hereof, Code Section 423(b)(8) and fractional-share limitations on the amount of stock a participant would be entitled to purchase, and the Plan will terminate immediately thereafter.

Article 13 - No Transfer or Assignment of Employee’s Rights.

An option granted under the Plan may not be transferred or assigned, except by will or the laws of descent and distribution, and will be exercised, during a participant’s lifetime, only by the participant.

Article 14 - Termination of Employee’s Rights.

Whenever a participant ceases to be an eligible employee because of retirement, voluntary or involuntary termination, resignation, layoff, discharge, death or for any other reason, his or her rights under the Plan will immediately terminate, and the Company will promptly refund, without interest, the entire balance of his or her payroll deduction account under the Plan. Notwithstanding the foregoing, eligible employment will be treated as continuing intact while the participant is on military leave, sick leave, or other bona fide leave of absence (such as temporary employment by the government) if the period of such leave does not exceed 3 months, or if longer, so long as the participant’s right to reemployment with the Company or the participating subsidiary is provided either by statute or by contract. If the period of leave exceeds 3 months and the participant’s right to reemployment with the Company or the participating subsidiary is not provided either by statute or by contract, the employment relationship will be deemed to terminate on the first day immediately following such three-month period.

Article 15 - Termination and Amendments to Plan.

Unless terminated sooner as provided below, the Plan will terminate on the tenth anniversary of its approval by the Company’s stockholders. The Plan may be terminated at any time by the Board but such termination will not affect options then outstanding under the Plan. The Plan will terminate in any case when all or substantially all of the unissued shares of stock reserved for the purposes of the Plan have been purchased. If at any time shares of stock reserved for the purpose of the Plan remain available for purchase but not in sufficient number to satisfy all then unfilled purchase requirements, the available shares will be apportioned among participants in proportion to the amount of payroll deductions accumulated on behalf of each participant that would otherwise be used to purchase stock, and the Plan will terminate. Upon such termination or any other termination of the Plan, all payroll deductions not used to purchase stock will be refunded, without interest.

The Committee or the Board may from time to time adopt amendments to the Plan provided that, without the approval of the stockholders of the Company, no amendment may (i) increase the number of shares that may be issued under the Plan; (ii) change the class of employees eligible to receive options under the Plan, if such action would be treated as the adoption of a new plan for purposes of Section 423(b) of the Code; or (iii) be made if it would be treated as the adoption of a new plan for purposes of Section 423(b) of the Code or would require stockholder approval under the exchange listing rules applicable to the Company.

Article 16 - Limits on Sale of Stock Purchased under the Plan.

The Committee will designate a financial services firm or other agent to maintain accounts on behalf of participants who have purchased shares of Common Stock under the Plan (“Designated Broker”). Promptly following each Exercise Date, the number of shares of Common Stock purchased by each participant will be deposited into his or her account established in his or her name with the Designated Broker (“ESPP Share Account”). A participant will be free to undertake a sale of the shares of Common Stock in his or her ESPP Share Account at any time, subject to compliance with applicable laws and the Company’s insider trading policy, but in the absence of such a sale, except as otherwise determined by the Committee, the shares of Common Stock must remain in the participant’s ESPP Share Account at the Designated Broker until the holding period set forth in Section 423 of the Code (i.e., the later of one year from the Exercise Date and two years from the start of the Offering Period corresponding to such Exercise Date) has been satisfied. With respect to shares of Common Stock for which the holding period set forth in Section 423 of the Code have been satisfied, the participant may move those shares of Common Stock to another brokerage account of the participant’s choosing.

B-6

Article 17 - Participating Subsidiaries.

The term “participating subsidiary” will mean any present or future subsidiary of the Company, as that term is defined in Section 424(f) of the Code, which is designated from time to time by the Board to participate in the Plan. The Board will have the power to make such designation before or after the Plan is approved by the stockholders. Any such currently designated participating subsidiary is listed on Annex A hereto, which may be updated by the Board from time to time.

Article 18 - Optionees Not Stockholders.

Neither the granting of an option to an employee nor the deductions from his or her pay will constitute such employee a stockholder of the shares covered by an option until such shares have been actually purchased by the employee. A participant will have no interest or voting right in shares covered by the participant’s option until such shares are actually purchased on the participant’s behalf in accordance with the applicable provisions of the Plan. Except as set forth in Article 12, no adjustment will be made for dividends, distributions or other rights for which the record date is prior to the date of such purchase.

Article 19 - Application of Funds.

The proceeds received by the Company from the sale of Common Stock pursuant to options granted under the Plan will be used for general corporate purposes.

Article 20 - Designation of Beneficiary

Each participant may file a designation (using such form or method (including electronic forms) as the Committee may designate from time to time) of a beneficiary who is to receive any shares and cash, if any, from the participant’s account under the Plan in the event of such participant’s death. If a participant is married and the designated beneficiary is not the spouse, spousal consent will be required for such designation to be effective. Such designation of beneficiary may be changed by the participant (and the participant’s spouse, if any) at any time by written notice (using such form or method (including electronic forms) as the Committee may designate from time to time). In the event of the death of a participant and in the absence of a beneficiary validly designated under the Plan who is living (or in existence) at the time of such participant’s death, the Company will deliver such shares and/or cash to the executor or administrator of the estate of the participant, or if no such executor or administrator has been appointed (to the knowledge of the Committee), the Committee will deliver such shares and/or cash to the spouse (or domestic partner, as determined by the Committee) of the participant, or if no spouse (or domestic partner) is known to the Committee, then to the issue of the participant, such distribution to be made per stirpes (by right of representation), or if no issue are known to the Committee, then to the heirs at law of the participant determined in accordance with applicable law.

B-7

Article 21 - Withholding of Additional Income Taxes.

By electing to participate in the Plan, each participant acknowledges that the Company and its participating subsidiaries are required to withhold taxes with respect to the amounts deducted from the participant’s compensation and accumulated for the benefit of the participant under the Plan, and each participant agrees that the Company and its participating subsidiaries may deduct additional amounts from the participant’s compensation, when amounts are added to the participant’s account, used to purchase Common Stock or refunded, in order to satisfy such withholding obligations. Each participant further acknowledges that when Common Stock is purchased under the Plan the Company and its participating subsidiaries may be required to withhold taxes with respect to all or a portion of the difference between the Fair Market Value of the Common Stock purchased and its purchase price, and each participant agrees that such taxes may be withheld from compensation otherwise payable to such participant. It is intended that tax withholding will be accomplished in such a manner that the full amount of payroll deductions elected by the participant under Article 7 will be used to purchase Common Stock. However, if amounts sufficient to satisfy applicable tax withholding obligations have not been withheld from compensation otherwise payable to any participant, then, notwithstanding any other provision of the Plan, the Company may withhold such taxes from the participant’s accumulated payroll deductions and apply the net amount to the purchase of Common Stock, unless the participant pays to the Company, prior to the relevant Exercise Date, an amount sufficient to satisfy such withholding obligations. Each participant further acknowledges that the Company and its participating subsidiaries may be required to withhold taxes in connection with the disposition of stock acquired under the Plan and agrees that the Company or any participating subsidiary may take whatever action it considers appropriate to satisfy such withholding requirements, including deducting from compensation otherwise payable to such participant an amount sufficient to satisfy such withholding requirements or conditioning any disposition of Common Stock by the participant upon the payment to the Company or such subsidiary of an amount sufficient to satisfy such withholding requirements.

Article 22 - Governmental Regulations.

The Company’s obligation to sell and deliver shares of Common Stock under the Plan is subject to the approval of any governmental authority required in connection with the authorization, issuance or sale of such shares.

Government regulations may impose reporting or other obligations on the Company with respect to the Plan. For example, the Company may be required to identify shares of Common Stock issued under the Plan on its stock ownership records and send tax information statements to employees and former employees who transfer title to such shares.

Article 23 - Governing Law.

The validity and construction of the Plan will be governed by the laws of Delaware, without giving effect to the principles of conflicts of law thereof.

Article 24 - Approval of Board and Stockholders of the Company.

The Plan was adopted by the Board on March 17, 2021 and was approved by the stockholders of the Company on [●], 2021.

B-8

ANNEX A

DESIGNATED SUBSIDIARIES

Arthrosurface, Inc.

Parcus Medical, LLC

B-9

Appendix C

Anika Therapeutics, Inc.

2021 Annual Meeting of Stockholders

Rules of Conduct and Procedures

Welcome to the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Anika Therapeutics, Inc. (the “Company”). In the interest of providing a fair and informative Annual Meeting, participants are required to honor the following Rules of Conduct and Procedures:

The Company’s bylaws describe requirements for meetings of our stockholders, and the Annual Meeting will be conducted consistent with those requirements.

The Company’s Chief Executive Officer will serve as the chair of the Annual Meeting (the “Chair”) and will have the authority and discretion necessary to preside over the Annual Meeting, including following adjournment of the formal business of the Annual Meeting. In the event of disorder, technical malfunction or any other issue that disrupts the Annual Meeting, the Chair may adjourn, recess or expedite the Annual Meeting or may take any other action that she determines is appropriate in light of the circumstances. In the event of any question of conduct or procedures that is not addressed expressly and clearly by these Rules of Conduct and Procedure, the Chair is authorized to address the question in the manner she determines, in her reasonable judgment, to be in the best interest of conducting a fair and informative Annual Meeting consistent with the purposes of the Annual Meeting.

The Annual Meeting is a virtual-only meeting. The live audio webcast of the Annual Meeting will be available for listening by the general public, but participation in the Annual Meeting, including voting shares and submitting questions, will be limited to stockholders.

Participants may access a live webcast of the Annual Meeting, and stockholders may submit questions and vote their shares, at www.virtualshareholdermeeting.com/ANIK2021.

Each stockholder of record as of 5 p.m., Eastern time, on April 20, 2021 may log into the webcast by entering the 16-digit control number included on the Notice of Internet Availability of Proxy Materials or proxy card received from the Company. If you have voted your shares prior to the start of the Annual Meeting, your vote has been received by the Company’s inspector of elections and there is no need to vote those shares during the Annual Meeting, unless you wish to revoke or change your vote.

The Meeting will begin at 9:00 a.m., Eastern time, on June 16, 2021. The only business to be conducted at the Annual Meeting will consist of the consideration of, and voting on, the five proposals set forth in the Proxy Statement. These proposals will be considered sequentially at the Annual Meeting, in the order they are enumerated and set forth in the Proxy Statement.

If a stockholder has a question about one of the agenda matters that is to be voted on at the Annual Meeting as set forth in the Proxy Statement, the question may be submitted in the field provided in the web portal at or before the time the matters are presented for consideration at the Annual Meeting. We will answer questions on any matters set forth in the Proxy Statement to be voted on by the stockholders at the Annual Meeting before voting is closed. During this period, the Company will not permit discussions or questions that are not relevant or pertinent to the agenda matter then being discussed, as determined by the Chair in her reasonable judgment.

C-1

Following adjournment of the formal business of the Annual Meeting, the Company will address appropriate general business-related questions as time allows from stockholders regarding the Company. The following rules will apply to this process:

To ensure that as many stockholders as possible are able to ask questions, each stockholder will be permitted to submit no more than two questions. Questions must be succinct and cover a single topic.

Questions from multiple stockholders related to the same topic, or that are otherwise related, may be grouped and answered together.

ii.

Any second question from a stockholder will be deferred until such time as all appropriate first questions from stockholders have been addressed.

iii.

If more questions are presented than time permits to be answered, the Chair shall determine, in her discretion, which questions the Company will answer.

The views, questions and constructive comments of all stockholders are valued and welcomed. The purpose of the Annual Meeting must be observed, however, and the Company will not permit questions that:

are not relevant or pertinent to the business of the Company;

ii.

are related to material non-public information of the Company;

iii.

are related to pending or threatened litigation or investigations;

iv.

are in furtherance of a stockholder’s personal or business interests;

are repetitious of statements made by another stockholder;

vi.

are related to personal grievances;

vii.

include derogatory references to individuals or are otherwise in bad taste; or

viii.

are out of order or not otherwise suitable for the conduct of the Annual Meeting as determined by the Chair in her reasonable judgment.

If there are any matters of individual concern to a stockholder and not of general concern to all stockholders, or if a question posed was not otherwise answered, such matters may be raised separately after the Annual Meeting by contacting Investor Relations at investorrelations@anika.com.

10.

Recording of the Annual Meeting is prohibited without the prior written permission of the Company. A webcast playback of the Annual Meeting will be available at https://ir.anikatherapeutics.com/financial-information/annual-reports within approximately 24 hours after the completion of the Annual Meeting and will remain publicly available until our annual meeting of stockholders in 2022. The webcast playback will include each stockholder question addressed during the Annual Meeting.

11.

A violation of any of the above conduct requirements will be cause for dismissal from the Annual Meeting.

THANK YOU FOR YOUR COOPERATION AND FOR JOINING THE ANNUAL MEETING.

C-2

KEEP THIS PORTION FOR YOUR RECORDS DETAC H AN D RETUR N THI S PORTIO N ONLY TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: ~~KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY~~ THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. ~~D15766~~Signatur e (Join t Owners) Signature [PLEASE SIGN WITHIN BOX] Date Date 0000512371_1 R1.0.0.177 For Against Abstain 0 0 0 0 0 0 For Against Abstain 0 0 0 0 0 0 0 0 0 0 0 0 ANIKA THERAPEUTICS, INC. ATTN: DAVID COLLERAN 32 WIGGINS AVE. BEDFORD, MA 01730 VOTE BY INTERNET - ~~P39407~~www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information. Vote by 11:59 P.M. ET on 06/15/2021 for shares held directly and by 11:59 P.M. ET on 06/13/2021 for shares held in a Plan. Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form. VOTE BY PHONE - 1 - 800 - 690 - 6903 Use any touch - tone telephone to transmit your voting instructions. Vote by 11:59 P.M. ET on 06/15/2021 for shares held directly and by 11:59 P.M. ET on 06/13/2021 for shares held in a Plan. Have your proxy card in hand when you call and then follow the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage - paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 . The Board of Directors recommends you vote FOR the following: 1. Election of Directors Nominees 1a. Stephen O. Richard 1b. Jeffery S. Thompson The Board of Directors recommends you vote FOR proposals 2, 3, 4 and ~~4. For Against Abstain~~5. 2. Approval of the amendment to the Anika Therapeutics, Inc. 2017 Omnibus Incentive ~~Plan ! ! !~~Plan. 3. Approval of the Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan. 4. Ratification of Deloitte & Touche LLP as the Company's independent registered public accounting ~~firm ! ! ! 4.~~firm. 5. Advisory vote on the compensation of the Company's named executive ~~officers ! ! !~~officers. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. ~~For address changes and/or comments, please check this box and write them on the back where indicated.~~ Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. 1. Election of Director Nominee: 1) Susan N. Vogt For Withhold For All A ll Al l Except ! ! ! ! ANIKA THERAPEUTICS, INC. To withhold authority to vote for any individual nominee(s), mark "For All Except" and write the number(s) of the nominee(s) on the line below . The Board of Directors recommends you vote FOR the following: ANIKA THERAPEUTICS, INC. ATTN: DAVID COLLERAN 32 WIGGINS AVE. BEDFORD, MA 01730 VOTE BY INTERNET Before The Meeting - Go to www.proxyvote.com Use the Internet to transmit your voting instructions and for electronic delivery of information up until 11 : 59 p . m . Eastern Time on June 15 , 2020 . Have your proxy card in hand when you access the web site and follow the instructions to obtain your records and to create an electronic voting instruction form . During The Meeting - Go to www.virtualshareholdermeeting.com/ANIK2020 You may attend the meeting via the Internet and vote during the meeting . Have the information that is printed in the box marked by the arrow available and follow the instructions . VOTE BY PHONE - 1 - 800 - 690 - 6903 Use any touch - tone telephone to transmit your voting instructions up until 11 : 59 p . m . Eastern Time on June 15 , 2020 . Have your proxy card in hand when you call and then follow the instructions . VOTE BY MAIL Mark, sign and date your proxy card and return it in the postage - paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717 .

~~Address Changes/Comments:~~0000512371_2 R1.0.0.177 Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting: The Notice and Proxy Statement and Annual Report are available at ~~www.proxyvote.com. D15767 - P39407~~www.proxyvote.com ANIKA THERAPEUTICS, INC. Annual Meeting of Stockholders June 16, ~~2020 11:30~~2021 9:00 AM This proxy is solicited on behalf of the Board of Directors The undersigned, having received notice of the Annual Meeting of Stockholders and the Proxy Statement furnished herewith, revoking all prior proxies, hereby appoints Dr . Cheryl Blanchard, MsMr . ~~Sylvia Cheung,~~David Colleran and Mr . ~~David Colleran,~~Michael L . Levitz, and each of them, with full power of substitution, as proxies to represent and vote all shares of common stock which the undersigned would be entitled to vote, if personally present, at the ~~2020~~2021 Annual Meeting of Stockholders of Anika Therapeutics, Inc . (the "Company") to be held live via webcast at www . virtualshareholdermeeting . com/ANIK ~~2020~~2021 on ~~Tuesday,~~Wednesday, June 16 , ~~2020~~2021 , at 119 : 3000 a . m . , local time, and at any adjournment or postponement thereof, with respect to the matters set forth on the reverse side . Any proxy may be revoked by a stockholder by delivery of a written revocation or a subsequently dated proxy to the Secretary of the Company before the taking of the vote at the ~~2020~~2021 Annual Meeting, by properly casting a new vote via the Internet or Telephone at any time before the closure of the Internet or Telephone facilities . Attendance of the stockholder at the meeting or any adjournment or postponement thereof will not in and of itself constitute revocation of this proxy . This proxy, when properly executed, will be voted in the manner directed herein . If no such direction is made, this proxy will be voted "FOR" the election of each of the ~~director~~directors and "FOR" items 2 , 3 , 4 , and 45 , in each case, in accordance with the Board of Directors' recommendations, and voted in accordance with the discretion of the persons named as proxies on any other matters that may properly come before the Annual Meeting . ~~(If you noted any Address Changes/Comments above, please mark corresponding box on the reverse side.)~~ Continued and to be signed on reverse side


Check the appropriate box:
☐	Preliminary Proxy Statement
☐	Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒	Definitive Proxy Statement
☐	Definitive Additional Materials
☐	Soliciting Material Pursuant to §240.14a-12

Payment of Filing Fee (Check the appropriate box):
☒	No fee required.
☐	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
	(1)	Title of each class of securities to which transaction applies:
	(2)	Aggregate number of securities to which transaction applies:
	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
	(4)	Proposed maximum aggregate value of transaction:
	(5)	Total fee paid:
☐	Fee paid previously with preliminary materials.
☐	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
	(1)	Amount Previously Paid:
	(2)	Form, Schedule or Registration Statement No.:
	(3)	Filing Party:
	(4)	Date Filed:

Time and Date	~~11:30~~	9:00 a.m., Eastern time, on June 16, ~~2020~~2021
Meeting Webcast Address		virtualshareholdermeeting.com/~~ANIK2020~~ANIK2021 —To join, a stockholder will need the control number located on the stockholder’s Notice of Internet Availability of Proxy Materials or proxy card
Record Date		5:00 p.m., Eastern time, on April 20, ~~2020~~2021
Voting		Stockholders will be entitled to one vote at the Annual Meeting for each outstanding share of common stock they hold of record as of the record date
Outstanding Common Stock	~~14,197,948~~	14,366,686 shares as of the record date

· By mailing your proxy card		By telephone	By Internet:

Cast your ballot, sign your proxy card and send by free post		Dial toll-free 24/7 1-800-690-6903	Visit 24/7 www.proxyvote.com

·	~~Telephone~~~~: +1-800-690-6903 if you are the stockholder of record or beneficially hold shares in “street name”~~

·	~~Dated, signed,~~ Mark, sign and ~~returned~~date your proxy card and return it in the postage-paid envelope included in your proxy materials. Your proxy card must arrive by June 15, 2021.

*Board Recommendation:*		The Board of Directors recommends a vote “FOR” the reelection of ~~Ms. Vogt.~~each of Mr. Richard and Mr. Thompson.

*Vote Required for Approval:*		Affirmative vote of a majority of the shares of common stock that are voting in the election of directors, meaning that, to be elected, the shares voted “FOR” a nominee must exceed the number ~~“WITHHELD” from~~of shares voted “AGAINST” that nominee.

		Under our Majority Voting in Uncontested Director Elections Policy, if a director receives a greater number of votes “against” than “for” his election, such director shall promptly offer his resignation for consideration by the Governance and Nominating Committee. Please see the section captioned “Majority Voting in Uncontested Director Elections Policy” for more details on this policy and its impact on the election of director nominees.

		Abstentions and ~~broker~~Broker non-votes ~~will not be treated as votes cast and~~ will have no ~~impact~~effect on the ~~proposal.~~outcome of this proposal because they are not counted as “votes cast.”

1.	~~election of one Class III director;~~

2.	~~amendment of the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;~~

3.	~~ratification of the appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2020;~~

4.	~~advisory “say on pay” vote on executive compensation; and~~

5.	~~any other matters that properly come before the Annual Meeting.~~

	1.	election of two Class I directors;
	2.	amendment of Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan;
	3.	approval of Anika Therapeutics, Inc. 2021 Employee Stock Purchase Plan;
	4.	ratification of appointment of Deloitte & Touche LLP as Anika’s independent auditor for 2021;
	5.	advisory “say-on-pay” vote on executive compensation; and
	6.	any other matters that properly come before the Annual Meeting.

	The Annual Meeting is scheduled to be held as follows:

	Date		~~Tuesday,~~Wednesday, June 16, ~~2020~~2021

	Time		~~11:30~~9:00 a.m., Eastern time

	Meeting Webcast Address		virtualshareholdermeeting.com/~~ANIK2020~~ANIK2021

~~2020~~2021 Proxy Summary	1
Questions and Answers about the Annual Meeting	810
Proposal 1: Election of Directors	1214
Information Regarding Directors	1315
Governance of the Company	20
Board’s Role in Risk Oversight	1720
Board’s Increased Involvement due to COVID-19 and Executive Team Changes	20
Board Leadership Structure	1720
Corporate Governance and Board Matters	1720
Board Committees	1821
Board Membership Qualifications and Procedures	2125
Communications with Directors	2226
Code of Business Conduct and Ethics	2327
Commitment to Compliance	27
Corporate Social Responsibility – Environmental Sustainability, Social, and Governance Matters	2327
Human Capital Management	28
Director Overboarding Guidelines	30
Prohibition on Employee, Officer, and Director Hedging and Pledging	30
Majority Voting in Uncontested Director Elections Policy	2330
Transactions with Related Persons and Conflict of Interest Policy	2431
Beneficial Ownership of Common Stock	25
~~Section 16(a) Beneficial Ownership Reporting Compliance~~	2832
Executive Officers	2935
Compensation Discussion and Analysis	3136
Executive Summary	3136
Compensation Philosophy	3338
Key Compensation Policies and Practices	3439
~~2019~~2020 Compensation Decisions	3642
Other Compensation Matters	4047
Compensation Committee Report	4451
Executive and Director Compensation	4552
Summary Compensation Table	4552
~~Option~~ Grants ~~and Plan~~of Plan-Based Awards in ~~2019~~2020	4653
Outstanding Equity Awards at December 31, ~~2019~~2020	4755
~~2019 Equity Award~~2020 Option Exercises and Stock Vested	4856
Potential Payments Upon Termination or Change in Control	4857
CEO Pay Ratio	4958
Director Compensation	5059
Director and Executive Officer Stock Retention Guidelines	5160
Compensation Committee Interlocks and Insider Participation	5161
Equity Compensation Plan Information	5261
Proposal 2: Amendment of 2017 Omnibus Incentive Plan	5362
Proposal 3: Approval of 2021 Employee Stock Purchase Plan	71
Audit Committee Report	6277
Proposal 3:4: Ratification of Appointment of Independent Auditor for ~~2020~~2021	6479
Proposal 4:5: Advisory Vote on Executive Compensation	6780
Other Matters	6883
Solicitation Expenses	6883
Stockholder Proposals	6883
Householding	6984
Appendix A	70A-1
Appendix B	B-1
Appendix C	C-1

Proposal		Board Recommendation
1	Election of two Class ~~III director~~I directors	FOR ~~the~~each nominee
2	Amendment of 2017 Omnibus Incentive Plan	FOR
3	Approval of 2021 Employee Stock Purchase Plan	FOR
4	Ratification of independent auditor for ~~2020~~2021	FOR
45	Advisory ~~“say on pay”~~“say-on-pay” vote	FOR

DIVERSITY	INDEPENDENCE	TENURE

3 of our 7 continuing directors and director nominees voluntarily self-identify as having a diverse identity (gender, race/ethnicity, or LGBTQ+).	6 of our 7 continuing directors and director nominees qualify as independent under NASDAQ standards and SEC regulations.	The tenure of our continuing directors and director nominees (average 5.5 years) reflects a balance of experience and fresh perspective.

Director	Blanchard	Henneman	Land	Larsen	Richard	Thompson	Vogt
Age	Our directors range in age from 55 to 76
Skills and Experience
CEO/CFO Experience	•	•	•	•	•	•	•
Medical Devices/Pharmaceutical	•	•	•	•	•	•	•
Manufacturing	•			•		•	•
R&D/Innovation	•			•		•	•
Regulatory	•	•		•		•	•
Financial Oversight/Accounting		•	•	•	•		•
Human Capital Management	•	•	•	•	•	•	•
Commercialization/Marketing	•		•		•	•	•
Public Company Governance/Corporate Responsibility	•	•	•	•	•	•	•
M&A/Business Development	•	•	•	•		•
International/Global Business	•	•	•	•	•	•	•
Other Public Company Experience	•	•	•	•	•	•	•

*Elections:*	~~In-Person Stockholder Meeting~~		Yes*
	Voting Standard		Majority ~~with plurality carve-out for contested elections~~⁽¹⁾
	Resignation Policy		Yes
	Mandatory Retirement Age or Tenure		No
*Chair:*	Separate Chair of the Board and CEO		Yes
	Independent Chair of the Board		Yes
	Robust Responsibilities and Duties Assigned to Independent Chair		Yes
*Meetings:*	Number of Board Meetings Held in ~~2019~~2020		1023
	All Directors ~~Attending Fewer~~Attended More than ~~80%~~90% of Board Meetings in ~~2019~~2020		~~None~~Yes
	Independent Directors Meet without Management Present		Yes
	Number of Standing Committee Meetings Held in ~~2019~~2020		1628
	All Members ~~Attending Less~~Attended more than ~~80%~~90% of Committee Meetings in ~~2019~~2020		~~None~~Yes
*Director Status:*	All Directors ~~Overboarded per ISS or Glass Lewis Voting~~in compliance with our Overboarding Guidelines		~~None~~Yes
	Material Related-Party Transactions with Directors		None
	Standing Board Committee Membership Independence		100%
	Board Oversight of Company Strategy and Risk		Yes
	~~Shares Hedged or Pledged by~~All Directors in Compliance with Hedging and Pledging Prohibitions		~~None~~Yes
	All Directors in Compliance with Stock Ownership Guidelines		Yes
*~~Shareholder~~Stockholder Rights:*	Dual Class Common Stock		No
*~~Shareholder~~Stockholder Rights:*		Poison Pill		No
	Cumulative Voting		No

Key ~~2017 Plan~~ Provision		Summary Description
Shares reserved		Up to ~~1,565,109~~1,858,748 shares of common stock, representing approximately ~~11.0%~~12.9% of the fully diluted common stock outstanding as of April 20, ~~2020,~~2021, would be available for ~~grant.~~ grant, subject to adjustment by the plan administrator as set forth in the plan.
Multiple award types		Various types of awards may be granted as compensation tools to motivate our workforce, including incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, and other types of share and cash-based awards.
Minimum vesting requirements		Awards must have a vesting period of at least 1 year, except that: • up to 5% of the share pool can be granted without asuch minimum vesting period; and • awards may be accelerated due to a participant’s, retirement, death, disability or a change in control of ~~the company,~~Anika, if such term was included in the award ~~agreement~~ agreement.
Maximum award terms		Awards may have terms of up to 10 years.
Director limits		The plan specifies annual limits on the value of awards that may be granted to non-employee directors.
No repricing		Awards may not be repriced without stockholder approval.
No transferability		Awards generally may not be transferred, except by will or laws of descent and distribution.
~~Tax deductible awards~~	~~Awards may qualify as “performance-based” compensation under Section 162(m) of the Internal Revenue Code.~~

Board Recommendation:		The Board recommends a vote “FOR” the amendment of our 2017 Omnibus Incentive Plan.

Vote Required for Approval:		Affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal.

Key ESPP Provision		Summary Description
Shares reserved		A total of 200,000 shares of common stock would be reserved, subject to adjustment by the ESPP plan administrator as set forth in the ESPP.
Eligible participants		Except as otherwise determined by the ESPP plan administrator, all employees employed for at least one month prior to the start date of an offering period would be eligible to participate for that offering period.
Offering periods		Except as otherwise determined by the ESPP plan administrator, offering periods would extend for six months commencing on November 15, 2021 and on each May 15 and November 15 thereafter.
Limitations		Except as otherwise determined by the ESPP plan administrator, participants would be granted an option to purchase a maximum of 800 shares of common stock for an offering period, subject to adjustment by the ESPP plan administrator as more fully set forth in Appendix B. No participant could be granted an option to purchase shares to accrue at a rate that exceeds $25,000 of fair market value of common stock for each calendar year the option is outstanding. Except as otherwise determined by the ESPP plan administrator, a participant’s payroll deductions in connection with purchases under the ESPP could not be less than 1% or more than 15% of the participant’s compensation.
Option price		The exercise price of an option for an offering period would equal 85% of the lesser of (a) the fair market value of common stock on the start date of the offering period and (b) the fair market value of common stock on the exercise date. The ESPP plan administrator may increase, but not decrease, the exercise price.
Transferability		Options generally could not be transferred, except by will or laws of descent and distribution.
Termination		The ESPP would terminate on June 16, 2031 (the tenth anniversary of its approval by stockholders), unless terminated earlier in accordance with its terms.

Board Recommendation:		The Board recommends a vote “FOR” the approval of the 2021 Employee Stock Purchase Plan.

Vote Required for Approval:		Affirmative vote of the holders of a majority of the shares of common stock that are voting on the matter. Abstentions and broker non-votes will not be treated as votes cast and will have no impact on the proposal.

Compensation Element	Description	Objectives
Base ~~Salary~~salary	· • Fixed cash compensation	· • Provide appropriate level of fixed compensation based on role, responsibility, performance and competitive market practices
Cash ~~Bonuses~~bonuses	· • Annual cash award based on performance of company and individual · • Prorated in the year of hire if employment begins before October 1 · • Overall cash bonus capped at 200% of the target payout	· • Reward the achievement of financial results, organizational development, business and technical development, individual goals and contribution to building stockholder value · • Encourage retention based on achievement of near-term goals consistent with long-term strategy
~~Equity-Based Grants~~Equity-based grants	· • Grants of equity awards, including restricted stock unit awards and stock options, under our equity plan · ~~Include~~ • Includes performance-based and time-vesting equity awards	· • Align interests of our executive officers with those of our stockholders · in terms of value generation • Provide executive officers with opportunity to be compensated based on common stock price appreciation · • Encourage retention through long-term value creation

Name and Principal Position	Year		Salary ($)		Bonus		Stock Awards ($)		Option Awards ($)		All Other Compensation ($)		Total ($)
Cheryl R. Blanchard, Ph.D.		2020	$	548,077	$	458,510	$	5,335,439	$	3,659,450	$	27,958	$	10,029,434
President and Chief
Executive Officer
Michael L. Levitz		2020	$	173,077	$	73,601	$	799,971	$	799,993	$	11,318	$	1,857,960
EVP, Chief Financial Officer
and Treasurer
David Colleran		2020	$	344,077	$	143,931	$	645,900	$	553,445	$	18,263	$	1,705,616
EVP, General Counsel
and Secretary
Thomas Finnerty		2020	$	353,505	$	143,169	$	626,367	$	-	$	20,746	$	1,143,787
EVP, Human Resources

James Loerop		2020	$	381,563	$	171,703	$	464,449	$	-	$	22,156	$	1,039,871
EVP, Business Development
and Strategic Planning
Joseph G. Darling		2020	$	80,752	$	-	$	-	$	-	$	208,001	$	288,753
President and Chief
Executive Officer
Sylvia Cheung		2020	$	294,252	$	-	$	924,637	$	-	$	89,644	$	1,308,534
Chief Financial Officer, Treasurer
and Assistant Secretary

Name and Principal Position	Year		Salary		Bonus		Option Awards		Stock Awards		All Other Compensation		Total
Joseph G. Darling		2019	$	599,500	$	764,363	$	-	$	4,098,780	$	127,539	$	5,590,182
President and Chief		2018	$	523,462	$	412,500	$	728,335	$	399,998	$	105,892	$	2,170,187
Executive Officer		2017	$	181,987	$	93,990	$	750,281	$	749,960	$	5,993	$	1,782,212
Sylvia Cheung		2019	$	392,094	$	220,553	$	-	$	585,540	$	20,680	$	1,218,867
Chief Financial Officer		2018	$	371,653	$	167,244	$	728,335	$	-	$	19,970	$	1,287,202
		2017	$	359,085	$	185,827	$	709,054	$	-	$	18,720	$	1,272,686
Thomas Finnerty		2019	$	341,550	$	184,437	$	-	$	585,540	$	24,352	$	1,135,879
EVP of Human Resources		2018	$	330,000	$	118,800	$	285,831	$	-	$	24,002	$	758,633
		2017	$	44,423	$	-	$	301,451	$	367,812	$	2,508	$	716,194
James Loerop		2019	$	165,865	$	202,500	$	377,772	$	732,060	$	1,429	$	1,479,626
EVP of Business Development
and Strategic Planning
Edward S. Ahn, Ph.D.		2019	$	202,628	$	-	$	-	$	292,770	$	184,044	$	679,442
Chief Technology and		2018	$	357,660	$	80,474	$	455,126	$	-	$	20,330	$	913,590
Strategy Officer		2017	$	347,243	$	125,007	$	599,331	$	-	$	19,080	$	1,090,662

Director Name	Age	Director Since	Term Expires	Age	Director Since	Term Expires
*Class I Directors*
Joseph L Bower	81	1993	2021	82	1993	2021
Stephen O. Richard				58	2020	2021
Jeffery S. Thompson	54	2011	2021	55	2011	2021
*Class II Directors*
Cheryl R. Blanchard Ph.D.	55	2018	2022	56	2018	2022
Raymond J. Land	75	2006	2022	76	2006	2022
Glenn R. Larsen, Ph.D.	65	2015	2022	66	2015	2022
*Class III Directors*
John B. Henneman III				59	2020	2023
Susan N. Vogt	66	2018	2020	67	2018	2023

	·	President and Chief Executive Officer of Anika ~~effective~~since April ~~26,~~ 2020,
·	and Interim Chief Executive Officer of Anika from February 2020 through April 2020

	·	President and Chief Executive Officer of Microchips Biotech, Inc., a venture-backed biotechnology company developing regenerative medicine and drug delivery products, from 2014 until its sale to Daré Bioscience, Inc. in November 2019
	·	Various offices, including Senior Vice President, Chief Scientific Officer, and general manager of Zimmer Biologics, of Zimmer, Inc., a medical device company focused on musculoskeletal products, from 2000 to 2012

	·	Executive Vice President and Chief Financial Officer of NewLink Genetics Corporation, a public biotechnology company, from October 2014 to July 2018 and Chief Administrative Officer of NewLink from July 2018 through his retirement in November 2018
·	~~Chair of the Board since March 2018, lead director of the Board from 2005 to March 2018 and director since 1993~~
·	~~Donald Kirk David Professor Emeritus at Harvard Business School since July 2014~~
·	~~Baker Foundation Professor of Business Administration at Harvard Business School from 2008 to July 2014~~
·	~~Donald Kirk David Professor of Business Administration from 1963 to 2008~~
·	Various ~~administrative roles,~~offices of Integra LifeSciences Holdings Corp., a medical devices company, from 1998 to 2014, including ~~Senior Associate Dean, during tenure at Harvard Business School~~Chief Financial Officer from 2007 to 2014 and earlier as General Counsel and Chief Administrative Officer

Beneficial Owner	Amount and Nature of Beneficial Ownership		Percentage of Common Stock Outstanding
Directors and Named Executive officers:
Joseph L. Bower	19,117	⁽¹⁾	*
Raymond J. Land	13,399	⁽²⁾	*
Glenn R. Larsen, Ph.D.	11,697	⁽²⁾	*
Jeffery S. Thompson	10,949	⁽²⁾	*
Susan N. Vogt	11,652	⁽²⁾	*
Steven E. Wheeler	34,594	⁽³⁾	*
Cheryl R. Blanchard	11,697	⁽⁴⁾	*
Sylvia Cheung	262,924	⁽⁵⁾	1.82%
David Colleran	-	⁽⁶⁾	*
Thomas Finnerty	23,648	⁽⁷⁾	*
James Loerop	-	⁽⁸⁾	*
Joseph G. Darling	40,341	⁽⁹⁾	*
Edward S. Ahn, Ph.D.	-	⁽¹⁰⁾	*
Current directors and executive officers as a group (9 persons)	365,083	⁽¹¹⁾	2.53%
5% and Above Stockholders:
Blackrock, Inc.
55 East 52nd Street
New York, NY 10055	2,127,249	⁽¹²⁾	14.88%
Kayne Anderson Rudnick Investment Management LLC
1800 Avenue of the Stars, 2nd Floor
Los Angeles, CA 90067	1,383,328	⁽¹³⁾	9.74%
Dimensional Fund Advisors LP
Building One, 6300 Bee Cave Road
Austin, TX 78746	1,001,294	⁽¹⁴⁾	7.05%
The Vanguard Group
100 Vanguard Blvd.
Malvern, PA 19355	915,596	⁽¹⁵⁾	6.45%
State Street Corporation
1 Lincoln Street
Boston, MA 02111	860,507	⁽¹⁶⁾	5.69%

* Indicates less than 1%

Name	2018 Salary	2019 Salary	% Change
Joseph G. Darling	$550,000	$599,500	9.0%
Sylvia Cheung	$371,653	$392,094	5.5%
Thomas Finnerty	$330,000	$341,550	3.5%
James Loerop	n/a	$375,000	n/a
Edward S. Ahn, Ph.D.	$357,660	$364,813	2.0%

Name	Stock Option Target	% Achieved	Stock Options Granted
Joseph G. Darling	14,300	53.2%	7,609
Sylvia Cheung	14,300	53.2%	7,609
Edward Ahn, Ph.D.	8,900	63.2%	5,625
Thomas Finnerty	4,500	63.9%	2,873
Richard Hague	7,100	53.2%	3,777

Name and Principal Position	Year		Salary⁽¹⁾			Bonus⁽²⁾		Option Awards⁽³⁾			Stock Awards⁽³⁾			All Other Compensation⁽⁴⁾			Total
Joseph G. Darling⁽⁵⁾		2019	$	599,500		$	764,363	$	-		$	4,098,780		$	127,539	⁽¹⁰⁾	$	5,590,182
President and Chief		2018	$	523,462	⁽⁵⁾	$	412,500	$	728,335		$	399,998	⁽⁹⁾	$	105,892	⁽¹¹⁾	$	2,170,187
Executive Officer		2017	$	181,987		$	93,990	$	750,281	⁽⁸⁾	$	749,960	⁽⁸⁾	$	5,993	⁽¹²⁾	$	1,782,212
Sylvia Cheung		2019	$	392,094		$	220,553	$	-		$	585,540		$	20,680		$	1,218,867
Chief Financial Officer		2018	$	371,653		$	167,244	$	728,335		$	-		$	19,970		$	1,287,202
		2017	$	359,085		$	185,827	$	709,054		$	-		$	18,720		$	1,272,686
Thomas Finnerty		2019	$	341,550		$	184,437	$	-		$	585,540		$	24,352		$	1,135,879
EVP of Human Resources		2018	$	330,000		$	118,800	$	285,831		$	-		$	24,002		$	758,633
		2017	$	44,423		$	-	$	301,451		$	367,812		$	2,508		$	716,194
James Loerop⁽⁶⁾		2019	$	165,865	⁽⁶⁾	$	202,500	$	377,772		$	732,060		$	1,429	⁽¹³⁾	$	1,479,626
EVP of Business Development			$	-		$	-	$	-		$	-		$	-
and Strategic Planning			$	-		$	-	$	-		$	-		$	-
Edward S. Ahn, Ph.D.⁽⁷⁾		2019	$	202,628	⁽⁷⁾	$	-	$	-		$	292,770		$	184,044	⁽¹⁴⁾	$	679,442
Chief Technology and		2018	$	357,660		$	80,474	$	455,126		$	-		$	20,330		$	913,590
Strategy Officer		2017	$	347,243		$	125,007	$	599,331		$	-		$	19,080		$	1,090,662

	Option Awards							Stock Awards
													Equity Incentive Plan Awards

Name		Number of	Number of			Option	Option		Number			Market		Number of		Market or Payout
		Securities	Securities			Exercise	Expiration		of			Value of		Unearned and		Value of Unearned
		Underlying	Underlying			Price	Date		Unvested			Unvested		Unvested Shares,		and Unvested
		Exercisable	Unexercisable						Shares or			Shares or		Units, or Other		Shares, Units,
		Options⁽¹⁾	Options⁽¹⁾						Units of Stock⁽¹⁾			Units of Stock⁽²⁾		Rights		or Other Rights
Joesph G. Darling		-	-			-			126,000	(*)	$	6,533,100		-	$	-
		-	-			-			3,738		$	193,815		-	$	-
		7,252	21,757		$	61.47	1/24/2028		-		$	-		-	$	-
		27,739	13,870		$	51.70	7/27/2027		4,835		$	250,695		-	$	-
Total		34,991	35,627						134,573		$	6,977,610

Sylvia Cheung		-	-			-			18,000	(*)	$	933,300		-	$	-
		7,252	21,757		$	61.47	1/24/2028		-		$	-		-	$	-
		24,192	12,096	(*)	$	50.13	1/27/2027		-		$	-		-	$	-
		22,350	7,450		$	38.11	2/4/2026		1,975		$	102,404		-	$	-
		21,624	-		$	39.69	2/3/2025		-		$	-		-	$	-
		13,800	-		$	32.02	1/27/2024		-		$	-		-	$	-
		45,000	-		$	10.87	1/29/2023		-		$	-		-	$	-
		15,000	-		$	9.10	1/25/2022		-		$	-		-	$	-
		20,000	-	(*)	$	6.99	6/7/2021		-		$	-		-	$	-
		25,000	-		$	6.98	1/18/2021		-		$	-		-	$	-
Total		194,218	41,303					$	19,975		$	1,035,704

Thomas Finnerty									18,000	(*)	$	933,300		-	$	-
		2,393	7,180		$	61.47	1/24/2028		-		$	-		-	$	-
		11,333	5,667	(*)	$	54.09	10/30/2027		2,267		$	117,544		-	$	-
Total		13,726	12,847						20,267		$	1,050,844

James Loerop		-	27,000	(*)	$	40.67	7/8/2029		18,000	(*)	$	933,300		-	$	-
Total		-	27,000						18,000		$	933,300

Edward S. Ahn, Ph.D.⁽³⁾		-	-		$	-			-		$	-		-	$	-
Total		-	-						-		$	-

	Option and SARs Awards					Stock Awards
Name	Number of Shares Acquired on Exercise			Value Realized on Exercise		Number of Shares Acquired on Vesting		Value Realized on Vesting
Joseph G. Darling		-		$	-		6,705	$	327,394
Sylvia Cheung		31,319	⁽¹⁾	$	1,894,173		3,644	$	138,619
Thomas Finnerty		-		$	-		2,266	$	157,872
James Loerop		-		$	-		-	$	-
Edward Ahn		85,867		$	939,910		1,975	$	75,248

Name		Termination Without Cause		Termination Upon Change in Control^{(1) (2)}		Change in Control Without Termination or Death or Disability^{(1) (3)}
Joseph G. Darling	Salary Continuation	$	899,250	$	1,199,000	$	-
	Additional Cash Payment		764,363		1,019,150		-
	Equity Awards Vesting		6,983,851		6,983,851		-
	Health Care Benefits		30,232		37,208		-
		$	8,677,696	$	9,239,210	$	-

Sylvia Cheung	Salary Continuation	$	371,653	$	557,480	$	-
	Additional Cash Payment		167,244		250,866		-
	Equity Awards Vesting		-		6,548,473		-
	Health Care Benefits		20,154		30,232		-
		$	559,051	$	7,387,050	$	-

Thomas Finnerty	Salary Continuation	$	330,000	$	330,000	$	-
	Additional Cash Payment		-		148,500		-
	Equity Awards Vesting		-		1,050,844		-
	Health Care Benefits		20,154		20,154		-
		$	350,154	$	1,549,498	$	-

James Loerop	Salary Continuation	$	375,000	$	375,000	$	-
	Additional Cash Payment		-		168,750		-
	Equity Awards Vesting		-		1,235,160		-
	Health Care Benefits		15,629		15,629		-
		$	390,629	$	1,794,539	$	-

Edward S. Ahn, Ph.D.⁽⁴⁾	Salary Continuation	$	-	$	-	$	-
	Additional Cash Payment		-		-		-
	Equity Awards Vesting		-		-		-
	Health Care Benefits		-		-		-
		$	-	$	-	$	-

									Aggregate Number of Shares Outstanding
Name	Fees Earned or Paid in Cash ($)		Stock Awards ($)⁽¹⁾		Option Awards ($)		Total ($)		Options		Restricted Stock Units
Cheryl R. Blanchard		62,500		124,980		-		187,480		-		3,842
Joseph L. Bower		100,000		124,980		-		224,980		-		3,842
Raymond J. Land		75,000		124,980		-		199,980		-		3,842
Glenn R. Larsen, Ph.D.		62,500		124,980		-		187,480		-		3,842
Jeffery S. Thompson ⁽²⁾		76,389		124,980		-		201,369		-		3,842
Susan N. Vogt		60,000		124,980		-		184,980		-		3,842
Steven E. Wheeler⁽³⁾		7,313		-		-		7,313		-		-

Equity Compensation Plan Information
Plan category	Number of securities to be issued upon exercise of outstanding options, stock appreciation rights, performance shares and restricted stock units⁽¹⁾		Weighted Average exercise price of outstanding options, stock appreciation rights, and performance shares		Number of securities remaining available for future issuance under equity compensation plans
Equity compensation plans approved by security holders		967,250	$	41.65		1,728,869
Equity compensation plans not approved by security holders		N/A		N/A		N/A
Total		967,250	$	41.65		1,728,869

Award Type	FY 2017	FY 2018	FY 2019
Stock Options Granted	440,688	199,970	254,517
Stock Settled Restricted Stock/RSUs Granted	67,567	160,070	626,014
Basic Weighted. Avg. Common Shares Outstanding	14,575,000	14,442,000	14,121,000
Annual Burn Rate	3.49%	2.49%	6.24%
Three Year Avg. Burn Rate (FY 2017-2019)			4.07%